<!DOCTYPE html>
<html lang="en" class="pb-page"  data-request-id="d727efd1-d1cd-410d-81b3-df93e015d24d"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";journal:journal:lancet;ctype:string:Journal Content;pageGroup:string:Article View;article:article:pii\:S0140673620312083;requestedJournal:journal:lancet;page:string:Show Full Text;product:product:elsevier\:product\:lancet;wgroup:string:Default Website Group;website:website:lancet-site;csubtype:string:Ahead of Print"/>




<!-- if there is any customization for Responsive Project widget  -->

















        <meta name="robots" content="noarchive"/>
<meta name="pb-robots-disabled">
    






    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=1, user-scalable=1"/>









        <meta property="og:title" content="Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial" />
    


        <meta property="og:type" content="Article" />
    


        <meta property="og:url" content="https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31208-3/abstract" />
    



        <meta property="og:site_name" content="The Lancet" />
    


        <meta property="og:image" content="//els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/asset/b51eaa4d-94e7-4ee7-92f5-a884b3ec2256/gr1.jpg" />
    


        <meta property="og:description" content="The Ad5 vectored COVID-19 vaccine is tolerable and immunogenic at 28 days post-vaccination.
Humoral responses against SARS-CoV-2 peaked at day 28 post-vaccination in healthy
adults, and rapid specific T-cell responses were noted from day 14 post-vaccination.
Our findings suggest that the Ad5 vectored COVID-19 vaccine warrants further investigation." />
    







        <meta name="twitter:title" content="Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial" />
    




        <meta name="twitter:image" content="//els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/asset/b51eaa4d-94e7-4ee7-92f5-a884b3ec2256/gr1.jpg" />
    


        <meta name="twitter:description" content="The Ad5 vectored COVID-19 vaccine is tolerable and immunogenic at 28 days post-vaccination.
Humoral responses against SARS-CoV-2 peaked at day 28 post-vaccination in healthy
adults, and rapid specific T-cell responses were noted from day 14 post-vaccination.
Our findings suggest that the Ad5 vectored COVID-19 vaccine warrants further investigation." />
    



    <meta name="apple-itunes-app" content="app-id=483025114"/>


    <meta name="google-play-app" content="app-id=com.elsevier.jbsm.lancet" />


    <meta name="AppTitle" content="The Lancet"/>


    <meta name="AppAuthor" content="Elsevier Inc."/>


    <meta name="AppIconUrl" content="http://www.thelancet.com.marlin-prod.literatumonline.com/pb-assets/Lancet/Images/lancetLogo.png"/>



<title>Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial - The Lancet</title><meta name="citation_journal_title" content="The Lancet"/> <meta name="citation_journal_abbrev" content="The Lancet"/> <meta name="citation_publisher" content="Elsevier"/> <meta name="citation_title" content="Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial"/> <meta name="citation_online_date" content="2020/05/22"/> <meta name="citation_volume" content="0"/> <meta name="citation_issue" content="0"/> <meta name="citation_abstract_html_url" content="http://www.thelancet.com/article/S0140673620312083/abstract"/> <meta name="citation_fulltext_html_url" content="http://www.thelancet.com/article/S0140673620312083/fulltext"/> <meta name="citation_pdf_url" content="http://www.thelancet.com/article/S0140673620312083/pdf"/> <meta name="citation_issn" content="0140-6736"/> <meta name="citation_issn" content="1474-547X"/> <meta name="citation_language" content="English"/> <meta name="citation_doi" content="10.1016/S0140-6736(20)31208-3"/> <meta name="citation_author" content="Feng-Cai Zhu"></meta> <meta name="citation_author_email" content="jszfc@vip.sina.com"></meta> <meta name="citation_author_institution" content="NHC Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, China"></meta> <meta name="citation_author" content="Yu-Hua Li"></meta> <meta name="citation_author_institution" content="China National Institute for Food and Drug Control, Beijing, China"></meta> <meta name="citation_author" content="Xu-Hua Guan"></meta> <meta name="citation_author_institution" content="Hubei Provincial Center for Disease Control and Prevention, Wuhan, China"></meta> <meta name="citation_author" content="Li-Hua Hou"></meta> <meta name="citation_author_institution" content="Beijing Institute of Biotechnology, Beijing, China"></meta> <meta name="citation_author" content="Wen-Juan Wang"></meta> <meta name="citation_author_institution" content="NHC Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, China"></meta> <meta name="citation_author" content="Jing-Xin Li"></meta> <meta name="citation_author_institution" content="NHC Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, China"></meta> <meta name="citation_author" content="Shi-Po Wu"></meta> <meta name="citation_author_institution" content="Beijing Institute of Biotechnology, Beijing, China"></meta> <meta name="citation_author" content="Bu-Sen Wang"></meta> <meta name="citation_author_institution" content="Beijing Institute of Biotechnology, Beijing, China"></meta> <meta name="citation_author" content="Zhao Wang"></meta> <meta name="citation_author_institution" content="Hubei Provincial Center for Disease Control and Prevention, Wuhan, China"></meta> <meta name="citation_author" content="Lei Wang"></meta> <meta name="citation_author_institution" content="Hubei Provincial Center for Disease Control and Prevention, Wuhan, China"></meta> <meta name="citation_author" content="Si-Yue Jia"></meta> <meta name="citation_author_institution" content="NHC Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, China"></meta> <meta name="citation_author" content="Hu-Dachuan Jiang"></meta> <meta name="citation_author_institution" content="NHC Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, China"></meta> <meta name="citation_author" content="Ling Wang"></meta> <meta name="citation_author_institution" content="China National Institute for Food and Drug Control, Beijing, China"></meta> <meta name="citation_author" content="Tao Jiang"></meta> <meta name="citation_author_institution" content="Beijing Institute of Microbiology and Epidemiology, State Key Laboratory of Pathogen and Biosecurity, Beijing, China"></meta> <meta name="citation_author" content="Yi Hu"></meta> <meta name="citation_author_institution" content="Beijing Institute of Microbiology and Epidemiology, State Key Laboratory of Pathogen and Biosecurity, Beijing, China"></meta> <meta name="citation_author" content="Jin-Bo Gou"></meta> <meta name="citation_author_institution" content="CanSino Biologics, Tianjin, China"></meta> <meta name="citation_author" content="Sha-Bei Xu"></meta> <meta name="citation_author_institution" content="Clinical Research Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"></meta> <meta name="citation_author" content="Jun-Jie Xu"></meta> <meta name="citation_author_institution" content="Beijing Institute of Biotechnology, Beijing, China"></meta> <meta name="citation_author" content="Xue-Wen Wang"></meta> <meta name="citation_author_institution" content="Shanghai Canming Medical Technology, Shanghai, China"></meta> <meta name="citation_author" content="Wei Wang"></meta> <meta name="citation_author_email" content="wwang@vip.126.com"></meta> <meta name="citation_author_institution" content="Clinical Research Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"></meta> <meta name="citation_author" content="Wei Chen"></meta> <meta name="citation_author_email" content="cw0226@foxmail.com"></meta> <meta name="citation_author_institution" content="Beijing Institute of Biotechnology, Beijing, China"></meta> <meta name="citation_reference" content="citation_title=A novel coronavirus from patients with pneumonia in China, 2019; citation_author=N Zhu; citation_author=D Zhang; citation_author=W Wang; citation_author=et al.; citation_journal_title=N Engl J Med; citation_volume=382; citation_firstpage=727; citation_lastpage=733; citation_publication_date=2020; "></meta> <meta name="citation_reference" content="citation_title=Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia; citation_author=Q Li; citation_author=X Guan; citation_author=P Wu; citation_author=et al.; citation_journal_title=N Engl J Med; citation_volume=382; citation_firstpage=1199; citation_lastpage=1207; citation_publication_date=2020; "></meta> <meta name="citation_reference" content="citation_title=Compassionate use of remdesivir for patients with severe Covid-19; citation_author=J Grein; citation_author=N Ohmagari; citation_author=D Shin; citation_author=et al.; citation_journal_title=N Engl J Med; citation_publication_date=2020; "></meta> <meta name="citation_reference" content="citation_title=Clinical course and mortality risk of severe COVID-19; citation_author=P Weiss; citation_author=DR Murdoch; citation_journal_title=Lancet; citation_volume=395; citation_firstpage=1014; citation_lastpage=1015; citation_publication_date=2020; "></meta> <meta name="citation_reference" content="citation_title=Coronavirus disease (COVID-2019) situation reports; citation_author=WHO; citation_publication_date=2020; "></meta> <meta name="citation_reference" content="citation_title=Impact assessment of non-pharmaceutical interventions against coronavirus disease 2019 and influenza in Hong Kong: an observational study; citation_author=BJ Cowling; citation_author=ST Ali; citation_author=TWY Ng; citation_author=et al.; citation_journal_title=Lancet Public Health; citation_volume=5; citation_firstpage=e279; citation_lastpage=e288; citation_publication_date=2020; "></meta> <meta name="citation_reference" content="citation_title=Spread of SARS-CoV-2 in the Icelandic population; citation_author=DF Gudbjartsson; citation_author=A Helgason; citation_author=H Jonsson; citation_author=et al.; citation_journal_title=N Engl J Med; citation_publication_date=2020; "></meta> <meta name="citation_reference" content="citation_title=SARS-CoV-2 vaccines: status report; citation_author=F Amanat; citation_author=F Krammer; citation_journal_title=Immunity; citation_volume=52; citation_firstpage=583; citation_lastpage=589; citation_publication_date=2020; "></meta> <meta name="citation_reference" content="citation_title=DRAFT landscape of COVID-19 candidate vaccines–30 April 2020; citation_author=WHO; citation_publication_date=2020; "></meta> <meta name="citation_reference" content="citation_title=Protocol. A single-center, open-label, dose-escalating phase I clinical trial of the recombinant novel coronavirus vaccine (adenovirus type 5 vector) in healthy adults aged between 18 and 60 years in China; citation_author=F-C Zhu; citation_author=X-H Guan; citation_author=W Wang; citation_author=et al.; citation_publication_date=2020; "></meta> <meta name="citation_reference" content="citation_author=National Medical Products Administration; citation_publication_date=2019; "></meta> <meta name="citation_reference" content="citation_title=Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2; citation_author=J Nie; citation_author=Q Li; citation_author=J Wu; citation_author=et al.; citation_journal_title=Emerg Microbes Infect; citation_volume=9; citation_firstpage=680; citation_lastpage=686; citation_publication_date=2020; "></meta> <meta name="citation_reference" content="citation_title=A monovalent chimpanzee adenovirus Ebola vaccine boosted with MVA; citation_author=K Ewer; citation_author=T Rampling; citation_author=N Venkatraman; citation_author=et al.; citation_journal_title=N Engl J Med; citation_volume=374; citation_firstpage=1635; citation_lastpage=1646; citation_publication_date=2016; "></meta> <meta name="citation_reference" content="citation_title=Safety and immunogenicity of a chimpanzee adenovirus-vectored Ebola vaccine in healthy adults: a randomised, double-blind, placebo-controlled, dose-finding, phase 1/2a study; citation_author=O De Santis; citation_author=R Audran; citation_author=E Pothin; citation_author=et al.; citation_journal_title=Lancet Infect Dis; citation_volume=16; citation_firstpage=311; citation_lastpage=320; citation_publication_date=2016; "></meta> <meta name="citation_reference" content="citation_title=Quantifying adenovirus-neutralizing antibodies by luciferase transgene detection: addressing preexisting immunity to vaccine and gene therapy vectors; citation_author=MC Sprangers; citation_author=W Lakhai; citation_author=W Koudstaal; citation_author=et al.; citation_journal_title=J Clin Microbiol; citation_volume=41; citation_firstpage=5046; citation_lastpage=5052; citation_publication_date=2003; "></meta> <meta name="citation_reference" content="citation_title=Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial; citation_author=FC Zhu; citation_author=LH Hou; citation_author=JX Li; citation_author=et al.; citation_journal_title=Lancet; citation_volume=385; citation_firstpage=2272; citation_lastpage=2279; citation_publication_date=2015; "></meta> <meta name="citation_reference" content="citation_title=T cell responses are required for protection from clinical disease and for virus clearance in severe acute respiratory syndrome coronavirus-infected mice; citation_author=J Zhao; citation_author=J Zhao; citation_author=S Perlman; citation_journal_title=J Virol; citation_volume=84; citation_firstpage=9318; citation_lastpage=9325; citation_publication_date=2010; "></meta> <meta name="citation_reference" content="citation_title=Virus-specific memory CD8 T cells provide substantial protection from lethal severe acute respiratory syndrome coronavirus infection; citation_author=R Channappanavar; citation_author=C Fett; citation_author=J Zhao; citation_author=DK Meyerholz; citation_author=S Perlman; citation_journal_title=J Virol; citation_volume=88; citation_firstpage=11034; citation_lastpage=11044; citation_publication_date=2014; "></meta> <meta name="citation_reference" content="citation_title=Neutralizing antibodies responses to SARS-CoV-2 in COVID-19 inpatients and convalescent patients; citation_author=X Wang; citation_author=X Guo; citation_author=Q Xin; citation_author=et al.; citation_journal_title=medRxiv; citation_publication_date=2020; "></meta> <meta name="citation_reference" content="citation_title=Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications; citation_author=F Wu; citation_author=A Wang; citation_author=M Liu; citation_author=et al.; citation_journal_title=medRxiv; citation_publication_date=2020; "></meta> <meta name="citation_reference" content="citation_title=Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study; citation_author=N Chen; citation_author=M Zhou; citation_author=X Dong; citation_author=et al.; citation_journal_title=Lancet; citation_volume=395; citation_firstpage=507; citation_lastpage=513; citation_publication_date=2020; "></meta> <meta name="citation_reference" content="citation_title=Clinical characteristics of severe acute respiratory syndrome coronavirus 2 reactivation; citation_author=G Ye; citation_author=Z Pan; citation_author=Y Pan; citation_author=et al.; citation_journal_title=J Infect; citation_volume=80; citation_firstpage=e14; citation_lastpage=e17; citation_publication_date=2020; "></meta> <meta name="citation_reference" content="citation_title=Developing Covid-19 vaccines at pandemic speed; citation_author=N Lurie; citation_author=M Saville; citation_author=R Hatchett; citation_author=J Halton; citation_journal_title=N Engl J Med; citation_publication_date=2020; "></meta> <meta name="citation_reference" content="citation_title=COVID-19: immunopathology and its implications for therapy; citation_author=X Cao; citation_journal_title=Nat Rev Immunol; citation_volume=20; citation_firstpage=269; citation_lastpage=270; citation_publication_date=2020; "></meta> <meta name="citation_reference" content="citation_title=Safety and immunogenicity of a heterologous prime-boost Ebola virus vaccine regimen in healthy adults in the United Kingdom and Senegal; citation_author=N Venkatraman; citation_author=BP Ndiaye; citation_author=G Bowyer; citation_author=et al.; citation_journal_title=J Infect Dis; citation_volume=219; citation_firstpage=1187; citation_lastpage=1197; citation_publication_date=2019; "></meta> <meta name="citation_reference" content="citation_title=Safety and immunogenicity of GamEvac-Combi, a heterologous VSV- and Ad5-vectored Ebola vaccine: an open phase I/II trial in healthy adults in Russia; citation_author=IV Dolzhikova; citation_author=OV Zubkova; citation_author=AI Tukhvatulin; citation_author=et al.; citation_journal_title=Hum Vaccin Immunother; citation_volume=13; citation_firstpage=613; citation_lastpage=620; citation_publication_date=2017; "></meta> <meta name="citation_reference" content="citation_title=A two-dose heterologous prime-boost vaccine regimen eliciting sustained immune responses to Ebola Zaire could support a preventive strategy for future outbreaks; citation_author=G Shukarev; citation_author=B Callendret; citation_author=K Luhn; citation_author=M Douoguih; citation_journal_title=Hum Vaccin Immunother; citation_volume=13; citation_firstpage=266; citation_lastpage=270; citation_publication_date=2017; "></meta> <meta name="citation_reference" content="citation_title=Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area; citation_author=S Richardson; citation_author=JS Hirsch; citation_author=M Narasimhan; citation_author=et al.; citation_journal_title=JAMA; citation_publication_date=2020; "></meta> <meta name="citation_reference" content="citation_title=Recent advances in the vaccine development against Middle East respiratory syndrome-coronavirus; citation_author=CY Yong; citation_author=HK Ong; citation_author=SK Yeap; citation_author=KL Ho; citation_author=WS Tan; citation_journal_title=Front Microbiol; citation_volume=10; citation_publication_date=2019; "></meta> <meta name="citation_reference" content="citation_title=A human SARS-CoV neutralizing antibody against epitope on S2 protein; citation_author=J Duan; citation_author=X Yan; citation_author=X Guo; citation_author=et al.; citation_journal_title=Biochem Biophys Res Commun; citation_volume=333; citation_firstpage=186; citation_lastpage=193; citation_publication_date=2005; "></meta> <meta name="citation_reference" content="citation_title=Immunodominant SARS coronavirus epitopes in humans elicited both enhancing and neutralizing effects on infection in non-human primates; citation_author=Q Wang; citation_author=L Zhang; citation_author=K Kuwahara; citation_author=et al.; citation_journal_title=ACS Infect Dis; citation_volume=2; citation_firstpage=361; citation_lastpage=376; citation_publication_date=2016; "></meta> <meta name="citation_reference" content="citation_title=Recombinant adenovirus type 5 HIV gag/pol/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 503/Phambili study; citation_author=GE Gray; citation_author=Z Moodie; citation_author=B Metch; citation_author=et al.; citation_journal_title=Lancet Infect Dis; citation_volume=14; citation_firstpage=388; citation_lastpage=396; citation_publication_date=2014; "></meta> <meta name="citation_abstract" content="&lt;h2&gt;Summary&lt;/h2&gt;&lt;h3&gt;Background&lt;/h3&gt;&lt;p&gt;A vaccine to protect against COVID-19 is urgently needed. We aimed to assess the safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 (Ad5) vectored COVID-19 vaccine expressing the spike glycoprotein of a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) strain.&lt;/p&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;p&gt;We did a dose-escalation, single-centre, open-label, non-randomised, phase 1 trial of an Ad5 vectored COVID-19 vaccine in Wuhan, China. Healthy adults aged between 18 and 60 years were sequentially enrolled and allocated to one of three dose groups (5 × 10&lt;sup&gt;10&lt;/sup&gt;, 1 × 10&lt;sup&gt;11&lt;/sup&gt;, and 1·5 × 10&lt;sup&gt;11&lt;/sup&gt; viral particles) to receive an intramuscular injection of vaccine. The primary outcome was adverse events in the 7 days post-vaccination. Safety was assessed over 28 days post-vaccination. Specific antibodies were measured with ELISA, and the neutralising antibody responses induced by vaccination were detected with SARS-CoV-2 virus neutralisation and pseudovirus neutralisation tests. T-cell responses were assessed by enzyme-linked immunospot and flow-cytometry assays. This study is registered with ClinicalTrials.gov, NCT04313127.&lt;/p&gt;&lt;h3&gt;Findings&lt;/h3&gt;&lt;p&gt;Between March 16 and March 27, 2020, we screened 195 individuals for eligibility. Of them, 108 participants (51% male, 49% female; mean age 36·3 years) were recruited and received the low dose (n=36), middle dose (n=36), or high dose (n=36) of the vaccine. All enrolled participants were included in the analysis. At least one adverse reaction within the first 7 days after the vaccination was reported in 30 (83%) participants in the low dose group, 30 (83%) participants in the middle dose group, and 27 (75%) participants in the high dose group. The most common injection site adverse reaction was pain, which was reported in 58 (54%) vaccine recipients, and the most commonly reported systematic adverse reactions were fever (50 [46%]), fatigue (47 [44%]), headache (42 [39%]), and muscle pain (18 [17%]. Most adverse reactions that were reported in all dose groups were mild or moderate in severity. No serious adverse event was noted within 28 days post-vaccination. ELISA antibodies and neutralising antibodies increased significantly at day 14, and peaked 28 days post-vaccination. Specific T-cell response peaked at day 14 post-vaccination.&lt;/p&gt;&lt;h3&gt;Interpretation&lt;/h3&gt;&lt;p&gt;The Ad5 vectored COVID-19 vaccine is tolerable and immunogenic at 28 days post-vaccination. Humoral responses against SARS-CoV-2 peaked at day 28 post-vaccination in healthy adults, and rapid specific T-cell responses were noted from day 14 post-vaccination. Our findings suggest that the Ad5 vectored COVID-19 vaccine warrants further investigation.&lt;/p&gt;&lt;h3&gt;Funding&lt;/h3&gt;&lt;p&gt;National Key R&D Program of China, National Science and Technology Major Project, and CanSino Biologics.&lt;/p&gt;"></meta><meta charset="UTF-8" /><!--

    Pagebuild admin UI
-->





<noscript>
    <style>.requiresJS {
        display: none
    }

    .dartAd {
        display: block !important
    }</style>
</noscript>
        <script type="text/javascript" src="/wro/itai~selected-legacy.js"></script>
        <link rel="stylesheet" type="text/css" href="/wro/itai~selected-legacy.css"/>
        <link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Open+Sans"/>
        
            <link rel="stylesheet" type="text/css" href="/products/marlin/lancet/releasedAssets/css/build.css"/>
        




<script rel="preconnect" src="//assets.adobedtm.com/376c5346e33126fdb6b2dbac81e307cbacfd7935/satelliteLib-8e350dc4ceceb17a5d77c03f66d95608807a5585.js"></script>

<script async src="https://www.youtube.com/iframe_api"></script>

<!---->
<meta http-equiv="X-UA-Compatible" content="IE=edge">






    







    
        
    


















































    
        <script type="text/javascript">
            function optimizelyTimeout() {
                window.optimizely = window.optimizely || [];
                if (!window.optimizely.data) {
                    window.optimizely.push("timeout")
                }
            }
            (function () {
                var e = "https:" == document.location.protocol ? "https://" : "http://";
                var t = document.createElement("script");
                t.type = "text/javascript";
                t.async = true;
                t.src = e + "cdn.optimizely.com/js/537300906.js";
                var n = document.getElementsByTagName("script")[0];
                n.parentNode.insertBefore(t, n)
            })();
            setTimeout(optimizelyTimeout, 1e3)
        </script>
    



<script type="text/javascript" async src="//s7.addthis.com/js/250/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script></head>
<body class="pb-ui">
    <div class="skip">
        <a href="#pageBody"
                  id="skipNavigationLink"
                  title="Skip to Main Content" tabIndex="0">Skip to Main Content</a>
    </div>


<script type="text/javascript">

        if(true) {
            document.getElementById("skipNavigationLink").onclick =function skipElement () {
                document.getElementById('pageBody').setAttribute('tabindex','0');
                document.getElementById('pageBody').focus();
            }

        }

</script>


    <script type="text/javascript" async defer
            src="//cdn.mathjax.org/mathjax/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>



    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="ux3-layout-widget" data-widget-id="5019c3ed-aeec-4bec-a97a-cd7d6ecea46c" class="ux3">
        
    

        


    

            

            
                <div class="lancet">
            

            <div data-widget-id="5019c3ed-aeec-4bec-a97a-cd7d6ecea46c" data-widget-name="ux3-layout-widget"><div>
    

        


    

            

            
                <div class="ux3-ads">
            

            <div class="pb-ad">
            <!-- To be kept in sync with Global Commercial Publishing Operations-->
<!-- Start: GPT Async -->
<script type="text/javascript">

	var gptadslots=[];
	var googletag = googletag ||
	{
	};

	googletag.cmd = googletag.cmd || [];

	(function()
		{
			var gads = document.createElement('script');

			gads.async = true; gads.type = 'text/javascript';

			var useSSL = 'https:' == document.location.protocol;

			gads.src = (useSSL ? 'https:' : 'http:') + '//securepubads.g.doubleclick.net/tag/js/gpt.js';

			var node = document.getElementsByTagName('script')[0];

			node.parentNode.insertBefore(gads, node);

		})();

</script>

<script type="text/javascript">
	//--------------------------------------------------------------------------
	$(document).ready(function ()
		{
			//Once the dom has loaded, begin the process to init the ads.
			gpt_InitAds();
		});
	//--------------------------------------------------------------------------
	function GPT_CheckForNULL(x, valueifnull) {
	    if (typeof valueifnull == "undefined") { valueifnull = null; }

	    if (typeof x == 'undefined') {
	        return valueifnull;
	    }
	    if (x == null) {
	        return valueifnull;
	    }
	    if (x == "null") {
	        return valueifnull;
	    }
	    if ($.trim(x) == '') {
	        return valueifnull;
	    }
	    else {
	        return x;
	    }
	}
	//--------------------------------------------------------------------------
	function gpt_GetAdditionalTargeting()
	{
		//adds page level targeting of custom variables
		//the id (minus gpt) and the value will be used as a key-value pair
		//eg: <input type="hidden" id="gptissuepii" value="x" class="gpt-Target">
		//eg: target issuepii=x
		$(".gpt-Target").each(function( index )
			{
				var gptTargetId = $(this).attr('id');
				gptTargetId = gptTargetId.replace('gpt','').toLowerCase();
				if(gptTargetId!='')
				{
					gpt_Target(gptTargetId);
				}
			})
    }
    //--------------------------------------------------------------------------
    function gpt_TargetAccessType() {
        var currentAccessType = $('#gptAccessType').val();
        if (typeof currentAccessType == "undefined") {
            currentAccessType = "";
        }
        if (currentAccessType.indexOf('ANON_IP') >= 0) {
            googletag.pubads().setTargeting("loggedin", "yes");
        }
        else {
            gpt_Target("LoggedIn");
        }
    }
    //--------------------------------------------------------------------------
    function gpt_CheckForStaging() {
        //Check to see if we are on the marlin-stag env
        //if so, set a targeting value
        if (window.location.hostname.toLowerCase().indexOf('.marlin-stag.') >= 0) {
            $('#gpt-Variables').append('<input type="hidden" id="gptEnvironment" value="marlin-stag">');
            gpt_Target("Environment");
        }
    }    
	//--------------------------------------------------------------------------
	function enableStickySideBar(){
		var stickyStatus = 0;
		var scrollx, skytop, voffset;
		skytop = $(".widget.literatumAd.alignCenter.GPT-ad-placeholder.widget-verticalAd").offset().top;

		$(window).scroll(function() {
			if (stickyStatus == 1) {
				if (rightColHeight != $(".widget.literatumAd.alignCenter.GPT-ad-placeholder.widget-verticalAd").parent().height()) {
			        rightColHeight = $(".widget.literatumAd.alignCenter.GPT-ad-placeholder.widget-verticalAd").parent().height();
			        skytop = $(".widget.literatumAd.alignCenter.GPT-ad-placeholder.widget-verticalAd").offset().top;
				}
			}

			scrollx = $(window).scrollTop();

			// IF THE LEADERBOARD AD IS FIXED
			if ($(".widget.literatumAd.alignCenter.GPT-ad-placeholder.widget-horizontalAd").css("position") == "fixed") {
				voffset = 110;
			} else {
				voffset = 0;
			}

			if ($("#jbs-fixed-hdr").length!=0){
				if ($("#jbs-fixed-hdr").css("display") == "block") {
				    voffset += $("#jbs-fixed-hdr").outerHeight();
				}
			}

			if (scrollx >= (skytop-voffset)) {   // MAKE AD IN RIGHT COLUMN STICKY
				var tmpWidth;
				tmpWidth = $(".widget.literatumAd.alignCenter.GPT-ad-placeholder.widget-verticalAd").width();
				$(".widget.literatumAd.alignCenter.GPT-ad-placeholder.widget-verticalAd").attr("style","top: " + voffset + "px !important;position: fixed !important;display:block !important;width:" + tmpWidth + "px !important;");
			} else {       // REVERT BACK TO ORIGINAL AD PLACEMENT
				$(".widget.literatumAd.alignCenter.GPT-ad-placeholder.widget-verticalAd").attr("style","position: static !important; display:block !important;");
				skytop = $(".widget.literatumAd.alignCenter.GPT-ad-placeholder.widget-verticalAd").offset().top;
				stickyStatus = 0;
			}
		});
	}
	//--------------------------------------------------------------------------
	function handleStickyLeaderboard()
	{
		var forceStickyLeaderboard = gpt_GetQuerystring('forcestickyleaderboard',0);
		if(forceStickyLeaderboard==0){
			// THIS FUNCTION REMOVES THE STICKY FEATURE OF THE LEADERBOARD
			$("#pb-page-content").attr("style","margin-top:0 !important;");
			$(".widget.literatumAd.alignCenter.GPT-ad-placeholder.widget-horizontalAd").attr("style","margin-top: 0px !important;position: static !important;display:block !important;background-color: transparent;padding:0;");

			$("#jbs-fixed-hdr").attr("style","top: 0 !important;");

			if ($(".denialInfo").length === 0 && $("#jbs-fixed-hdr").length > 0)
			{
				var topY = window.pageYOffset;
				if (topY > 300)
				{
					$("#jbs-fixed-hdr").attr("style","top: 0 !important;display:block !important");
				}
			}
			$(window).scroll();
		}
	}
	//--------------------------------------------------------------------------
	function handleStickyLeaderboard_CELL()
	{
		var forceStickyLeaderboard = gpt_GetQuerystring('forcestickyleaderboard',0);
		if(forceStickyLeaderboard==0){
			$("body").attr("style","padding-top:10px !important;");
			$(".cell-top-head").first().attr("style","margin-top: 0px !important;position: static !important;display:block !important;background-color: transparent;padding:0;");
			$(".article.enhanced .tab-nav").addClass("resetTop0");
			$(".article.enhanced #fixedPane").addClass("resetTop38");
			$(".article.enhanced .fixedArticle > .tab-nav").css("top","0px");
			$(".article.enhanced .fixedArticle #fixedPane").css("top","38px");
			var tmpStyle;
			tmpStyle = $(".article.enhanced .tab-nav").attr("style");
			tmpStyle = "top:0px;" + tmpStyle;
			$(".article.enhanced .tab-nav").removeAttr("style");
			$(".article.enhanced .tab-nav").attr("style",tmpStyle);
			tmpStyle = $(".article.enhanced #fixedPane").attr("style");
			tmpStyle = "top:38px;" + tmpStyle;
			$(".article.enhanced #fixedPane").removeAttr("style");
			$(".article.enhanced #fixedPane").attr("style",tmpStyle);
			$(".skip").addClass("skip-post-stickyleaderboard");
		}
	}
	//--------------------------------------------------------------------------
	function gpt_GetQuerystring(key, default_)
	{
		//function to read querystring variables
		if (default_ == null) default_ = '';
		key = key.replace(/[\[]/, "\\\[").replace(/[\]]/, "\\\]");
		var regex = new RegExp("[\\?&]" + key + "=([^&#]*)");
		var qs = regex.exec(window.location.href);
		if (qs == null)
		return default_;
		else
		return qs[1];
	}
	//--------------------------------------------------------------------------
	function gpt_GetDFPTestId()
	{
		//Get any request for a test id from querystring and set custom targeting parameter
		var gptDFPTestId = gpt_GetQuerystring('dfptestid','');
		if(gptDFPTestId != '')
		{
			$('#gpt-Variables').append('<input type="hidden" id="gptDFPTestId">');
			$('#gptDFPTestId').val(gptDFPTestId);
			gpt_Target("DFPTestId");
		}
	}
	//--------------------------------------------------------------------------
	function gpt_Target(targetName)
	{
		//Set page level target if value is found
		if($('#gpt' + targetName).length>0)
		{
			var targetValue = $('#gpt' + targetName).val();

			if(targetValue!='')
			{
				targetValue = targetValue.replace(/[^-a-z0-9]/ig,'');	//Only Allow a-z, 0-9
				googletag.pubads().setTargeting(targetName.toLowerCase(),targetValue.toLowerCase());
			}
		}
	}
	//--------------------------------------------------------------------------
	function gpt_InitAds()
	{
		var disableStickyLeaderboard = 0;
		var disableStickySidebar = 0;
		var responsiveDesign = 0;

		// ux3 Class will only exist if the page is Responsive Design
		if ($('.ux3').length!=0) {
			//Responsive Design Found, so disable the sticky Leaderboard
			responsiveDesign = 1;
			disableStickyLeaderboard = 1;
		}
		else{
			//Page is not responsive so check for Disable on Querystring
			disableStickyLeaderboard = gpt_GetQuerystring('disableStickyLeaderboard',0);
		}

		if(disableStickyLeaderboard!=0){
			//Disable the sticky leaderbard
			//Check for page flag, if it does not exist, create it.
			if($('#disableStickyLeaderboard').length==0){
				$("body").append("<div id='disableStickyLeaderboard'></div>");
			}
		}

		if(responsiveDesign==1){
			//Page is responsive design, check if it is an article page
			if($("[data-widget-def='UX3articleContent']").length!=0){
				//Its an article page, disable the sticky sidebar
				disableStickySidebar = 1;
			}
		}
		if(disableStickySidebar==0){
			//Check for disableStickySidebar in Querystring
			disableStickySidebar = gpt_GetQuerystring('disableStickySidebar',0);
		}

		if(disableStickySidebar!=0){
			//Disable the sticky leaderbard
			//Check for page flag, if it does not exist, create it.
			if($('#disableStickySidebar').length==0){
				$("body").append("<div id='disableStickySidebar'></div>");
			}
		}

		//Load common stylesheet for all sites except Cell & Responsive Design
		if($('.cell-site-header').length==0 && responsiveDesign==0){
			$("body").append('<link href="/pb-assets/shared/leaderboards/gpt_jbs-1504880817473.css" rel="stylesheet" />');
		}

		googletag.cmd.push(function()
			{
				var gptAdSlots = [];

				//***********************************************
				//Start Define Size mapping based on client Viewport
				//***********************************************
				var gptLeaderboardSizeMapping = googletag.sizeMapping().
				addSize([768, 0], [[728, 90]]). 								// Leaderboard
				addSize([0, 0], [[320, 50], [300, 50]]). 						// Mobile Leaderboard
				build();

				var gptSideBarSizeMapping = googletag.sizeMapping().
        addSize([1140, 800], [[160, 600], [300, 250]]). 				// SkyScraper - Desktop (Require min 800 vertical), Fall back to Boombox
				addSize([1140, 450], [[300, 250]]). 							// BoomBox - Desktop (Require min 450 vertical)
				addSize([0, 0], []). 											// Phone-Tablet
				build();

				var gptSideBarNotResponsiveSizeMapping = googletag.sizeMapping().
        addSize([1140, 800], [[160, 600]]). 				// SkyScraper - Desktop (Require min 800 vertical)
				addSize([0, 0], []). 											// Phone-Tablet
				build();

				var gptSideBarNotStickySizeMapping = googletag.sizeMapping().
        addSize([1140, 800], [[160, 600], [300, 250]]). 				// SkyScraper Not Sticky (Require min 800 vertical), Fall back to Boombox
				addSize([1140, 450], [[300, 250]]). 							// BoomBox Not Sticky (Require min 450 vertical)
				addSize([0, 0], []). 											// Phone-Tablet
				build();


				//***********************************************
				//End Define Size mapping based on client Viewport
				//***********************************************

				//***********************************************
				//Start detection for ad slots on page
				//***********************************************
				$(".gpt-ad").each(function( index )
					{
						var gptSite = GPT_CheckForNULL($('#gptSite').val());
						var gptPage = '';
						var adSizeMapping='';
						var adId;
						var gptPOS;
						var gptMasterPage = GPT_CheckForNULL($('#gptPage').val());

						if (gptSite == null) {
							gptSite = GPT_CheckForNULL($('#gptAltSite').val());
							if (gptSite == null) {
								gptSite = GPT_CheckForNULL($(this).data('site'));
							}
						}
						if (gptSite == null) {
							gptSite = GPT_CheckForNULL($('#gptDefaultSite').val());
						}
						if(gptSite!=null){
							adId = 'gpt-ad-' + index + 1;

							gptPOS = parseInt($(this).data('pos')) || -1;
							if(gptPOS == -1){
								gptPOS = index + 1;
							}

                            if (gptMasterPage != null) {
                                gptPage = '/' + gptMasterPage;
                            }
                            else {
                                gptPage = GPT_CheckForNULL($(this).data('page'));
                                if (gptPage != null) {
                                    gptPage = '/' + gptPage;
                                }
                                else {
                                    gptPage = '';
                                }
                            }

							//Determine sizemapping based on data-adsize
							switch($(this).data('adsize'))
							{
								case 'cell-leaderboard':
									adSizeMapping = gptLeaderboardSizeMapping;
									if(gptPOS==1){
										$(this).addClass('GPT-Leaderboard-Cell');
									}
									break;
								case 'leaderboard':
									adSizeMapping = gptLeaderboardSizeMapping;
									$(this).addClass('GPT-Leaderboard');
									break;
								case 'boombox':
									adSizeMapping = gptBoomBoxSizeMapping;
									break;
								case 'skyscraper':
									if($(this).hasClass("disableStickySidebar")){
										adSizeMapping = gptSideBarNotStickySizeMapping;
									}
									else{
										$(this).addClass('GPT-StickySideBar');
										adSizeMapping = gptSideBarSizeMapping;
									}
								break;
								case 'skyscrapernotresponsive':
									adSizeMapping = gptSideBarNotResponsiveSizeMapping;
									break;
							}
						}

						//Ignore any invalid adsizes that could be on the page
						if(adSizeMapping!='')
						{
							$(this).addClass('gpt-ad-defined');
							$(this).attr('id',adId);
							gptAdSlots[index] = googletag.defineSlot('/6053/els.' + gptSite + gptPage, [], adId).defineSizeMapping(adSizeMapping).addService(googletag.pubads()).setTargeting("pos", gptPOS);
						}
						else
						{
							$(this).remove();
						}
					});
				//***********************************************
				//End detection for ad slots on page
				//***********************************************

                //***********************************************
                //Start page level targeting
                //***********************************************
                //Logged in or IP Access
                gpt_TargetAccessType();

                //Check for DFP Test
                gpt_GetDFPTestId();

                //Check for Staging
                gpt_CheckForStaging();

                //Check for Additional Targeting
                gpt_GetAdditionalTargeting()

                //***********************************************
                //End page level targeting
                //***********************************************

				//Enable google dfp services
				googletag.pubads().enableSingleRequest();
				googletag.pubads().collapseEmptyDivs();
				googletag.enableServices();

				//Add Listener for Leaderboard
				googletag.pubads().addEventListener('slotRenderEnded', function(event)
					{
						if (!event.isEmpty)
						{
							$('#' + event.slot.getSlotElementId()).closest(".GPT-ad-placeholder").css("display", "block");


							//Sticky LeaderBoard JBS
							if ($('#' + event.slot.getSlotElementId()).hasClass("GPT-Leaderboard"))
							{
								if($('#disableStickyLeaderboard').length==0){
									$('body').addClass("hasLeaderboard");

									// INJECT SOME CSS FOR STICKY LEADERBOARD
									// THIS INCLUDES CHANGING THE TOP OF THE STICKY HEADER #jbs-fixed-hdr
									$("body").append("<style>.prevNextHeader:first-of-type,.skip{height:0}.widget.literatumAd.alignCenter.GPT-ad-placeholder.widget-horizontalAd{position:fixed;top:0;left:0;width:100%;background-color:#d8d8d8;padding:10px 0 0;margin:0px !important}#pb-page-content{margin-top:120px}#jbs-fixed-hdr{top:108px!important;z-index:999999!important;height:26px!important}.horizontalAd iframe{}div.horizontalAdContainer{height:95px!important}.iHubLinkContainerX{margin:0!important} div.horizontalAdContainer{height:90px !important;}</style>");

									setTimeout(handleStickyLeaderboard, 8000);
								}
							}

							//Sticky LeaderBoard Cell
							if ($('#' + event.slot.getSlotElementId()).hasClass("GPT-Leaderboard-Cell"))
							{
								if($('#disableStickyLeaderboard').length==0){
									$("body").append('<link href="/pb-assets/shared/leaderboards/gpt_cell-1504880817443.css" rel="stylesheet" />');
									$("div.cell-top-head").attr("style","display:block !important;"); $("body").append("");
									var tmp;
									tmp = $(".article.enhanced .tab-nav").attr("style");
									tmp = "top:110px;" + tmp;
									$(".article.enhanced .tab-nav").removeAttr("style");
									$(".article.enhanced .tab-nav").attr("style",tmp);
									tmp = $(".article.enhanced #fixedPane").attr("style");
									tmp = "top:148px;" + tmp;
									$(".article.enhanced #fixedPane").removeAttr("style");
									$(".article.enhanced #fixedPane").attr("style",tmp);
									setTimeout(handleStickyLeaderboard_CELL, 8000);
								}

								// THE FOLLOWING MAKES SURE THAT THE FIGURES PANE POPULATES
								// (there might be a bug on the live site)
								$("li.showFullText a").click();
							}


							//Sticky SideBar
							if ($('#' + event.slot.getSlotElementId()).hasClass("GPT-StickySideBar")){
								if($('#disableStickySidebar').length==0){
									enableStickySideBar();
								}
							}
						}
					});

				//Populate Defined Ad Slots
				$(".gpt-ad-defined").each(function( index )
					{
						var adId = $(this).attr('id');
						googletag.cmd.push(function() {googletag.display(adId);});
					});

			});
	}
</script>
<div id="gpt-Variables" data-adfile="LancetGPTSlot" data-version="02032020">
	<input type="hidden" id="gptSite" value="lancet">
	<input type="hidden" id="gptLoggedIn" value="no">
	<input type="hidden" id="gptAccessType" value="ae:ANON_GUEST|ae:ANON_GUEST">
</div>

<!-- End: GPT -->

        </div>

            
                </div>
            

        

    

        


    

            

            

            <div data-widget-id="f3868982-daa5-45e3-92f6-84fdcc4ac3fe" data-widget-name="ux3-layout-widget"><header class="header base fixed">
    

        


    

            

            

            <div data-widget-id="ff5ec9a2-0ea8-4f5e-aece-0786cac88a5c" data-widget-name="ux3-layout-widget"><div>
    

        


    

                
                
                
                
                
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                        
                        
                        
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                
                
                <div class="widget literatumAd none adplaceholder adplaceholder--header js__adToHide widget-horizontalAd" id="ccbf3208-3db1-4c0b-bb0d-eacad1af308a">
                
                

                <div class="wrapped " >
                    
                    <div class="widget-body body body-horizontalAd "><div class="horizontalAdContainer">
    <div class="horizontalAdLabelContainer">
        <div class="horizontalAdLabel">
                <img src="/templates/jsp/_style2/_marlin/images/bg_adHoriz.gif" alt="Advertisement"/>
        </div>
    </div>
    <div class="horizontalAd">
        





        <div class="pb-ad">
            <div class="gpt-ad" data-adsize="leaderboard"></div>
        </div>
    

    </div>
</div></div>
                </div>
                </div>

        










        <div data-widget-def="ux3-layout-widget" data-widget-id="4014114d-054d-414e-bb5e-ea626d9a028c" class="header__wrapper clearfix" data-db-parent-of="quickSearch">
        
    

        


    

            

            

            <div data-widget-id="4014114d-054d-414e-bb5e-ea626d9a028c" data-widget-name="ux3-layout-widget"><div class="col-xs-6">
    

        


    

            

            
                <div class="journal-logos">
            

            <span data-widget-id="1f3f5ace-3a36-4970-a5f1-d69d6e7bf4b6" data-widget-name="ux3-general-image"><a href="/journals/lancet/home" title="The Lancet Journal"><img alt="The Lancet Journal" src="/pb-assets/ux3/logos/lancet/LANCET-1532516601370.svg"/></a></span>

            
                </div>
            

        
</div><div class="col-xs-6">
    

        


    

            

            

            <div data-widget-id="25bd95c4-9085-4b32-af0e-a8c71015a190" data-widget-name="ux3-layout-widget"><div class="header__nav row">
    

        


    

            

            

            <div data-widget-id="f133594e-2be9-4641-b3aa-38f20dd20d9d" data-widget-name="UX3MenuWidget" class="main-nav menu-drawer"><div class="menu-drawer__ctrl"><a href="#main-menu" data-target="main-menu" data-toggle="nav" title="Explore Lancet.com" aria-controls="main-menu" aria-expanded="false"><span class="menu-drawer--open"><i aria-hidden="true" class="icon-gizmo-hamburger"></i></span><span class="menu-drawer--close"><i aria-hidden="true" class="icon-close_thin"><span>Close</span></i></span></a></div><nav role="navigation" id="main-menu" data-ctrl-res="screen-sm" class="menu-drawer__nav drawer__nav gutterless"><span class="menu-drawer--holder hidden-md hidden-lg"></span><ul id="menubar" role="menubar" class="menubar rlist--inline"><li role="menuitem" aria-haspopup="true" aria-label="This Journal" id="menu-item-main-menu-0" class="dropdown menu-parent is--current"><a href="#" title="This Journal" id="main-menu-0" data-toggle="dropdown" class="dropdown__toggle"><span>This Journal</span><i aria-hidden="true" class="icon-arrow_r pull-right"></i></a><ul id="menu-items-0" role="menu" class="rlist dropdown__menu"><li role="menuitem" aria-haspopup="true" class="menu-drawer__back hidden-md hidden-lg"><a href="#" class="menu-drawer__back__ctrl"><i aria-hidden="true" class="icon-arrow_l"></i><span>Back</span></a></li><li role="menuitem" tabindex="-1" aria-label="Journal Home" class="menu-item"><a href="/journals/lancet/home" title="Journal Home"><span>Journal Home</span></a></li><li role="menuitem" tabindex="-1" aria-label="Online First" class="menu-item"><a href="/journals/lancet/onlineFirst" title="Online First"><span>Online First</span></a></li><li role="menuitem" tabindex="-1" aria-label="Current Issue" class="menu-item"><a href="/journals/lancet/issue/current" title="Current Issue"><span>Current Issue</span></a></li><li role="menuitem" tabindex="-1" aria-label="All Issues" class="menu-item"><a href="/journals/lancet/issues" title="All Issues"><span>All Issues</span></a></li><li role="menuitem" tabindex="-1" aria-label="Special Issues" class="menu-item"><a href="/journals/lancet/specialIssue" title="Special Issues"><span>Special Issues</span></a></li><li role="menuitem" tabindex="-1" aria-label="About the journal" class="menu-item"><a href="/lancet/about" title="About the journal"><span>About the journal</span></a></li></ul></li><li role="menuitem" aria-haspopup="true" aria-label="Journals" id="menu-item-main-menu-1" class="dropdown menu-parent"><a href="#" title="Journals" id="main-menu-1" data-toggle="dropdown" class="dropdown__toggle"><span>Journals</span><i aria-hidden="true" class="icon-arrow_r pull-right"></i></a><ul id="menu-items-1" role="menu" class="rlist dropdown__menu level-2"><li role="menuitem" aria-haspopup="true" class="menu-drawer__back hidden-md hidden-lg"><a href="#" class="menu-drawer__back__ctrl"><i aria-hidden="true" class="icon-arrow_l"></i><span>Back</span></a></li><li role="menuitem" tabindex="-1" aria-label="The Lancet" class="menu-item"><a href="/journals/lancet/home" title="The Lancet"><span>The Lancet</span></a></li><li role="menuitem" tabindex="-1" aria-label="The Lancet Child &amp; Adolescent Health" class="menu-item"><a href="/journals/lanchi/home" title="The Lancet Child &amp; Adolescent Health"><span>The Lancet Child & Adolescent Health</span></a></li><li role="menuitem" tabindex="-1" aria-label="The Lancet Diabetes &amp; Endocrinology" class="menu-item"><a href="/journals/landia/home" title="The Lancet Diabetes &amp; Endocrinology"><span>The Lancet Diabetes & Endocrinology</span></a></li><li role="menuitem" tabindex="-1" aria-label="The Lancet Digital Health" class="menu-item"><a href="/journals/landig/home" title="The Lancet Digital Health"><span>The Lancet Digital Health</span></a></li><li role="menuitem" tabindex="-1" aria-label="The Lancet Gastroenterology &amp;amp; Hepatology" class="menu-item"><a href="/journals/langas/home" title="The Lancet Gastroenterology &amp;amp; Hepatology"><span>The Lancet Gastroenterology &amp; Hepatology</span></a></li><li role="menuitem" tabindex="-1" aria-label="The Lancet Global Health" class="menu-item"><a href="/journals/langlo/home" title="The Lancet Global Health"><span>The Lancet Global Health</span></a></li><li role="menuitem" tabindex="-1" aria-label="The Lancet Haematology" class="menu-item"><a href="/journals/lanhae/home" title="The Lancet Haematology"><span>The Lancet Haematology</span></a></li><li role="menuitem" tabindex="-1" aria-label="The Lancet HIV" class="menu-item"><a href="/journals/lanhiv/home" title="The Lancet HIV"><span>The Lancet HIV</span></a></li><li role="menuitem" tabindex="-1" aria-label="The Lancet Infectious Diseases" class="menu-item"><a href="/journals/laninf/home" title="The Lancet Infectious Diseases"><span>The Lancet Infectious Diseases</span></a></li><li role="menuitem" tabindex="-1" aria-label="The Lancet Microbe" class="menu-item"><a href="/journals/lanmic/home" title="The Lancet Microbe"><span>The Lancet Microbe</span></a></li><li role="menuitem" tabindex="-1" aria-label="The Lancet Neurology" class="menu-item"><a href="/journals/laneur/home" title="The Lancet Neurology"><span>The Lancet Neurology</span></a></li><li role="menuitem" tabindex="-1" aria-label="The Lancet Oncology" class="menu-item"><a href="/journals/lanonc/home" title="The Lancet Oncology"><span>The Lancet Oncology</span></a></li><li role="menuitem" tabindex="-1" aria-label="The Lancet Planetary Health" class="menu-item"><a href="/journals/lanplh/home" title="The Lancet Planetary Health"><span>The Lancet Planetary Health</span></a></li><li role="menuitem" tabindex="-1" aria-label="The Lancet Psychiatry" class="menu-item"><a href="/journals/lanpsy/home" title="The Lancet Psychiatry"><span>The Lancet Psychiatry</span></a></li><li role="menuitem" tabindex="-1" aria-label="The Lancet Public Health" class="menu-item"><a href="/journals/lanpub/home" title="The Lancet Public Health"><span>The Lancet Public Health</span></a></li><li role="menuitem" tabindex="-1" aria-label="The Lancet Regional Health" class="menu-item"><a href="/regional-health" title="The Lancet Regional Health"><span>The Lancet Regional Health</span></a></li><li role="menuitem" tabindex="-1" aria-label="The Lancet Respiratory Medicine" class="menu-item"><a href="/journals/lanres/home" title="The Lancet Respiratory Medicine"><span>The Lancet Respiratory Medicine</span></a></li><li role="menuitem" tabindex="-1" aria-label="The Lancet Rheumatology" class="menu-item"><a href="/journals/lanrhe/home" title="The Lancet Rheumatology"><span>The Lancet Rheumatology</span></a></li><li role="menuitem" tabindex="-1" aria-label="EBioMedicine" class="menu-item"><a href="/journals/ebiom/home" title="EBioMedicine"><span>EBioMedicine</span></a></li><li role="menuitem" tabindex="-1" aria-label="EClinicalMedicine" class="menu-item"><a href="/journals/eclinm/home" title="EClinicalMedicine"><span>EClinicalMedicine</span></a></li></ul></li><li role="menuitem" aria-haspopup="true" aria-label="Clinical" id="menu-item-main-menu-2" class="dropdown menu-parent"><a href="#" title="Clinical" id="main-menu-2" data-toggle="dropdown" class="dropdown__toggle"><span>Clinical</span><i aria-hidden="true" class="icon-arrow_r pull-right"></i></a><ul id="menu-items-2" role="menu" class="rlist dropdown__menu level-3"><li role="menuitem" aria-haspopup="true" class="menu-drawer__back hidden-md hidden-lg"><a href="#" class="menu-drawer__back__ctrl"><i aria-hidden="true" class="icon-arrow_l"></i><span>Back</span></a></li><li role="menuitem" tabindex="-1" aria-label="The Lancet Clinic" class="menu-item"><a href="/clinical/diseases" title="The Lancet Clinic"><span>The Lancet Clinic</span></a></li><li role="menuitem" tabindex="-1" aria-label="Series" class="menu-item"><a href="/clinical/series" title="Series"><span>Series</span></a></li><li role="menuitem" tabindex="-1" aria-label="Commissions" class="menu-item"><a href="/clinical/commissions" title="Commissions"><span>Commissions</span></a></li><li role="menuitem" tabindex="-1" aria-label="Picture Quiz" class="menu-item"><a href="/picture-quiz" title="Picture Quiz"><span>Picture Quiz</span></a></li></ul></li><li role="menuitem" aria-haspopup="true" aria-label="Global Health" id="menu-item-main-menu-3" class="dropdown menu-parent"><a href="#" title="Global Health" id="main-menu-3" data-toggle="dropdown" class="dropdown__toggle"><span>Global Health</span><i aria-hidden="true" class="icon-arrow_r pull-right"></i></a><ul id="menu-items-3" role="menu" class="rlist dropdown__menu level-4"><li role="menuitem" aria-haspopup="true" class="menu-drawer__back hidden-md hidden-lg"><a href="#" class="menu-drawer__back__ctrl"><i aria-hidden="true" class="icon-arrow_l"></i><span>Back</span></a></li><li role="menuitem" tabindex="-1" aria-label="Hub" class="menu-item"><a href="/global-health" title="Hub"><span>Hub</span></a></li><li role="menuitem" tabindex="-1" aria-label="Series" class="menu-item"><a href="/global-health/series" title="Series"><span>Series</span></a></li><li role="menuitem" tabindex="-1" aria-label="Commissions" class="menu-item"><a href="/global-health/commissions" title="Commissions"><span>Commissions</span></a></li><li role="menuitem" tabindex="-1" aria-label="Global Burden of Diseases" class="menu-item"><a href="/gbd" title="Global Burden of Diseases"><span>Global Burden of Diseases</span></a></li></ul></li><li role="menuitem" aria-haspopup="true" aria-label="Information" id="menu-item-main-menu-4" class="dropdown menu-parent"><a href="#" title="Information" id="main-menu-4" data-toggle="dropdown" class="dropdown__toggle"><span>Information</span><i aria-hidden="true" class="icon-arrow_r pull-right"></i></a><ul id="menu-items-4" role="menu" class="rlist dropdown__menu level-5"><li role="menuitem" aria-haspopup="true" class="menu-drawer__back hidden-md hidden-lg"><a href="#" class="menu-drawer__back__ctrl"><i aria-hidden="true" class="icon-arrow_l"></i><span>Back</span></a></li><li role="menuitem" tabindex="-1" aria-label="About" class="menu-item"><a href="/about-us" title="About"><span>About</span></a></li><li role="menuitem" tabindex="-1" aria-label="Authors" class="menu-item"><a href="/for-authors" title="Authors"><span>Authors</span></a></li><li role="menuitem" tabindex="-1" aria-label="Readers" class="menu-item"><a href="/access-to-content" title="Readers"><span>Readers</span></a></li><li role="menuitem" tabindex="-1" aria-label="The Lancet App" class="menu-item"><a href="/app" title="The Lancet App"><span>The Lancet App</span></a></li><li role="menuitem" tabindex="-1" aria-label="Advertisers" class="menu-item"><a href="/for-advertisers" title="Advertisers"><span>Advertisers</span></a></li><li role="menuitem" tabindex="-1" aria-label="Press" class="menu-item"><a href="/press-room" title="Press"><span>Press</span></a></li><li role="menuitem" tabindex="-1" aria-label="Careers" class="menu-item"><a href="http://careers.thelancet.com/home/" title="Careers"><span>Careers</span></a></li><li role="menuitem" tabindex="-1" aria-label="Conferences" class="menu-item"><a href="/conferences" title="Conferences"><span>Conferences</span></a></li></ul></li><li role="menuitem" aria-haspopup="true" aria-label="Submit a Paper" id="menu-item-main-menu-5" class="dropdown menu-parent"><a href="#" title="Submit a Paper" id="main-menu-5" data-toggle="dropdown" class="dropdown__toggle"><span>Submit a Paper</span><i aria-hidden="true" class="icon-arrow_r pull-right"></i></a><ul id="menu-items-5" role="menu" class="rlist dropdown__menu level-6"><li role="menuitem" aria-haspopup="true" class="menu-drawer__back hidden-md hidden-lg"><a href="#" class="menu-drawer__back__ctrl"><i aria-hidden="true" class="icon-arrow_l"></i><span>Back</span></a></li><li role="menuitem" tabindex="-1" aria-label="The Lancet" class="menu-item"><a href="/lancet/about" title="The Lancet"><span>The Lancet</span></a></li><li role="menuitem" tabindex="-1" aria-label="The Lancet Child &amp; Adolescent Health" class="menu-item"><a href="/lanchi/about" title="The Lancet Child &amp; Adolescent Health"><span>The Lancet Child & Adolescent Health</span></a></li><li role="menuitem" tabindex="-1" aria-label="The Lancet Diabetes &amp; Endocrinology" class="menu-item"><a href="/landia/about" title="The Lancet Diabetes &amp; Endocrinology"><span>The Lancet Diabetes & Endocrinology</span></a></li><li role="menuitem" tabindex="-1" aria-label="The Lancet Digital Health" class="menu-item"><a href="/landig/about" title="The Lancet Digital Health"><span>The Lancet Digital Health</span></a></li><li role="menuitem" tabindex="-1" aria-label="The Lancet Gastroenterology &amp; Hepatology" class="menu-item"><a href="/langas/about" title="The Lancet Gastroenterology &amp; Hepatology"><span>The Lancet Gastroenterology & Hepatology</span></a></li><li role="menuitem" tabindex="-1" aria-label="The Lancet Global Health" class="menu-item"><a href="/langlo/about" title="The Lancet Global Health"><span>The Lancet Global Health</span></a></li><li role="menuitem" tabindex="-1" aria-label="The Lancet Haematology" class="menu-item"><a href="/lanhae/about" title="The Lancet Haematology"><span>The Lancet Haematology</span></a></li><li role="menuitem" tabindex="-1" aria-label="The Lancet HIV" class="menu-item"><a href="/lanhiv/about" title="The Lancet HIV"><span>The Lancet HIV</span></a></li><li role="menuitem" tabindex="-1" aria-label="The Lancet Infectious Diseases" class="menu-item"><a href="/laninf/about" title="The Lancet Infectious Diseases"><span>The Lancet Infectious Diseases</span></a></li><li role="menuitem" tabindex="-1" aria-label="The Lancet Microbe" class="menu-item"><a href="/lanmic/about" title="The Lancet Microbe"><span>The Lancet Microbe</span></a></li><li role="menuitem" tabindex="-1" aria-label="The Lancet Neurology" class="menu-item"><a href="/laneur/about" title="The Lancet Neurology"><span>The Lancet Neurology</span></a></li><li role="menuitem" tabindex="-1" aria-label="The Lancet Oncology" class="menu-item"><a href="/lanonc/about" title="The Lancet Oncology"><span>The Lancet Oncology</span></a></li><li role="menuitem" tabindex="-1" aria-label="The Lancet Planetary Health" class="menu-item"><a href="/lanplh/about" title="The Lancet Planetary Health"><span>The Lancet Planetary Health</span></a></li><li role="menuitem" tabindex="-1" aria-label="The Lancet Psychiatry" class="menu-item"><a href="/lanpsy/about" title="The Lancet Psychiatry"><span>The Lancet Psychiatry</span></a></li><li role="menuitem" tabindex="-1" aria-label="The Lancet Public Health" class="menu-item"><a href="/lanpub/about" title="The Lancet Public Health"><span>The Lancet Public Health</span></a></li><li role="menuitem" tabindex="-1" aria-label="The Lancet Regional Health - Western Pacific" class="menu-item"><a href="/lanwpc/about" title="The Lancet Regional Health - Western Pacific"><span>The Lancet Regional Health - Western Pacific</span></a></li><li role="menuitem" tabindex="-1" aria-label="The Lancet Respiratory Medicine" class="menu-item"><a href="/lanres/about" title="The Lancet Respiratory Medicine"><span>The Lancet Respiratory Medicine</span></a></li><li role="menuitem" tabindex="-1" aria-label="The Lancet Rheumatology" class="menu-item"><a href="/lanrhe/about" title="The Lancet Rheumatology"><span>The Lancet Rheumatology</span></a></li><li role="menuitem" tabindex="-1" aria-label="EBioMedicine" class="menu-item"><a href="/ebiom/about" title="EBioMedicine"><span>EBioMedicine</span></a></li><li role="menuitem" tabindex="-1" aria-label="EClinicalMedicine" class="menu-item"><a href="/eclinm/about" title="EClinicalMedicine"><span>EClinicalMedicine</span></a></li><li role="menuitem" tabindex="-1" aria-label="Preprints with The Lancet" class="menu-item"><a href="/preprints" title="Preprints with The Lancet"><span>Preprints with The Lancet</span></a></li></ul></li><li role="menuitem" aria-label="COVID-19 Resource Centre" id="menu-item-main-menu-6" class="menu-item"><a href="/coronavirus" title="COVID-19 Resource Centre"><span>COVID-19 Resource Centre</span></a></li><li role="menuitem" aria-label="The Lancet Home" id="menu-item-main-menu-7" class="menu-item"><a href="/home" title="The Lancet Home"><span>The Lancet Home</span></a></li></ul></nav></div><div class="header__dropzone"><div class="pb-dropzone" data-pb-dropzone="menuDropzone" title="menuDropzone"></div></div>

            

        

    

        


    

            

            

            <div data-widget-id="036d7208-4ae6-4144-a35d-6a83657fa8f9" data-widget-name="UX3QuickSearchWidget" class="quick-search"><div class="dropBlock"><a href="#" title="Search" data-db-target-for="quickSearch" aria-expanded="false" aria-controls="quick-search-holder" class="search-drawer"><i aria-hidden="true" class="icon-search"></i></a><div data-db-target-of="quickSearch" id="quick-search-holder" class="dropBlock__holder quick-search__holder"><div class="tab row clearfix quick-search__wrapper"><input type="hidden" name="autoCompleteUrl" value="https://search-autocomplete.elsevier-jbs.com/autocomplete/jsonp" class="autoCompleteServerURL"/><form action="https://www.thelancet.com/action/doSearch?journalCode=lancet" name="quickSearchBar" method="get" title="Quick Search" onSubmit="return validateQuickSearchForm();"><div class="clearfix"><div class="col-sm-5 col-md-6 col-lg-7"><input type="hidden" name="searchType" value="quick" aria-hidden="true"/><div class="input-group quick-search__searchbar"><input type="text" name="searchText" placeholder="Search for..." class="autoComplete"/></div><button type="submit" title="Search" aria-label="Search" class="btn quick-search__button icon-search"><span>Go search</span></button></div><div class="col-sm-4 col-md-4 col-lg-3"><select class="quick-search__dropdown"><option value="all" selected="selected">All Content</option><option value="articleTitleAbstractKeywords">Article Title, Abstract, Keywords</option><option value="author">Authors</option><option value="articleTitle">Article Title</option><option value="abstract">Abstract</option></select><div class="quick-search__scope-options clearfix"><label for="searchScopeSeries" title="This Journal"><span>This Journal</span><input id="searchScopeSeries" type="radio" name="searchScope" title="This Journal" value="series" checked="checked"/></label><label for="searchScopeFullSite" title="Full Site"><span>Full Site</span><input id="searchScopeFullSite" type="radio" name="searchScope" value="fullSite" title="Full Site"/></label><input type="hidden" name="journalCode" value="lancet" aria-hidden="true"/><input type="hidden" name="seriesISSNFltraddfilter" value="0140-6736" aria-hidden="true"/></div></div><input type="hidden" name="occurrences" value="all" aria-hidden="true"/><div class="col-sm-3 col-md-2 col-lg-2"><div class="quick-search__advanced-region"><a href="https://www.thelancet.com/search/advanced?searchType=advanced&amp;journalCode=lancet&amp;seriesIssn=0140-6736" title="Advanced search" class="quick-search__advanced-link">Advanced Search</a></div></div><input type="hidden" name="code" value="lancet-site" aria-hidden="true"/><input type="hidden" name="journalCode" value="lancet" aria-hidden="true"/></div></form><a href="#" title="Close search bar" class="quick-search__ctrl quick-search__close hidden-xs hidden-sm"><i aria-hidden="true" class="icon-tools_close"></i></a></div></div></div></div>

            

        

    

        


    

            

            

            <ul data-widget-id="09747bb0-d356-41e4-8906-6599a06f29d5" data-widget-name="UX3ProfileLinksWidget" class="rlist rlist--inline profile-links"><li><a href="/action/showLogin?redirectUri=https%3A%2F%2Fwww.thelancet.com%2Fjournals%2Flancet%2Farticle%2FPIIS0140-6736%2820%2931208-3%2Ffulltext&amp;pii=S0140-6736%2820%2931208-3" title="Log in to Lancet.com">Log in</a></li><li class="profile-links__register"><a href="/action/registration?journalCode=lancet&amp;redirectUri=https%3A%2F%2Fwww.thelancet.com%2Fjournals%2Flancet%2Farticle%2FPIIS0140-6736%2820%2931208-3%2Ffulltext" title="Register a username and password for free">Register</a></li><li class="profile-links__subscribe"><a href="/journals/lancet/subscribe" title="Subscribe to a Lancet journal">Subscribe</a></li><li class="profile-links__claim"><a href="/journals/lancet/activate" title="Claim your online subscription">Claim</a></li></ul>

            

        
</div></div>

            

        
</div></div>

            

        

        </div>
    

    

        


    

                
                
                
                
                
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                
                    
                
                    
                
                    
                
                    
                
                    
                        
                        
                        
                    
                
                    
                
                    
                
                    
                
                    
                
                
                
                <div class="widget csasInstitutionBanner none  widget-none" id="bb5194fa-af01-4fe9-8c3b-ab27bff6c471">
                
                

                <div class="wrapped " >
                    
                    <div class="widget-body body body-none "><div class="ui-state-highlight ui-corner-all csas-institution-banner hidden" data-doi="10.1016/S0140-6736(20)31208-3">
    <span class="ui-icon ui-icon-close banner-close"></span>
    <p>
        Access provided by <span class="accountName"></span>
    </p>
</div>

<style>
    .csas-institution-banner {
        padding: 10px 0 0 10px;
        margin: 5px;
    }

    .csas-institution-banner.ui-state-highlight .ui-icon {
        background-image: url("/templates/jsp/css/jquery-ui-1.10.2/base/images/ui-icons_454545_256x240.png");
        margin-right: 5px;
        margin-top: -4px;
    }

    .csas-institution-banner .banner-close {
        float: right;
    }
</style>

<script>

    function resetBanner(doi) {
        $.get('/action/getAccount?doi=' + doi, function(data) {
            if (data) {
                $(".csas-institution-banner p .accountName").html(data);
                $(".csasInstitutionBanner").fadeIn();
                $(".csas-institution-banner").fadeIn();
            }
        });
    }

    var flag = 0;
    $(document).ready(function() {
        if(!$(".csas-institution-banner").is(":visible")){
            $(".csasInstitutionBanner").hide();
        }

        $(".banner-close").click(function() {
            $.get("/action/dismissBanner", function(data) {
                $(".csasInstitutionBanner").fadeOut(function () {
                    if(typeof UX !== 'undefined') {
                        UX.pageBody.init();
                    }
                });
            });
        });

        $(".articleContent .tabs li[role='tab'].showFullText").click(function() {
           flag = 1;
        });

        $(document).on("reloadTabsContent", function() {
            var isSelected = $(".articleContent .tabs li[role='tab'].showFullText").hasClass("active");
            if (isSelected) {
                var isHidden =  $(".csas-institution-banner").is(".hidden");
                if (!isHidden) {
                    resetBanner($(".csas-institution-banner").data("doi"));
                    console.log("fadeIn");
                }
            } else {
                $(".csas-institution-banner").fadeOut();
                console.log("fadeOut");
            }
            flag = 0;
        });

        $(document).on("click", ".articleContent .tabs li[role='tab']", function() {

        });
    });
</script></div>
                </div>
                </div>

        
</div></div>

            

        
</header></div>

            

        










        <main data-widget-def="UX3articleContent" data-widget-id="613c3767-893e-4bf8-99cb-7afbffa7b9ed" class="content">
        
    

        


    

            

            

            <article data-widget-id="613c3767-893e-4bf8-99cb-7afbffa7b9ed" data-widget-name="UX3articleContent" data-pii="S0140-6736(20)31208-3"><div id="articleHeader" class="article__header"><div class="article-header"><div class="article-header__overlay"></div><div class="what-image__wrapper"><img data-src="//els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/b51eaa4d-94e7-4ee7-92f5-a884b3ec2256/gr1.jpg" aria-hidden="true" class="what-image b-lazy"></img></div><div class="article-header__wrapper"><div class="article-header__top"><div class="row"><div class="col-md-6"><div class="article-header__meta"><span class="article-header__journal">Articles</span><span class="article-header__sep">|</span><a href="https://www.thelancet.com/journals/lancet/onlinefirst" class="article-header__vol faded">Online First</a><span></span><span class="article-header__date faded"></span></div></div><div class="col-md-6"><div class="article-header__dropZone pb-dropzone" data-pb-dropzone="articleTools-dropzone"><div data-widget-id="daeead20-90ca-40c7-9a88-59138e573056" data-widget-name="UX3ArticleToolsWidget" class="article-tools"><div class="article-tools__wrapper"><span class="article-tools__header"><!--.transplant(data-target="article h1" data-remove="false" data-target-class="hidden-xs hidden-sm" data-toggle="transplant" data-transplant="content")--></span><div class="article-tools__holder pull-right"><ul class="rlist rlist--inline article-tools__list"><li class="article-tools__item article-tools__pdf"><a href="/action/showPdf?pii=S0140-6736%2820%2931208-3" title="Standard PDF (opens in a new tab)" target="_blank" aria-hidden="false" class="article-tools__ctrl article-tools__item__pdf"><i aria-hidden="true" class="icon-gizmo-pdf-file"></i><span class="basic">PDF [889 KB]</span><span class="alternative">Download PDF [889 KB]</span></a></li><li class="article-tools__item article-tools__figures"><div aria-hidden="true" class="dropBlock article-tools__dropblock article-tools__figures"><a href="#" title="open Figures menu" data-db-target-for="article-tools-figures" aria-expanded="false" class="article-tools__ctrl article-tools__item__figures"><i aria-hidden="true" class="icon-gizmo-image_figure"></i><span>Figures</span></a><div data-db-target-of="article-tools-figures" class="dropBlock__holder article-tools__dropblock__holder"><ul class="rlist article-tools__sub-list"><li class="article-tools__sub-item"><a href="#" title="Figure Viewer (opens in a new tab)" target="_blank" class="article-tools__item__displayFigureViewer js--openFigureViewer">Figure Viewer</a></li><li class="article-tools__sub-item"><a href="/journals/lancet/article/PIIS0140-6736(20)31208-3/ppt" title="Download Figures (PPT) (opens in a new tab)" target="_blank" class="article-tools__item__displayDownloadFigures">Download Figures (PPT)</a></li></ul></div></div></li><li class="article-tools__item article-tools__save"><div aria-hidden="false" class="dropBlock article-tools__dropblock article-tools__save"><a href="#" title="open Save menu" data-db-target-for="article-tools-save" aria-expanded="false" class="article-tools__ctrl article-tools__item__save"><i aria-hidden="true" class="icon-gizmo-folder-in"></i><span>Save</span></a><div data-db-target-of="article-tools-save" class="dropBlock__holder article-tools__dropblock__holder"><ul class="rlist article-tools__sub-list"><li class="article-tools__sub-item"><a href="#" title="Add To Online Library" class="article-tools__item__displayAddToOnlineLibrary mendeley">Add To Online Library</a><span class="powered-by"><span>Powered By</span><i class="icon-mendeley"></i><span>Mendeley</span></span></li><li class="article-tools__sub-item"><a href="https://www.thelancet.com/personalize/addFavoritePublication?doi=10.1016%2FS0140-6736%2820%2931208-3" title="Add To My Reading List (opens in a new tab)" target="_blank" class="article-tools__item__displayAddToMyReadingList">Add To My Reading List</a></li><li class="article-tools__sub-item"><a href="https://www.thelancet.com/action/showCitFormats?doi=10.1016%2FS0140-6736%2820%2931208-3&amp;pii=S0140-6736%2820%2931208-3" title="Export Citation (opens in a new tab)" target="_blank" class="article-tools__item__displayExportCitation">Export Citation</a></li><li class="article-tools__sub-item"><a href="https://www.thelancet.com/action/addCitationAlert?doi=10.1016%2FS0140-6736%2820%2931208-3" title="Create Citation Alert (opens in a new tab)" target="_blank" class="article-tools__item__displayCreateCitationAlert">Create Citation Alert</a></li></ul></div></div></li><li class="article-tools__item">
    

        


    

            

            

            <!-- Go to www.addthis.com/dashboard to customize your tools --><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div data-widget-id="0e608a79-d2e8-493e-a0b1-73ebdad146a2" data-widget-name="UX3share" class="dropBlock article-tools__dropblock article-tools__share"><a href="#" data-db-target-for="0e608a79-d2e8-493e-a0b1-73ebdad146a2" aria-expanded="false" class="article-tools__ctrl share__ctrl"><i aria-hidden="true" class="icon-gizmo-share"></i><span>Share</span></a><div data-db-target-of="0e608a79-d2e8-493e-a0b1-73ebdad146a2" id="0e608a79-d2e8-493e-a0b1-73ebdad146a2_Pop" class="share__block dropBlock__holder article-tools__dropblock__holder"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook3"></i><span>Facebook</span></a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter3"></i><span>Twitter</span></a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin3"></i><span>LinkedIn</span></a></li><li><a role="link" class="addthis_button_mendeley"><i aria-hidden="true" class="at-icon-wrapper icon-mendeley"></i><span>Mendeley</span></a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-gizmo-email"></i><span>Email</span></a></li><li><a role="link" class="addthis_button_sinaweibo"><i aria-hidden="true" class="at-icon-wrapper icon-weibo"></i><span>Sina Weibo</span></a></li></ul></div></div>

            

        
</li><li><div class="dropBlock article-tools__dropblock article-tools__more"><a href="#" title="Show more tools menu" data-db-target-for="article-tools-more" aria-expanded="false" class="article-tools__ctrl"><i aria-hidden="true" class="icon-dots-three-horizontal"></i><span>more</span></a><div data-db-target-of="article-tools-more" class="dropBlock__holder article-tools__dropblock__holder"><ul class="rlist"><li><a href="http://reprints.elsevier.com/index.php?option=com_oscommerce&amp;amp;osMod=raq&amp;amp;Itemid=7&amp;amp;publicationName=The Lancet&amp;amp;title=Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial&amp;amp;creator=Feng-Cai+Zhu+and+colleagues&amp;amp;volume=0&amp;amp;number=0&amp;amp;startingPage=&amp;amp;endingPage=" title="Reprints" class="article-tools__item__reprints"><i aria-hidden="true" class="icon-gizmo-reprints"></i><span>Reprints</span></a></li><li><a href="https://s100.copyright.com/AppDispatchServlet?publisherName=ELS&amp;contentID=S0140673620312083&amp;orderBeanReset=true&amp;orderSource=Phoenix" title="Request" class="article-tools__item__request"><i aria-hidden="true" class="icon-copyright"></i><span>Request</span></a></li></ul></div></div></li><li><a href="#" class="back-to-top"><i aria-hidden="true" class="icon-arrow_u_p"></i><span>Top</span></a></li></ul></div></div></div></div></div></div></div><div class="article-header__middle"><h1 class="article-header__title">Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial</h1><span class="article-header__sub-title"></span><ul class="rlist loa inline-bullet-list " data-number-of-author="6"><li class="loa__item author"><div class="dropBlock article-header__info"><a href="#" data-db-target-for="au10-authorcard" aria-expanded="false" aria-controls="au10" class="loa__item__name article-header__info__ctrl loa__item__email" title="Correspondence information about the author Prof Feng-Cai Zhu, MSc ">Prof Feng-Cai Zhu, MSc <i aria-hidden="true" class="icon-gizmo-person faded"></i></a> <a href="#" data-db-target-for="cecref30" aria-expanded="false" aria-controls="cecref30" class="loa__item__name faded article-header__info__ctrl article-header__footnotes"><span><sup>†</sup></span></a><div data-db-target-of="cecref30" class="dropBlock__holder article-header__info__holder lefted"><div class="article-header__info__scrollable"><div class="article-header__info__label">Author Footnotes</div><div class="article-header__info__body"><div title="Footnotes" class="article-header__info__item article-header__info__date">† Contributed equally<br/></div></div><a href="#" title="Close info" class="dropBlock__ctrl--close"><i aria-hidden="true" class="icon-close_thin"></i></a></div></div><div data-db-target-of="au10-authorcard" class="dropBlock__holder article-header__info__holder lefted"><div class="article-header__info__scrollable"><div class="article-header__info__label">Feng-Cai Zhu</div><span class="article-header__info__group__label">Correspondence</span><div class="article-header__info__sub-label">Prof Feng-Cai Zhu, NHC Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing 210009, China</div><div class="article-header__info__body"><div class="article-header__info__social"><a class="article-header__info__email default" href="/cdn-cgi/l/email-protection#d5bfa6afb3b695a3bca5fba6bcbbb4fbb6bab8" title="Send email to Prof Feng-Cai Zhu, MSc "><i aria-hidden="true" class="icon-Email"></i><span>
                            Contact
                        </span></a></div><div class="article-header__info__group"><span class="article-header__info__group__label">Footnotes</span><div class="article-header__info__group__body">† Contributed equally<br/></div></div><div class="article-header__info__group"><span class="article-header__info__group__label">Affiliations</span><div class="article-header__info__group__body">NHC Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, China</div></div><a href="/action/doSearch?searchType=authorLookUp&amp;author=Zhu,&#xA;            Feng-Cai&amp;prod=LN" class="author__search" target="_blank"><i class="icon-arrow_r"></i><span>Search for articles by this author</span></a></div></div><a href="#" title="Close info" class="dropBlock__ctrl--close"><i aria-hidden="true" class="icon-close_thin"></i></a></div></div><div class="dropBlock article-header__info"><a title="Send email to Feng-Cai Zhu" class="loa__item__name  loa__item__email" href="/cdn-cgi/l/email-protection#69031a130f0a291f0019471a000708470a0604"><i aria-hidden="true" class="icon-Email faded"></i></a></div></li><li class="loa__item author"><div class="dropBlock article-header__info"><a href="#" data-db-target-for="au20-authorcard" aria-expanded="false" aria-controls="au20" class="loa__item__name article-header__info__ctrl loa__item__email" title="Correspondence information about the author Prof Yu-Hua Li, PhD ">Prof Yu-Hua Li, PhD </a> <a href="#" data-db-target-for="cecref60" aria-expanded="false" aria-controls="cecref60" class="loa__item__name faded article-header__info__ctrl article-header__footnotes"><span><sup>†</sup></span></a><div data-db-target-of="cecref60" class="dropBlock__holder article-header__info__holder lefted"><div class="article-header__info__scrollable"><div class="article-header__info__label">Author Footnotes</div><div class="article-header__info__body"><div title="Footnotes" class="article-header__info__item article-header__info__date">† Contributed equally<br/></div></div><a href="#" title="Close info" class="dropBlock__ctrl--close"><i aria-hidden="true" class="icon-close_thin"></i></a></div></div><div data-db-target-of="au20-authorcard" class="dropBlock__holder article-header__info__holder lefted"><div class="article-header__info__scrollable"><div class="article-header__info__label">Yu-Hua Li</div><div class="article-header__info__body"><div class="article-header__info__social"><ul class="rlist inline-bullet-list"></ul></div><div class="article-header__info__group"><span class="article-header__info__group__label">Footnotes</span><div class="article-header__info__group__body">† Contributed equally<br/></div></div><div class="article-header__info__group"><span class="article-header__info__group__label">Affiliations</span><div class="article-header__info__group__body">China National Institute for Food and Drug Control, Beijing, China</div></div><a href="/action/doSearch?searchType=authorLookUp&amp;author=Li,&#xA;            Yu-Hua&amp;prod=LN" class="author__search" target="_blank"><i class="icon-arrow_r"></i><span>Search for articles by this author</span></a></div></div><a href="#" title="Close info" class="dropBlock__ctrl--close"><i aria-hidden="true" class="icon-close_thin"></i></a></div></div></li><li class="loa__item author"><div class="dropBlock article-header__info"><a href="#" data-db-target-for="au30-authorcard" aria-expanded="false" aria-controls="au30" class="loa__item__name article-header__info__ctrl loa__item__email" title="Correspondence information about the author Prof Xu-Hua Guan, PhD ">Prof Xu-Hua Guan, PhD </a><div data-db-target-of="au30-authorcard" class="dropBlock__holder article-header__info__holder lefted"><div class="article-header__info__scrollable"><div class="article-header__info__label">Xu-Hua Guan</div><div class="article-header__info__body"><div class="article-header__info__social"><ul class="rlist inline-bullet-list"></ul></div><div class="article-header__info__group"><span class="article-header__info__group__label">Affiliations</span><div class="article-header__info__group__body">Hubei Provincial Center for Disease Control and Prevention, Wuhan, China</div></div><a href="/action/doSearch?searchType=authorLookUp&amp;author=Guan,&#xA;            Xu-Hua&amp;prod=LN" class="author__search" target="_blank"><i class="icon-arrow_r"></i><span>Search for articles by this author</span></a></div></div><a href="#" title="Close info" class="dropBlock__ctrl--close"><i aria-hidden="true" class="icon-close_thin"></i></a></div></div></li><li class="loa__item author"><div class="dropBlock article-header__info"><a href="#" data-db-target-for="au40-authorcard" aria-expanded="false" aria-controls="au40" class="loa__item__name article-header__info__ctrl loa__item__email" title="Correspondence information about the author Prof Li-Hua Hou, PhD ">Prof Li-Hua Hou, PhD </a><div data-db-target-of="au40-authorcard" class="dropBlock__holder article-header__info__holder lefted"><div class="article-header__info__scrollable"><div class="article-header__info__label">Li-Hua Hou</div><div class="article-header__info__body"><div class="article-header__info__social"><ul class="rlist inline-bullet-list"></ul></div><div class="article-header__info__group"><span class="article-header__info__group__label">Affiliations</span><div class="article-header__info__group__body">Beijing Institute of Biotechnology, Beijing, China</div></div><a href="/action/doSearch?searchType=authorLookUp&amp;author=Hou,&#xA;            Li-Hua&amp;prod=LN" class="author__search" target="_blank"><i class="icon-arrow_r"></i><span>Search for articles by this author</span></a></div></div><a href="#" title="Close info" class="dropBlock__ctrl--close"><i aria-hidden="true" class="icon-close_thin"></i></a></div></div></li><li class="loa__item author"><div class="dropBlock article-header__info"><a href="#" data-db-target-for="au50-authorcard" aria-expanded="false" aria-controls="au50" class="loa__item__name article-header__info__ctrl loa__item__email" title="Correspondence information about the author Wen-Juan Wang, MSc ">Wen-Juan Wang, MSc </a><div data-db-target-of="au50-authorcard" class="dropBlock__holder article-header__info__holder lefted"><div class="article-header__info__scrollable"><div class="article-header__info__label">Wen-Juan Wang</div><div class="article-header__info__body"><div class="article-header__info__social"><ul class="rlist inline-bullet-list"></ul></div><div class="article-header__info__group"><span class="article-header__info__group__label">Affiliations</span><div class="article-header__info__group__body">NHC Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, China</div></div><a href="/action/doSearch?searchType=authorLookUp&amp;author=Wang,&#xA;            Wen-Juan&amp;prod=LN" class="author__search" target="_blank"><i class="icon-arrow_r"></i><span>Search for articles by this author</span></a></div></div><a href="#" title="Close info" class="dropBlock__ctrl--close"><i aria-hidden="true" class="icon-close_thin"></i></a></div></div></li><li class="loa__item author"><div class="dropBlock article-header__info"><a href="#" data-db-target-for="au60-authorcard" aria-expanded="false" aria-controls="au60" class="loa__item__name article-header__info__ctrl loa__item__email" title="Correspondence information about the author Prof Jing-Xin Li, PhD ">Prof Jing-Xin Li, PhD </a><div data-db-target-of="au60-authorcard" class="dropBlock__holder article-header__info__holder lefted"><div class="article-header__info__scrollable"><div class="article-header__info__label">Jing-Xin Li</div><div class="article-header__info__body"><div class="article-header__info__social"><ul class="rlist inline-bullet-list"></ul></div><div class="article-header__info__group"><span class="article-header__info__group__label">Affiliations</span><div class="article-header__info__group__body">NHC Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, China</div></div><a href="/action/doSearch?searchType=authorLookUp&amp;author=Li,&#xA;            Jing-Xin&amp;prod=LN" class="author__search" target="_blank"><i class="icon-arrow_r"></i><span>Search for articles by this author</span></a></div></div><a href="#" title="Close info" class="dropBlock__ctrl--close"><i aria-hidden="true" class="icon-close_thin"></i></a></div></div></li><li class="loa__item author"><div class="dropBlock article-header__info"><a href="#" data-db-target-for="au70-authorcard" aria-expanded="false" aria-controls="au70" class="loa__item__name article-header__info__ctrl loa__item__email" title="Correspondence information about the author Shi-Po Wu, PhD ">Shi-Po Wu, PhD </a><div data-db-target-of="au70-authorcard" class="dropBlock__holder article-header__info__holder lefted"><div class="article-header__info__scrollable"><div class="article-header__info__label">Shi-Po Wu</div><div class="article-header__info__body"><div class="article-header__info__social"><ul class="rlist inline-bullet-list"></ul></div><div class="article-header__info__group"><span class="article-header__info__group__label">Affiliations</span><div class="article-header__info__group__body">Beijing Institute of Biotechnology, Beijing, China</div></div><a href="/action/doSearch?searchType=authorLookUp&amp;author=Wu,&#xA;            Shi-Po&amp;prod=LN" class="author__search" target="_blank"><i class="icon-arrow_r"></i><span>Search for articles by this author</span></a></div></div><a href="#" title="Close info" class="dropBlock__ctrl--close"><i aria-hidden="true" class="icon-close_thin"></i></a></div></div></li><li class="loa__item author"><div class="dropBlock article-header__info"><a href="#" data-db-target-for="au80-authorcard" aria-expanded="false" aria-controls="au80" class="loa__item__name article-header__info__ctrl loa__item__email" title="Correspondence information about the author Bu-Sen Wang, PhD ">Bu-Sen Wang, PhD </a><div data-db-target-of="au80-authorcard" class="dropBlock__holder article-header__info__holder lefted"><div class="article-header__info__scrollable"><div class="article-header__info__label">Bu-Sen Wang</div><div class="article-header__info__body"><div class="article-header__info__social"><ul class="rlist inline-bullet-list"></ul></div><div class="article-header__info__group"><span class="article-header__info__group__label">Affiliations</span><div class="article-header__info__group__body">Beijing Institute of Biotechnology, Beijing, China</div></div><a href="/action/doSearch?searchType=authorLookUp&amp;author=Wang,&#xA;            Bu-Sen&amp;prod=LN" class="author__search" target="_blank"><i class="icon-arrow_r"></i><span>Search for articles by this author</span></a></div></div><a href="#" title="Close info" class="dropBlock__ctrl--close"><i aria-hidden="true" class="icon-close_thin"></i></a></div></div></li><li class="loa__item author"><div class="dropBlock article-header__info"><a href="#" data-db-target-for="au90-authorcard" aria-expanded="false" aria-controls="au90" class="loa__item__name article-header__info__ctrl loa__item__email" title="Correspondence information about the author Zhao Wang, MPH ">Zhao Wang, MPH </a><div data-db-target-of="au90-authorcard" class="dropBlock__holder article-header__info__holder lefted"><div class="article-header__info__scrollable"><div class="article-header__info__label">Zhao Wang</div><div class="article-header__info__body"><div class="article-header__info__social"><ul class="rlist inline-bullet-list"></ul></div><div class="article-header__info__group"><span class="article-header__info__group__label">Affiliations</span><div class="article-header__info__group__body">Hubei Provincial Center for Disease Control and Prevention, Wuhan, China</div></div><a href="/action/doSearch?searchType=authorLookUp&amp;author=Wang,&#xA;            Zhao&amp;prod=LN" class="author__search" target="_blank"><i class="icon-arrow_r"></i><span>Search for articles by this author</span></a></div></div><a href="#" title="Close info" class="dropBlock__ctrl--close"><i aria-hidden="true" class="icon-close_thin"></i></a></div></div></li><li class="loa__item author"><div class="dropBlock article-header__info"><a href="#" data-db-target-for="au100-authorcard" aria-expanded="false" aria-controls="au100" class="loa__item__name article-header__info__ctrl loa__item__email" title="Correspondence information about the author Lei Wang, MPH ">Lei Wang, MPH </a><div data-db-target-of="au100-authorcard" class="dropBlock__holder article-header__info__holder lefted"><div class="article-header__info__scrollable"><div class="article-header__info__label">Lei Wang</div><div class="article-header__info__body"><div class="article-header__info__social"><ul class="rlist inline-bullet-list"></ul></div><div class="article-header__info__group"><span class="article-header__info__group__label">Affiliations</span><div class="article-header__info__group__body">Hubei Provincial Center for Disease Control and Prevention, Wuhan, China</div></div><a href="/action/doSearch?searchType=authorLookUp&amp;author=Wang,&#xA;            Lei&amp;prod=LN" class="author__search" target="_blank"><i class="icon-arrow_r"></i><span>Search for articles by this author</span></a></div></div><a href="#" title="Close info" class="dropBlock__ctrl--close"><i aria-hidden="true" class="icon-close_thin"></i></a></div></div></li><li class="loa__item author"><div class="dropBlock article-header__info"><a href="#" data-db-target-for="au110-authorcard" aria-expanded="false" aria-controls="au110" class="loa__item__name article-header__info__ctrl loa__item__email" title="Correspondence information about the author Si-Yue Jia, MPH ">Si-Yue Jia, MPH </a><div data-db-target-of="au110-authorcard" class="dropBlock__holder article-header__info__holder lefted"><div class="article-header__info__scrollable"><div class="article-header__info__label">Si-Yue Jia</div><div class="article-header__info__body"><div class="article-header__info__social"><ul class="rlist inline-bullet-list"></ul></div><div class="article-header__info__group"><span class="article-header__info__group__label">Affiliations</span><div class="article-header__info__group__body">NHC Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, China</div></div><a href="/action/doSearch?searchType=authorLookUp&amp;author=Jia,&#xA;            Si-Yue&amp;prod=LN" class="author__search" target="_blank"><i class="icon-arrow_r"></i><span>Search for articles by this author</span></a></div></div><a href="#" title="Close info" class="dropBlock__ctrl--close"><i aria-hidden="true" class="icon-close_thin"></i></a></div></div></li><li class="loa__item author"><div class="dropBlock article-header__info"><a href="#" data-db-target-for="au120-authorcard" aria-expanded="false" aria-controls="au120" class="loa__item__name article-header__info__ctrl loa__item__email" title="Correspondence information about the author Hu-Dachuan Jiang, BSc ">Hu-Dachuan Jiang, BSc </a><div data-db-target-of="au120-authorcard" class="dropBlock__holder article-header__info__holder lefted"><div class="article-header__info__scrollable"><div class="article-header__info__label">Hu-Dachuan Jiang</div><div class="article-header__info__body"><div class="article-header__info__social"><ul class="rlist inline-bullet-list"></ul></div><div class="article-header__info__group"><span class="article-header__info__group__label">Affiliations</span><div class="article-header__info__group__body">NHC Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, China</div></div><a href="/action/doSearch?searchType=authorLookUp&amp;author=Jiang,&#xA;            Hu-Dachuan&amp;prod=LN" class="author__search" target="_blank"><i class="icon-arrow_r"></i><span>Search for articles by this author</span></a></div></div><a href="#" title="Close info" class="dropBlock__ctrl--close"><i aria-hidden="true" class="icon-close_thin"></i></a></div></div></li><li class="loa__item author"><div class="dropBlock article-header__info"><a href="#" data-db-target-for="au130-authorcard" aria-expanded="false" aria-controls="au130" class="loa__item__name article-header__info__ctrl loa__item__email" title="Correspondence information about the author Ling Wang, PhD ">Ling Wang, PhD </a><div data-db-target-of="au130-authorcard" class="dropBlock__holder article-header__info__holder lefted"><div class="article-header__info__scrollable"><div class="article-header__info__label">Ling Wang</div><div class="article-header__info__body"><div class="article-header__info__social"><ul class="rlist inline-bullet-list"></ul></div><div class="article-header__info__group"><span class="article-header__info__group__label">Affiliations</span><div class="article-header__info__group__body">China National Institute for Food and Drug Control, Beijing, China</div></div><a href="/action/doSearch?searchType=authorLookUp&amp;author=Wang,&#xA;            Ling&amp;prod=LN" class="author__search" target="_blank"><i class="icon-arrow_r"></i><span>Search for articles by this author</span></a></div></div><a href="#" title="Close info" class="dropBlock__ctrl--close"><i aria-hidden="true" class="icon-close_thin"></i></a></div></div></li><li class="loa__item author"><div class="dropBlock article-header__info"><a href="#" data-db-target-for="au140-authorcard" aria-expanded="false" aria-controls="au140" class="loa__item__name article-header__info__ctrl loa__item__email" title="Correspondence information about the author Prof Tao Jiang, PhD ">Prof Tao Jiang, PhD </a><div data-db-target-of="au140-authorcard" class="dropBlock__holder article-header__info__holder lefted"><div class="article-header__info__scrollable"><div class="article-header__info__label">Tao Jiang</div><div class="article-header__info__body"><div class="article-header__info__social"><ul class="rlist inline-bullet-list"></ul></div><div class="article-header__info__group"><span class="article-header__info__group__label">Affiliations</span><div class="article-header__info__group__body">Beijing Institute of Microbiology and Epidemiology, State Key Laboratory of Pathogen and Biosecurity, Beijing, China</div></div><a href="/action/doSearch?searchType=authorLookUp&amp;author=Jiang,&#xA;            Tao&amp;prod=LN" class="author__search" target="_blank"><i class="icon-arrow_r"></i><span>Search for articles by this author</span></a></div></div><a href="#" title="Close info" class="dropBlock__ctrl--close"><i aria-hidden="true" class="icon-close_thin"></i></a></div></div></li><li class="loa__item author"><div class="dropBlock article-header__info"><a href="#" data-db-target-for="au150-authorcard" aria-expanded="false" aria-controls="au150" class="loa__item__name article-header__info__ctrl loa__item__email" title="Correspondence information about the author Yi Hu, PhD ">Yi Hu, PhD </a><div data-db-target-of="au150-authorcard" class="dropBlock__holder article-header__info__holder lefted"><div class="article-header__info__scrollable"><div class="article-header__info__label">Yi Hu</div><div class="article-header__info__body"><div class="article-header__info__social"><ul class="rlist inline-bullet-list"></ul></div><div class="article-header__info__group"><span class="article-header__info__group__label">Affiliations</span><div class="article-header__info__group__body">Beijing Institute of Microbiology and Epidemiology, State Key Laboratory of Pathogen and Biosecurity, Beijing, China</div></div><a href="/action/doSearch?searchType=authorLookUp&amp;author=Hu,&#xA;            Yi&amp;prod=LN" class="author__search" target="_blank"><i class="icon-arrow_r"></i><span>Search for articles by this author</span></a></div></div><a href="#" title="Close info" class="dropBlock__ctrl--close"><i aria-hidden="true" class="icon-close_thin"></i></a></div></div></li><li class="loa__item author"><div class="dropBlock article-header__info"><a href="#" data-db-target-for="au160-authorcard" aria-expanded="false" aria-controls="au160" class="loa__item__name article-header__info__ctrl loa__item__email" title="Correspondence information about the author Jin-Bo Gou, PhD ">Jin-Bo Gou, PhD </a><div data-db-target-of="au160-authorcard" class="dropBlock__holder article-header__info__holder lefted"><div class="article-header__info__scrollable"><div class="article-header__info__label">Jin-Bo Gou</div><div class="article-header__info__body"><div class="article-header__info__social"><ul class="rlist inline-bullet-list"></ul></div><div class="article-header__info__group"><span class="article-header__info__group__label">Affiliations</span><div class="article-header__info__group__body">CanSino Biologics, Tianjin, China</div></div><a href="/action/doSearch?searchType=authorLookUp&amp;author=Gou,&#xA;            Jin-Bo&amp;prod=LN" class="author__search" target="_blank"><i class="icon-arrow_r"></i><span>Search for articles by this author</span></a></div></div><a href="#" title="Close info" class="dropBlock__ctrl--close"><i aria-hidden="true" class="icon-close_thin"></i></a></div></div></li><li class="loa__item author"><div class="dropBlock article-header__info"><a href="#" data-db-target-for="au170-authorcard" aria-expanded="false" aria-controls="au170" class="loa__item__name article-header__info__ctrl loa__item__email" title="Correspondence information about the author Prof Sha-Bei Xu, PhD ">Prof Sha-Bei Xu, PhD </a><div data-db-target-of="au170-authorcard" class="dropBlock__holder article-header__info__holder lefted"><div class="article-header__info__scrollable"><div class="article-header__info__label">Sha-Bei Xu</div><div class="article-header__info__body"><div class="article-header__info__social"><ul class="rlist inline-bullet-list"></ul></div><div class="article-header__info__group"><span class="article-header__info__group__label">Affiliations</span><div class="article-header__info__group__body">Clinical Research Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China</div></div><a href="/action/doSearch?searchType=authorLookUp&amp;author=Xu,&#xA;            Sha-Bei&amp;prod=LN" class="author__search" target="_blank"><i class="icon-arrow_r"></i><span>Search for articles by this author</span></a></div></div><a href="#" title="Close info" class="dropBlock__ctrl--close"><i aria-hidden="true" class="icon-close_thin"></i></a></div></div></li><li class="loa__item author"><div class="dropBlock article-header__info"><a href="#" data-db-target-for="au180-authorcard" aria-expanded="false" aria-controls="au180" class="loa__item__name article-header__info__ctrl loa__item__email" title="Correspondence information about the author Prof Jun-Jie Xu, PhD ">Prof Jun-Jie Xu, PhD </a><div data-db-target-of="au180-authorcard" class="dropBlock__holder article-header__info__holder lefted"><div class="article-header__info__scrollable"><div class="article-header__info__label">Jun-Jie Xu</div><div class="article-header__info__body"><div class="article-header__info__social"><ul class="rlist inline-bullet-list"></ul></div><div class="article-header__info__group"><span class="article-header__info__group__label">Affiliations</span><div class="article-header__info__group__body">Beijing Institute of Biotechnology, Beijing, China</div></div><a href="/action/doSearch?searchType=authorLookUp&amp;author=Xu,&#xA;            Jun-Jie&amp;prod=LN" class="author__search" target="_blank"><i class="icon-arrow_r"></i><span>Search for articles by this author</span></a></div></div><a href="#" title="Close info" class="dropBlock__ctrl--close"><i aria-hidden="true" class="icon-close_thin"></i></a></div></div></li><li class="loa__item author"><div class="dropBlock article-header__info"><a href="#" data-db-target-for="au190-authorcard" aria-expanded="false" aria-controls="au190" class="loa__item__name article-header__info__ctrl loa__item__email" title="Correspondence information about the author Xue-Wen Wang, MD ">Xue-Wen Wang, MD </a><div data-db-target-of="au190-authorcard" class="dropBlock__holder article-header__info__holder lefted"><div class="article-header__info__scrollable"><div class="article-header__info__label">Xue-Wen Wang</div><div class="article-header__info__body"><div class="article-header__info__social"><ul class="rlist inline-bullet-list"></ul></div><div class="article-header__info__group"><span class="article-header__info__group__label">Affiliations</span><div class="article-header__info__group__body">Shanghai Canming Medical Technology, Shanghai, China</div></div><a href="/action/doSearch?searchType=authorLookUp&amp;author=Wang,&#xA;            Xue-Wen&amp;prod=LN" class="author__search" target="_blank"><i class="icon-arrow_r"></i><span>Search for articles by this author</span></a></div></div><a href="#" title="Close info" class="dropBlock__ctrl--close"><i aria-hidden="true" class="icon-close_thin"></i></a></div></div></li><li class="loa__item author"><div class="dropBlock article-header__info"><a href="#" data-db-target-for="au200-authorcard" aria-expanded="false" aria-controls="au200" class="loa__item__name article-header__info__ctrl loa__item__email" title="Correspondence information about the author Prof Wei Wang, PhD ">Prof Wei Wang, PhD <i aria-hidden="true" class="icon-gizmo-person faded"></i></a><div data-db-target-of="au200-authorcard" class="dropBlock__holder article-header__info__holder lefted"><div class="article-header__info__scrollable"><div class="article-header__info__label">Wei Wang</div><span class="article-header__info__group__label">Correspondence</span><div class="article-header__info__sub-label">Prof Wei Wang, Clinical Research Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430032, China</div><div class="article-header__info__body"><div class="article-header__info__social"><a class="article-header__info__email default" href="/cdn-cgi/l/email-protection#106767717e77506679603e2122263e737f7d" title="Send email to Prof Wei Wang, PhD "><i aria-hidden="true" class="icon-Email"></i><span>
                            Contact
                        </span></a></div><div class="article-header__info__group"><span class="article-header__info__group__label">Affiliations</span><div class="article-header__info__group__body">Clinical Research Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China</div></div><a href="/action/doSearch?searchType=authorLookUp&amp;author=Wang,&#xA;            Wei&amp;prod=LN" class="author__search" target="_blank"><i class="icon-arrow_r"></i><span>Search for articles by this author</span></a></div></div><a href="#" title="Close info" class="dropBlock__ctrl--close"><i aria-hidden="true" class="icon-close_thin"></i></a></div></div><div class="dropBlock article-header__info"><a title="Send email to Wei Wang" class="loa__item__name  loa__item__email" href="/cdn-cgi/l/email-protection#dbacacbab5bc9badb2abf5eae9edf5b8b4b6"><i aria-hidden="true" class="icon-Email faded"></i></a></div></li><li class="loa__item author"><div class="dropBlock article-header__info"><a href="#" data-db-target-for="au210-authorcard" aria-expanded="false" aria-controls="au210" class="loa__item__name article-header__info__ctrl loa__item__email" title="Correspondence information about the author Prof Wei Chen, PhD ">Prof Wei Chen, PhD <i aria-hidden="true" class="icon-gizmo-person faded"></i></a><div data-db-target-of="au210-authorcard" class="dropBlock__holder article-header__info__holder lefted"><div class="article-header__info__scrollable"><div class="article-header__info__label">Wei Chen</div><span class="article-header__info__group__label">Correspondence</span><div class="article-header__info__sub-label">Correspondence to: Prof Wei Chen, Beijing Institute of Biotechnology, Beijing 100071, China</div><div class="article-header__info__body"><div class="article-header__info__social"><a class="article-header__info__email default" href="/cdn-cgi/l/email-protection#0261753230303442646d7a6f636b6e2c616d6f" title="Send email to Prof Wei Chen, PhD "><i aria-hidden="true" class="icon-Email"></i><span>
                            Contact
                        </span></a></div><div class="article-header__info__group"><span class="article-header__info__group__label">Affiliations</span><div class="article-header__info__group__body">Beijing Institute of Biotechnology, Beijing, China</div></div><a href="/action/doSearch?searchType=authorLookUp&amp;author=Chen,&#xA;            Wei&amp;prod=LN" class="author__search" target="_blank"><i class="icon-arrow_r"></i><span>Search for articles by this author</span></a></div></div><a href="#" title="Close info" class="dropBlock__ctrl--close"><i aria-hidden="true" class="icon-close_thin"></i></a></div></div><div class="dropBlock article-header__info"><a title="Send email to Wei Chen" class="loa__item__name  loa__item__email" href="/cdn-cgi/l/email-protection#c0a3b7f0f2f2f680a6afb8ada1a9aceea3afad"><i aria-hidden="true" class="icon-Email faded"></i></a></div></li> <li class="loa__item"><div class="dropBlock article-header__info article-header__footnotes"><a href="#" data-db-target-for="foot-notes" aria-expanded="false" aria-controls="" class="loa__item__name faded article-header__info__ctrl article-header__footnotes"><span class="show">Show footnotes</span><span class="hide">Hide footnotes</span></a><div data-db-target-of="foot-notes" class="dropBlock__holder article-header__info__holder lefted"><div class="article-header__info__scrollable"><div class="article-header__info__label">Author Footnotes</div><div class="article-header__info__body"><div title="Footnotes" class="article-header__info__item article-header__info__date">† Contributed equally<br/></div></div><a href="#" title="Close info" class="dropBlock__ctrl--close"><i aria-hidden="true" class="icon-close_thin"></i></a></div></div></div></li></ul><div class="inline-it"><span class="article-header__publish-date bulleted"><span class="article-header__publish-date__label">Published:</span><span class="article-header__publish-date__value">May 22, 2020</span></span><span class="article-header__doi bulleted"><span class="article-header__doi__label">DOI:</span><a class="article-header__doi__value" href="https://doi.org/10.1016/S0140-6736(20)31208-3">https://doi.org/10.1016/S0140-6736(20)31208-3</a></span><span class="article-header__mark bulleted"><a id="open-crossmark" data-target="crossmark"><img id="crossmark-icon" width="150" src="//crossmark-cdn.crossref.org/widget/v2.0/logos/CROSSMARK_Color_horizontal.svg"></img></a><meta name="dc.identifier" scheme="doi" content="doi:10.1016/S0140-6736(20)31208-3"></meta></span></div></div><div class="article-header__bottom clearfix row"><div class="col-md-6 static-md"></div><div class="col-md-6 static-md"><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" src="//d39af2mgp1pqhg.cloudfront.net/widget-popup.js"></script><a href="https://plu.mx/plum/a/?doi=10.1016/S0140-6736(20)31208-3" class="plumx-plum-print-popup plum-jbs-theme article-header__metrics" data-popup="left" data-hide-when-empty="true" data-hide-usage="true" data-pass-hidden-categories="true" data-site="plum" data-badge="true" data-size="small">Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial</a></div></div></div><div class="article-header__dropZone pb-dropzone" data-pb-dropzone="articleNavigation-Dropzone"><div data-widget-id="45024cb7-3a38-4932-876d-1ddfe7426788" data-widget-name="UX3ArticleNavigation" class="content-navigation clearfix"><div class="content-navigation__extra"></div><div class="content-navigation__btn__wrapper--next"><a href="/journals/lancet/article/PIIS0140-6736(20)31180-6/fulltext" title="Next Article" class="content-navigation__btn--next default"><span class="content-navigation__body next"><span class="content-navigation__body__top">Next Article</span><span class="content-navigation__body__title">Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis</span></span><i aria-hidden="true" class="icon-arrow_r"></i></a></div></div></div></div></div><div class="article__body"><button title="open table of sections" aria-label="open table of sections" type="button" class="left-side-nav__ctrl"><i aria-hidden="true" class="icon-sub-menu"></i></button><div class="left-side-nav col-md-2 col-lg-1"><ul class="rlist left-side-nav__upper"></ul><ul class="rlist left-side-nav__bottom"></ul></div><div class="adplaceholders hidden-xs hidden-sm">
    

        


    

            

            

            <div data-widget-id="99e315f6-ba9f-411b-a345-4bd3b79d4800" data-widget-name="UX3HTMLWidget"><!--HubSpot Call-to-Action Code --><span class="hs-cta-wrapper" id="hs-cta-wrapper-79472462-b4ce-48bc-a460-7e5d92c4f21f"><span class="hs-cta-node hs-cta-79472462-b4ce-48bc-a460-7e5d92c4f21f" id="hs-cta-79472462-b4ce-48bc-a460-7e5d92c4f21f"><!--[if lte IE 8]><div id="hs-cta-ie-element"></div><![endif]--><a href="https://cta-redirect.hubspot.com/cta/redirect/3798016/79472462-b4ce-48bc-a460-7e5d92c4f21f"  target="_blank" ><img class="hs-cta-img" id="hs-cta-img-79472462-b4ce-48bc-a460-7e5d92c4f21f" style="border-width:0px;" src="https://no-cache.hubspot.com/cta/default/3798016/79472462-b4ce-48bc-a460-7e5d92c4f21f.png"  alt="Recommend this journal  to your librarian"/></a></span><script charset="utf-8" src="https://js.hscta.net/cta/current.js"></script><script type="text/javascript"> hbspt.cta.load(3798016, '79472462-b4ce-48bc-a460-7e5d92c4f21f', {}); </script></span><!-- end HubSpot Call-to-Action Code --></div>

            

        

    

        


    

                
                
                
                
                
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                        
                        
                        
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                
                
                <div class="widget literatumAd alignCenter  widget-verticalAd" id="c54c51f6-527b-4406-9aea-c93b1e1c1e66">
                
                

                <div class="wrapped " >
                    
                    <div class="widget-body body body-verticalAd "><div class="verticalAdContainer">
    <div class="verticalAdLabelContainer">
        <div class="verticalAdLabel">
                <img src="/templates/jsp/_style2/_marlin/images/bg_adVert.gif" alt="Advertisement"/>
        </div>
    </div>
    <div class="verticalAd">
        





        <div class="pb-ad">
            <div class="gpt-ad disableStickySidebar" data-adsize="skyscraper"></div>
        </div>
    

    </div>
</div></div>
                </div>
                </div>

        


</div><div class="container"><div class="row"><div class="col-md-2 col-lg-1 hidden-sm"></div><div class="col-md-7 col-lg-9 article__sections"><section><h2 class="top" id="seccestitle10" data-left-hand-nav="Summary"><span class="top__sub"></span><span class="top__text">Summary</span></h2><div class="section-paragraph"><h3>Background</h3><div class="section-paragraph">A vaccine to protect against COVID-19 is urgently needed. We aimed to assess the safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 (Ad5) vectored COVID-19 vaccine expressing the spike glycoprotein of a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) strain.</div><h3>Methods</h3><div class="section-paragraph">We did a dose-escalation, single-centre, open-label, non-randomised, phase 1 trial of an Ad5 vectored COVID-19 vaccine in Wuhan, China. Healthy adults aged between 18 and 60 years were sequentially enrolled and allocated to one of three dose groups (5 × 10<sup>10</sup>, 1 × 10<sup>11</sup>, and 1·5 × 10<sup>11</sup> viral particles) to receive an intramuscular injection of vaccine. The primary outcome was adverse events in the 7 days post-vaccination. Safety was assessed over 28 days post-vaccination. Specific antibodies were measured with ELISA, and the neutralising antibody responses induced by vaccination were detected with SARS-CoV-2 virus neutralisation and pseudovirus neutralisation tests. T-cell responses were assessed by enzyme-linked immunospot and flow-cytometry assays. This study is registered with <a href="http://ClinicalTrials.gov" target="_blank">ClinicalTrials.gov</a>, <a href="http://clinicaltrials.gov/show/NCT04313127" target="_blank">NCT04313127</a>.</div><h3>Findings</h3><div class="section-paragraph">Between March 16 and March 27, 2020, we screened 195 individuals for eligibility. Of them, 108 participants (51% male, 49% female; mean age 36·3 years) were recruited and received the low dose (n=36), middle dose (n=36), or high dose (n=36) of the vaccine. All enrolled participants were included in the analysis. At least one adverse reaction within the first 7 days after the vaccination was reported in 30 (83%) participants in the low dose group, 30 (83%) participants in the middle dose group, and 27 (75%) participants in the high dose group. The most common injection site adverse reaction was pain, which was reported in 58 (54%) vaccine recipients, and the most commonly reported systematic adverse reactions were fever (50 [46%]), fatigue (47 [44%]), headache (42 [39%]), and muscle pain (18 [17%]. Most adverse reactions that were reported in all dose groups were mild or moderate in severity. No serious adverse event was noted within 28 days post-vaccination. ELISA antibodies and neutralising antibodies increased significantly at day 14, and peaked 28 days post-vaccination. Specific T-cell response peaked at day 14 post-vaccination.</div><h3>Interpretation</h3><div class="section-paragraph">The Ad5 vectored COVID-19 vaccine is tolerable and immunogenic at 28 days post-vaccination. Humoral responses against SARS-CoV-2 peaked at day 28 post-vaccination in healthy adults, and rapid specific T-cell responses were noted from day 14 post-vaccination. Our findings suggest that the Ad5 vectored COVID-19 vaccine warrants further investigation.</div><h3>Funding</h3><div class="section-paragraph">National Key R&amp;D Program of China, National Science and Technology Major Project, and CanSino Biologics.</div></div></section><div data-pb-dropzone="relatedItems-dropzone" class="relatedItems-dropzone pb-dropzone"><div data-widget-id="6211e606-91ef-4fed-96eb-a6bff90d54e7" data-widget-name="UX3HTMLWidget"><div id="related-links-container"></div></div></div><section id="cesec10" data-locator="cesec10"><h2 class="top" id="seccestitle70" data-left-hand-nav="Introduction"><span class="top__sub"></span><span class="top__text">Introduction</span></h2><div class="section-paragraph">Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first reported in January, 2020. The virus is highly transmissible between humans and has spread rapidly, causing the COVID-19 pandemic.<div class="dropBlock reference-citations"><sup><a href="#" id="back-bib1" data-db-target-for="bib1-d13208547e1243" class="reference-citations__ctrl" aria-expanded="false" aria-controls="bib1">1</a></sup><div data-db-target-of="bib1-d13208547e1243" class="dropBlock__holder"><div class="dropBlock__body"><ul title="list of authors" class="rlist reference-citations__loa inline-bullet-list"><li class="loa__item">Zhu N </li><li class="loa__item">Zhang D </li><li class="loa__item">Wang W </li><li>et al.</li></ul><div class="reference-citations__detials">A novel coronavirus from patients with pneumonia in China, 2019.<div class="popup-ref"><span class="ref__series"><i>N Engl J Med.</i> <span class="ref__seriesDate">2020; </span><span class="ref__seriesVolume">382</span></span>: <span class="ref__seriesPages">727-733</span></div></div><div class="reference-citations__links"><ul class="rlist inline-bullet-list"><li><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=382&publication_year=2020&pages=727-733&journal=N+Engl+J+Med&author=Zhu+N&author=Zhang+D&author=Wang+W&title=A+novel+coronavirus+from+patients+with+pneumonia+in+China%2C+2019">Google Scholar</a></li></ul></div></div><a href="#" class="dropBlock__ctrl--close" title="Close info"><i aria-hidden="true" class="icon-close_thin"></i></a></div></div><sup>, </sup> <div class="dropBlock reference-citations"><sup><a href="#" id="back-bib2" data-db-target-for="bib2-d13208547e1243" class="reference-citations__ctrl" aria-expanded="false" aria-controls="bib2">2</a></sup><div data-db-target-of="bib2-d13208547e1243" class="dropBlock__holder"><div class="dropBlock__body"><ul title="list of authors" class="rlist reference-citations__loa inline-bullet-list"><li class="loa__item">Li Q </li><li class="loa__item">Guan X </li><li class="loa__item">Wu P </li><li>et al.</li></ul><div class="reference-citations__detials">Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia.<div class="popup-ref"><span class="ref__series"><i>N Engl J Med.</i> <span class="ref__seriesDate">2020; </span><span class="ref__seriesVolume">382</span></span>: <span class="ref__seriesPages">1199-1207</span></div></div><div class="reference-citations__links"><ul class="rlist inline-bullet-list"><li><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=382&publication_year=2020&pages=1199-1207&journal=N+Engl+J+Med&author=Li+Q&author=Guan+X&author=Wu+P&title=Early+transmission+dynamics+in+Wuhan%2C+China%2C+of+novel+coronavirus-infected+pneumonia">Google Scholar</a></li></ul></div></div><a href="#" class="dropBlock__ctrl--close" title="Close info"><i aria-hidden="true" class="icon-close_thin"></i></a></div></div> Patients infected with SARS-CoV-2, especially older patients and those with pre-existing respiratory or cardiovascular conditions are at greater risk for severe complications, including severe pneumonia, acute respiratory distress syndrome, multiple organ failure, and in some cases, death.<div class="dropBlock reference-citations"><sup><a href="#" id="back-bib3" data-db-target-for="bib3-d13208547e1247" class="reference-citations__ctrl" aria-expanded="false" aria-controls="bib3">3</a></sup><div data-db-target-of="bib3-d13208547e1247" class="dropBlock__holder"><div class="dropBlock__body"><ul title="list of authors" class="rlist reference-citations__loa inline-bullet-list"><li class="loa__item">Grein J </li><li class="loa__item">Ohmagari N </li><li class="loa__item">Shin D </li><li>et al.</li></ul><div class="reference-citations__detials">Compassionate use of remdesivir for patients with severe Covid-19.<div class="popup-ref"><span class="ref__series"><i>N Engl J Med.</i> <span class="ref__seriesDate">2020; </span><span class="ref__seriesVolume"></span> (<span class="refComment">published online April 10.</span>)</span><div class="citation-host"><a href="http://dx.doi.org/10.1056/NEJMoa2007016NEJMoa2007016" target="_blank">DOI:10.1056/NEJMoa2007016NEJMoa2007016</a></div></div></div><div class="reference-citations__links"><ul class="rlist inline-bullet-list"><li><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&journal=N+Engl+J+Med&author=Grein+J&author=Ohmagari+N&author=Shin+D&title=Compassionate+use+of+remdesivir+for+patients+with+severe+Covid-19">Google Scholar</a></li></ul></div></div><a href="#" class="dropBlock__ctrl--close" title="Close info"><i aria-hidden="true" class="icon-close_thin"></i></a></div></div><sup>, </sup> <div class="dropBlock reference-citations"><sup><a href="#" id="back-bib4" data-db-target-for="bib4-d13208547e1247" class="reference-citations__ctrl" aria-expanded="false" aria-controls="bib4">4</a></sup><div data-db-target-of="bib4-d13208547e1247" class="dropBlock__holder"><div class="dropBlock__body"><ul title="list of authors" class="rlist reference-citations__loa inline-bullet-list"><li class="loa__item">Weiss P </li><li class="loa__item">Murdoch DR </li></ul><div class="reference-citations__detials">Clinical course and mortality risk of severe COVID-19.<div class="popup-ref"><span class="ref__series"><i>Lancet.</i> <span class="ref__seriesDate">2020; </span><span class="ref__seriesVolume">395</span></span>: <span class="ref__seriesPages">1014-1015</span></div></div><div class="reference-citations__links"><ul class="rlist inline-bullet-list"><li><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=395&publication_year=2020&pages=1014-1015&journal=Lancet&author=Weiss+P&author=Murdoch+DR&title=Clinical+course+and+mortality+risk+of+severe+COVID-19">Google Scholar</a></li></ul></div></div><a href="#" class="dropBlock__ctrl--close" title="Close info"><i aria-hidden="true" class="icon-close_thin"></i></a></div></div> By May 20, 2020, SARS-CoV-2 had infected more than 4·7 million people across 215 countries or territories and killed more than 316 000 worldwide.<div class="dropBlock reference-citations"><sup><a href="#bib5" id="back-bib5" data-db-target-for="bib5-d13208547e1251" class="reference-citations__ctrl" aria-expanded="false" aria-controls="bib5">5</a></sup><div data-db-target-of="bib5-d13208547e1251" class="dropBlock__holder"><div class="dropBlock__body"><div class="reference-citations__detials"><span>WHO</span><br />Coronavirus disease (COVID-2019) situation reports.<div class="popup-ref"><div class="citation-host"><a href="https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports" target="_blank">https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports</a><div><span>Date: </span>2020</div><div><span>Date accessed: </span>May 5, 2020</div></div></div></div><div class="reference-citations__links"><ul class="rlist inline-bullet-list"><li><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=WHO&title=Coronavirus+disease+%28COVID-2019%29+situation+reports">Google Scholar</a></li></ul></div></div><a href="#" class="dropBlock__ctrl--close" title="Close info"><i aria-hidden="true" class="icon-close_thin"></i></a></div></div></div><div class="section-paragraph">In the absence of effective prevention measures, current management to control the epidemic is the enforcement of quarantine, isolation, and physical distancing.<div class="dropBlock reference-citations"><sup><a href="#" id="back-bib6" data-db-target-for="bib6-d13208547e1256" class="reference-citations__ctrl" aria-expanded="false" aria-controls="bib6">6</a></sup><div data-db-target-of="bib6-d13208547e1256" class="dropBlock__holder"><div class="dropBlock__body"><ul title="list of authors" class="rlist reference-citations__loa inline-bullet-list"><li class="loa__item">Cowling BJ </li><li class="loa__item">Ali ST </li><li class="loa__item">Ng TWY </li><li>et al.</li></ul><div class="reference-citations__detials">Impact assessment of non-pharmaceutical interventions against coronavirus disease 2019 and influenza in Hong Kong: an observational study.<div class="popup-ref"><span class="ref__series"><i>Lancet Public Health.</i> <span class="ref__seriesDate">2020; </span><span class="ref__seriesVolume">5</span></span>: <span class="ref__seriesPages">e279-e288</span></div></div><div class="reference-citations__links"><ul class="rlist inline-bullet-list"><li><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2020&pages=e279-e288&journal=Lancet+Public+Health&author=Cowling+BJ&author=Ali+ST&author=Ng+TWY&title=Impact+assessment+of+non-pharmaceutical+interventions+against+coronavirus+disease+2019+and+influenza+in+Hong+Kong%3A+an+observational+study">Google Scholar</a></li></ul></div></div><a href="#" class="dropBlock__ctrl--close" title="Close info"><i aria-hidden="true" class="icon-close_thin"></i></a></div></div><sup>, </sup> <div class="dropBlock reference-citations"><sup><a href="#" id="back-bib7" data-db-target-for="bib7-d13208547e1256" class="reference-citations__ctrl" aria-expanded="false" aria-controls="bib7">7</a></sup><div data-db-target-of="bib7-d13208547e1256" class="dropBlock__holder"><div class="dropBlock__body"><ul title="list of authors" class="rlist reference-citations__loa inline-bullet-list"><li class="loa__item">Gudbjartsson DF </li><li class="loa__item">Helgason A </li><li class="loa__item">Jonsson H </li><li>et al.</li></ul><div class="reference-citations__detials">Spread of SARS-CoV-2 in the Icelandic population.<div class="popup-ref"><span class="ref__series"><i>N Engl J Med.</i> <span class="ref__seriesDate">2020; </span><span class="ref__seriesVolume"></span> (<span class="refComment">published online April 14.</span>)</span><div class="citation-host"><a href="http://dx.doi.org/10.1056/NEJMoa2006100" target="_blank">DOI:10.1056/NEJMoa2006100</a></div></div></div><div class="reference-citations__links"><ul class="rlist inline-bullet-list"><li><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&journal=N+Engl+J+Med&author=Gudbjartsson+DF&author=Helgason+A&author=Jonsson+H&title=Spread+of+SARS-CoV-2+in+the+Icelandic+population">Google Scholar</a></li></ul></div></div><a href="#" class="dropBlock__ctrl--close" title="Close info"><i aria-hidden="true" class="icon-close_thin"></i></a></div></div> Effective vaccines against COVID-19 are urgently needed to reduce the enormous burden of mortality and morbidity associated with SARS-CoV-2 infection.<div class="dropBlock reference-citations"><sup><a href="#bib8" id="back-bib8" data-db-target-for="bib8-d13208547e1260" class="reference-citations__ctrl" aria-expanded="false" aria-controls="bib8">8</a></sup><div data-db-target-of="bib8-d13208547e1260" class="dropBlock__holder"><div class="dropBlock__body"><ul title="list of authors" class="rlist reference-citations__loa inline-bullet-list"><li class="loa__item">Amanat F </li><li class="loa__item">Krammer F </li></ul><div class="reference-citations__detials">SARS-CoV-2 vaccines: status report.<div class="popup-ref"><span class="ref__series"><i>Immunity.</i> <span class="ref__seriesDate">2020; </span><span class="ref__seriesVolume">52</span></span>: <span class="ref__seriesPages">583-589</span></div></div><div class="reference-citations__links"><ul class="rlist inline-bullet-list"><li><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2020&pages=583-589&journal=Immunity&author=Amanat+F&author=Krammer+F&title=SARS-CoV-2+vaccines%3A+status+report">Google Scholar</a></li></ul></div></div><a href="#" class="dropBlock__ctrl--close" title="Close info"><i aria-hidden="true" class="icon-close_thin"></i></a></div></div> There are more than 100 candidate vaccines in development worldwide,<div class="dropBlock reference-citations"><sup><a href="#bib9" id="back-bib9" data-db-target-for="bib9-d13208547e1264" class="reference-citations__ctrl" aria-expanded="false" aria-controls="bib9">9</a></sup><div data-db-target-of="bib9-d13208547e1264" class="dropBlock__holder"><div class="dropBlock__body"><div class="reference-citations__detials"><span>WHO</span><br />DRAFT landscape of COVID-19 candidate vaccines–30 April 2020.<div class="popup-ref"><div class="citation-host"><a href="https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines" target="_blank">https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines</a><div><span>Date: </span>2020</div><div><span>Date accessed: </span>May 5, 2020</div></div></div></div><div class="reference-citations__links"><ul class="rlist inline-bullet-list"><li><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=WHO&title=DRAFT+landscape+of+COVID-19+candidate+vaccines%E2%80%9330+April+2020">Google Scholar</a></li></ul></div></div><a href="#" class="dropBlock__ctrl--close" title="Close info"><i aria-hidden="true" class="icon-close_thin"></i></a></div></div> among them at least eight have started or will soon start clinical trials. These include Moderna's mRNA COVID-19 vaccine and CanSino's non-replicating adenovirus type-5 (Ad5) vectored COVID-19 vaccine, which both entered phase 1 clinical trials on March 16, 2020; Inovio Pharmaceuticals' DNA vaccine for COVID-19, which entered trials on April 3, 2020; three inactive COVID-19 vaccines manufactured by Sinovac, Wuhan Institute of Biological Products, and Beijing Institute of Biological Products entered clinical trials in April, 2020, successively; University of Oxford's non-replicating chimpanzee adenovirus vectored vaccine ChAdOx1 nCoV-19, and BioNTech's mRNA COVID-19 vaccine also started trials in recent months.</div><div class="section-paragraph"><div class="accordion--textbox"><div id="cetextbox10" class="accordion"><a href="#" aria-expanded="false" class="accordion__control" aria-controls="cetextbox10"><span></span><i aria-hidden="true" class="icon-section_arrow_d"></i></a><div class="accordion__content"><b>Research in context</b><div class="section-paragraph"><strong>Evidence before this study</strong></div><div class="section-paragraph">We searched PubMed on May 8, 2020, for clinical trial reports with the terms “COVID-19” or “SARS-CoV-2”, “vaccine”, and “clinical trial” and no date or language restrictions; no other data from a human clinical trial of COVID-19 vaccine have been reported thus far, to our knowledge. We also searched the <a href="http://ClinicalTrials.gov" target="_blank">ClinicalTrials.gov</a> registry for unpublished trials of COVID-19 vaccines, up to May 6, 2020. In addition to the adenovirus type-5 (Ad5) vectored COVID-19 vaccine reported here, seven candidate COVID-19 vaccines are in ongoing clinical trials, including Moderna's mRNA COVID-19 vaccine, Inovio Pharmaceuticals' DNA vaccine, Sinovac, Wuhan and Beijing Institute of Biological Products' inactive COVID-19 vaccines, University of Oxford's chimpanzee adenovirus-vectored vaccine, and BioNTech's mRNA COVID-19 vaccine.</div><div class="section-paragraph"><strong>Added value of this study</strong></div><div class="section-paragraph">This first-in-human trial showed that the Ad5 vectored COVID-19 vaccine was tolerable and immunogenic in healthy adults. One dose of the vaccine at all dose concentrations (5 × 10<sup>10</sup>, 1 × 10<sup>11</sup>, and 1·5 × 10<sup>11</sup> viral particles) tested induced both specific antibody and T-cell responses in most participants. Rapid specific T-cell responses were noted at day 14 and specific humoral responses against severe acute respiratory syndrome coronavirus 2 peaked at day 28 post-vaccination. Although we found that the high dose vaccine tended to be more immunogenic than the middle dose and low dose vaccines, it was also associated with a higher reactogenicity. Severe fever, fatigue, dyspnoea, muscle pain, and joint pain were reported in some of the recipients in the high dose group.</div><div class="section-paragraph"><strong>Implications of all the available evidence</strong></div><div class="section-paragraph">Many vaccine candidates are in rapid development, including recombinant-protein based vaccines, replicating or non-replicating viral vector-based vaccines, DNA vaccines, and mRNA vaccines (which mostly have focused on the spike glycoprotein or receptor binding domain), live attenuated vaccines, and inactivated virus vaccines. All of these vaccine platforms have advantages and disadvantages, and it is too soon to predict which will be more successful. Our study suggests that there is potential for further investigation of the Ad5 vectored COVID-19 vaccine for prevention of COVID-19.</div></div></div></div></div><div class="section-paragraph">Here, we report the preliminary assessment at 28 days post-vaccination of the safety, tolerability, and immunogenicity of CanSino's non-replicating Ad5 vectored COVID-19 vaccine in healthy adults in China.</div></section><section id="cesec20" data-locator="cesec20"><h2 class="top" id="seccestitle80" data-left-hand-nav="Method"><span class="top__sub"></span><span class="top__text">Method</span></h2><section id="cesec30" data-locator="cesec30"><h3 class="sectionTitle"><span class="top__sub"> </span><span class="top__text">Study design and participants</span></h3><div class="section-paragraph">We did a single-centre, open-label, non-randomised, dose-escalation phase 1 trial of an Ad5 vectored COVID-19 vaccine candidate in a rehabilitation centre in Wuhan, Hubei province, China. Eligible participants were healthy adults aged between 18 and 60 years, who did not have SARS-CoV-2 infection, confirmed by negative results of serum specific IgM and IgG antibodies with a commercial SARS-CoV-2 rapid test kit (Jinwofu, Beijing, China), negative nucleic acid for SARS-CoV-2 in pharyngeal swabs or sputum and anal swabs detected with a nucleic acid diagnostic kit (PCR-fluorescence probing, Sansure Biotech, Changsha, China), and a clear chest CT image with no evidence of lesions in the lungs at the time of screening. Exclusion criteria were a history of seizures or mental illness; allergy to any ingredient included in the vaccine; acute febrile disease on the day of enrolment; receipt of any blood products in the past 4 months; receipt of any research medicines or vaccine in the past month; and being unable to comply with the study schedule. Further details are outlined in the protocol.<div class="dropBlock reference-citations"><sup><a href="#bib10" id="back-bib10" data-db-target-for="bib10-d13208547e1313" class="reference-citations__ctrl" aria-expanded="false" aria-controls="bib10">10</a></sup><div data-db-target-of="bib10-d13208547e1313" class="dropBlock__holder"><div class="dropBlock__body"><ul title="list of authors" class="rlist reference-citations__loa inline-bullet-list"><li class="loa__item">Zhu F-C </li><li class="loa__item">Guan X-H </li><li class="loa__item">Wang W </li><li>et al.</li></ul><div class="reference-citations__detials">Protocol. A single-center, open-label, dose-escalating phase I clinical trial of the recombinant novel coronavirus vaccine (adenovirus type 5 vector) in healthy adults aged between 18 and 60 years in China.<div class="popup-ref"><div class="citation-host"><a href="http://www.jscdc.cn/jkfw/kygz/202005/P020200517367817987697.pdf" target="_blank">http://www.jscdc.cn/jkfw/kygz/202005/P020200517367817987697.pdf</a><div><span>Date: </span>2020</div><div><span>Date accessed: </span>May 20, 2020</div></div></div></div><div class="reference-citations__links"><ul class="rlist inline-bullet-list"><li><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=Zhu+F-C&author=Guan+X-H&author=Wang+W&title=Protocol.+A+single-center%2C+open-label%2C+dose-escalating+phase+I+clinical+trial+of+the+recombinant+novel+coronavirus+vaccine+%28adenovirus+type+5+vector%29+in+healthy+adults+aged+between+18+and+60+years+in+China">Google Scholar</a></li></ul></div></div><a href="#" class="dropBlock__ctrl--close" title="Close info"><i aria-hidden="true" class="icon-close_thin"></i></a></div></div> Participants were sequentially enrolled to receive a single intramuscular injection in a dose-escalating manner: the first group of participants were allocated to receive the low dose, followed up for a minimum of 3 days before proceeding to recruit further participants to receive the middle dose, and then after safety observation for 3 days, the last group of participants were recruited and allocated to receive the high dose. The administration of higher dose injections and new enrolment were paused if any criteria for pausing dose escalation were met.</div><div class="section-paragraph">The protocol and informed consent were approved by the institutional review board of the Jiangsu Provincial Center of Disease Control and Prevention. Written informed consent from all participants was obtained before screening. This study was undertaken by Jiangsu Provincial Center for Disease Control and Prevention, Hubei Provincial Center for Disease Control and Prevention, and Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology in accordance with the Declaration of Helsinki and Good Clinical Practice.</div></section><section id="cesec40" data-locator="cesec40"><h3 class="sectionTitle"><span class="top__sub"> </span><span class="top__text">Procedures</span></h3><div class="section-paragraph">The Ad5 vectored COVID-19 vaccine was developed by Beijing Institute of Biotechnology (Beijing, China) and CanSino Biologics (Tianjin, China). The vaccine is a replication defective Ad5 vectored vaccine expressing the spike glycoprotein of SARS-CoV-2. We cloned an optimised full-length spike gene based on Wuhan-Hu-1 (GenBank accession number YP_009724390) with the tissue plasminogen activator signal peptide gene into an E1 and E3 deleted Ad5 vector, and constructed the Ad5 vectored COVID-19 vaccine using the Admax system from Microbix Biosystem (Toronto, ON, Canada). The Ad5 vectored COVID-19 vaccine was manufactured as a liquid formulation containing 5 × 10<sup>10</sup> viral particles per 0·5 mL in a vial.</div><div class="section-paragraph">A single shot was allocated intramuscularly in the arm of the participants in the low dose group, with one vial of the Ad5 vectored COVID-19 vaccine (5 × 10<sup>10</sup> viral particles per 0·5 mL). The participants in the middle dose group received one shot intramuscularly in the arm with two vials of the Ad5 vectored COVID-19 vaccine (1 × 10<sup>11</sup> viral particles per mL). Participants in the high dose group received a double-shot regimen with one vial of the Ad5 vectored COVID-19 vaccine in one arm and two vials of the Ad5 vectored COVID-19 vaccine in the other arm (1·5 × 10<sup>11</sup> viral particles per 1·5 mL).</div><div class="section-paragraph">Adverse events were self-reported by the participants, but verified by investigators daily during the first 14 days after vaccination. Subsequently, adverse events were recorded by the participants on diary cards in the following weeks. Laboratory safety tests including white blood cell count, lymphocyte count, neutrophils, platelets, haemoglobin, alanine aminotransferase, aspartate aminotransferase, total bilirubin, fasting blood glucose, and creatinine were measured on day 7 to assess any toxic effects post-vaccination. We graded adverse events and abnormal changes in laboratory tests according to the scale issued by the China State Food and Drug Administration (version 2019).<div class="dropBlock reference-citations"><sup><a href="#bib11" id="back-bib11" data-db-target-for="bib11-d13208547e1340" class="reference-citations__ctrl" aria-expanded="false" aria-controls="bib11">11</a></sup><div data-db-target-of="bib11-d13208547e1340" class="dropBlock__holder"><div class="dropBlock__body"><div class="reference-citations__detials"><span>National Medical Products Administration</span><div class="popup-ref"><div class="citation-host"><a href="http://www.nmpa.gov.cn/WS04/CL2138/373037.html" target="_blank">http://www.nmpa.gov.cn/WS04/CL2138/373037.html</a><div><span>Date: </span>2019</div><div><span>Date accessed: </span>May 20, 2020</div></div></div></div><div class="reference-citations__links"><ul class="rlist inline-bullet-list"><li><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=National+Medical+Products+Administration&title=11">Google Scholar</a></li></ul></div></div><a href="#" class="dropBlock__ctrl--close" title="Close info"><i aria-hidden="true" class="icon-close_thin"></i></a></div></div></div><div class="section-paragraph">Blood samples were taken from participants for serology tests at the scheduled site visits before the vaccination, and on days 14 and 28 after the vaccination. We assessed binding antibody responses against the receptor binding domain (RBD) and spike glycoprotein with ELISA kits manufactured by Beijing Wantai BioPharm (Beijing, China). A dilution of 1:40 was the positivity cutoff value for ELISA. We also measured the neutralising antibody responses induced by vaccination using both live SARS-CoV-2 virus neutralisation (virus strain SARS-CoV-2/human/CHN/Wuhan_IME-BJ01/2020, GenBank number MT291831.1) and pseudovirus neutralisation tests (a vesicular stomatitis virus pseudovirus system expressing the spike glycoprotein).<div class="dropBlock reference-citations"><sup><a href="#bib12" id="back-bib12" data-db-target-for="bib12-d13208547e1345" class="reference-citations__ctrl" aria-expanded="false" aria-controls="bib12">12</a></sup><div data-db-target-of="bib12-d13208547e1345" class="dropBlock__holder"><div class="dropBlock__body"><ul title="list of authors" class="rlist reference-citations__loa inline-bullet-list"><li class="loa__item">Nie J </li><li class="loa__item">Li Q </li><li class="loa__item">Wu J </li><li>et al.</li></ul><div class="reference-citations__detials">Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2.<div class="popup-ref"><span class="ref__series"><i>Emerg Microbes Infect.</i> <span class="ref__seriesDate">2020; </span><span class="ref__seriesVolume">9</span></span>: <span class="ref__seriesPages">680-686</span></div></div><div class="reference-citations__links"><ul class="rlist inline-bullet-list"><li><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2020&pages=680-686&journal=Emerg+Microbes+Infect&author=Nie+J&author=Li+Q&author=Wu+J&title=Establishment+and+validation+of+a+pseudovirus+neutralization+assay+for+SARS-CoV-2">Google Scholar</a></li></ul></div></div><a href="#" class="dropBlock__ctrl--close" title="Close info"><i aria-hidden="true" class="icon-close_thin"></i></a></div></div> Peripheral blood mononuclear cells were isolated from whole blood before the vaccination and at days 14 and 28 post-vaccination. Specific T-cell responses were quantified with an interferon (IFN) γ enzyme-linked immunospot (ELISpot) assay using fresh peripheral blood mononuclear cells stimulated with overlapping spike glycoprotein peptide pools for about 12–24 h before detection, and expressed as the number of spot-forming cells per 100 000 cells. All measurements were subtracted from the unstimulated control values, and minus values were corrected to zero. The results were considered positive if there was at least a two-times increase in the number of IFNγ secreting T cells post-vaccination. We also assessed the CD4<sup>+</sup> and CD8<sup>+</sup> T-cell responses to vaccination according to the secretion of IFNγ, interleukin-2 (IL-2), and tumour necrosis factor α (TNFα), which were measured by intracellular cytokine staining assays in peripheral blood mononuclear cells after the stimulation with overlapping spike glycoprotein peptide pools for about 6 h and detected by flow cytometry. Similar methods to measure T-cell responses by intracellular cytokine staining assays have been reported previously.<div class="dropBlock reference-citations"><sup><a href="#" id="back-bib13" data-db-target-for="bib13-d13208547e1355" class="reference-citations__ctrl" aria-expanded="false" aria-controls="bib13">13</a></sup><div data-db-target-of="bib13-d13208547e1355" class="dropBlock__holder"><div class="dropBlock__body"><ul title="list of authors" class="rlist reference-citations__loa inline-bullet-list"><li class="loa__item">Ewer K </li><li class="loa__item">Rampling T </li><li class="loa__item">Venkatraman N </li><li>et al.</li></ul><div class="reference-citations__detials">A monovalent chimpanzee adenovirus Ebola vaccine boosted with MVA.<div class="popup-ref"><span class="ref__series"><i>N Engl J Med.</i> <span class="ref__seriesDate">2016; </span><span class="ref__seriesVolume">374</span></span>: <span class="ref__seriesPages">1635-1646</span></div></div><div class="reference-citations__links"><ul class="rlist inline-bullet-list"><li><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=374&publication_year=2016&pages=1635-1646&journal=N+Engl+J+Med&author=Ewer+K&author=Rampling+T&author=Venkatraman+N&title=A+monovalent+chimpanzee+adenovirus+Ebola+vaccine+boosted+with+MVA">Google Scholar</a></li></ul></div></div><a href="#" class="dropBlock__ctrl--close" title="Close info"><i aria-hidden="true" class="icon-close_thin"></i></a></div></div><sup>, </sup> <div class="dropBlock reference-citations"><sup><a href="#" id="back-bib14" data-db-target-for="bib14-d13208547e1355" class="reference-citations__ctrl" aria-expanded="false" aria-controls="bib14">14</a></sup><div data-db-target-of="bib14-d13208547e1355" class="dropBlock__holder"><div class="dropBlock__body"><ul title="list of authors" class="rlist reference-citations__loa inline-bullet-list"><li class="loa__item">De Santis O </li><li class="loa__item">Audran R </li><li class="loa__item">Pothin E </li><li>et al.</li></ul><div class="reference-citations__detials">Safety and immunogenicity of a chimpanzee adenovirus-vectored Ebola vaccine in healthy adults: a randomised, double-blind, placebo-controlled, dose-finding, phase 1/2a study.<div class="popup-ref"><span class="ref__series"><i>Lancet Infect Dis.</i> <span class="ref__seriesDate">2016; </span><span class="ref__seriesVolume">16</span></span>: <span class="ref__seriesPages">311-320</span></div></div><div class="reference-citations__links"><ul class="rlist inline-bullet-list"><li><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2016&pages=311-320&journal=Lancet+Infect+Dis&author=De+Santis+O&author=Audran+R&author=Pothin+E&title=Safety+and+immunogenicity+of+a+chimpanzee+adenovirus-vectored+Ebola+vaccine+in+healthy+adults%3A+a+randomised%2C+double-blind%2C+placebo-controlled%2C+dose-finding%2C+phase+1%2F2a+study">Google Scholar</a></li></ul></div></div><a href="#" class="dropBlock__ctrl--close" title="Close info"><i aria-hidden="true" class="icon-close_thin"></i></a></div></div> The pre-vaccination and post-vaccination anti-Ad5 neutralising antibody titres were detected with a serum neutralisation assay.<div class="dropBlock reference-citations"><sup><a href="#bib15" id="back-bib15" data-db-target-for="bib15-d13208547e1359" class="reference-citations__ctrl" aria-expanded="false" aria-controls="bib15">15</a></sup><div data-db-target-of="bib15-d13208547e1359" class="dropBlock__holder"><div class="dropBlock__body"><ul title="list of authors" class="rlist reference-citations__loa inline-bullet-list"><li class="loa__item">Sprangers MC </li><li class="loa__item">Lakhai W </li><li class="loa__item">Koudstaal W </li><li>et al.</li></ul><div class="reference-citations__detials">Quantifying adenovirus-neutralizing antibodies by luciferase transgene detection: addressing preexisting immunity to vaccine and gene therapy vectors.<div class="popup-ref"><span class="ref__series"><i>J Clin Microbiol.</i> <span class="ref__seriesDate">2003; </span><span class="ref__seriesVolume">41</span></span>: <span class="ref__seriesPages">5046-5052</span></div></div><div class="reference-citations__links"><ul class="rlist inline-bullet-list"><li><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2003&pages=5046-5052&journal=J+Clin+Microbiol&author=Sprangers+MC&author=Lakhai+W&author=Koudstaal+W&title=Quantifying+adenovirus-neutralizing+antibodies+by+luciferase+transgene+detection%3A+addressing+preexisting+immunity+to+vaccine+and+gene+therapy+vectors">Google Scholar</a></li></ul></div></div><a href="#" class="dropBlock__ctrl--close" title="Close info"><i aria-hidden="true" class="icon-close_thin"></i></a></div></div></div></section><section id="cesec50" data-locator="cesec50"><h3 class="sectionTitle"><span class="top__sub"> </span><span class="top__text">Outcomes</span></h3><div class="section-paragraph">We analysed all outcomes in the intention-to-treat cohort. The primary endpoint for safety was the occurrence of adverse reactions within 7 days after the vaccination. Any abnormal changes in laboratory measures at 7 days post-vaccination, and adverse events within 28 days across the treatment groups were also analysed as secondary safety endpoints. The specific ELISA antibody titres to RBD and the spike glycoprotein, and the neutralising antibody amounts against live SARS-CoV-2 and a pseudovirus were measured as humoral immunogenicity endpoints. We defined a positive antibody response (seroconversion) as at least a four-fold increase in post-vaccination titre from baseline. ELISpot IFNγ and positive T-cell responses measured by intracellular cytokine staining assays were compared across the groups as endpoints for cell-mediated responses. Stratified analyses of the immune responses were done based on the pre-existing Ad5 neutralising antibody titres among the participants as low or negative (≤1:200) or high (&gt;1:200).</div></section><section id="cesec60" data-locator="cesec60"><h3 class="sectionTitle"><span class="top__sub"> </span><span class="top__text">Statistical analysis</span></h3><div class="section-paragraph">The sample size was not determined on the basis of statistical power calculations; however, a minimum sample size of 20–30 participants for a pilot vaccine trial has been recommended by the National Medical Products Administration, China. We assessed the number and proportion of participants with adverse reactions post-vaccination and compared safety profiles across the dose groups. The antibodies against SARS-CoV-2 were presented as geometric mean titres with 95% CIs and the cellular responses were shown as a proportion of positive responders. We used the χ<sup>2</sup> test or Fisher's exact test to analyse categorical data, ANOVA to analyse the log transformed antibody titres, and Wilcoxon rank-sum test for data that were not normally distributed. When the overall difference across the three groups was significant, pairwise comparisons were made and the differences between groups were estimated with 95% CIs. Multivariable analysis was used to establish the possible effects on the immunogenicity and safety profile of the vaccine candidates. Hypothesis testing was two-sided with an α value of 0·05. Statistical analyses were done by a statistician using SAS (version 9.4) or GraphPad Prism 8·0·1. SPICE (version 6.0) was used for the analysis of data from multicolour flow cytometry experiments.</div><div class="section-paragraph">An independent data and safety monitoring committee, with one independent statistician, one clinician, and one epidemiologist, was established before the start of the trial. Safety data for the first 3 days post-vaccination were assessed and reviewed by the committee to ensure that there was sufficient holding time between dose escalation. This study is registered with <a href="http://ClinicalTrials.gov" target="_blank">ClinicalTrials.gov</a>, <a href="http://clinicaltrials.gov/show/NCT04313127" target="_blank">NCT04313127</a>.</div></section><section id="cesec70" data-locator="cesec70"><h3 class="sectionTitle"><span class="top__sub"> </span><span class="top__text">Role of the funding source</span></h3><div class="section-paragraph">The sponsors of the study participated in study design, but had no role in data collection, data analysis, data interpretation, or writing of the report. All authors had full access to all the data in the study and had final responsibility for the decision to submit for publication.</div></section></section><section id="cesec80" data-locator="cesec80"><h2 class="top" id="seccestitle140" data-left-hand-nav="Results"><span class="top__sub"></span><span class="top__text">Results</span></h2><div class="section-paragraph">Between March 16 and March 27, 2020, we screened 195 individuals for eligibility. Of them, 108 were sequentially enrolled and assigned to receive the low dose (n=36 [33%]), middle dose (n=36 [33%]), or high dose (n=36 [33%]) of the Ad5 vectored COVID-19 vaccine (<a href="#sec1" class="scroll-into-link">appendix p 2</a>). All participants completed the vaccination and the scheduled visits within 28 days. Baseline characteristics of the participants were similar across the treatment groups (<a href="#tbl1" id="back-tbl1" class="scroll-into-link">table 1</a>).<div class="floatDisplay"><div id="tbl1" class="inline-table"><div class="inline-table__head"><span class="inline-table__label">Table 1</span><span class="inline-table__title">Baseline characteristics</span></div><table width="100%" cellpadding="0" cellspacing="0" border="0" class="scrollable bordered"><thead><tr><th class="rowsep"></th><th class="rowsep"></th><th class="rowsep"><strong>Low dose group (n=36)</strong></th><th class="rowsep"><strong>Middle dose group (n=36)</strong></th><th class="rowsep"><strong>High dose group (n=36)</strong></th></tr></thead><tbody><tr><td colspan="5">Age, years</td></tr><tr><td></td><td>18–29</td><td>9 (25%)</td><td>12 (33%)</td><td>10 (28%)</td></tr><tr><td></td><td>30–39</td><td>13 (36%)</td><td>14 (39%)</td><td>15 (42%)</td></tr><tr><td></td><td>40–49</td><td>8 (22%)</td><td>3 (8%)</td><td>7 (19%)</td></tr><tr><td></td><td>50–60</td><td>6 (17%)</td><td>7 (19%)</td><td>4 (11%)</td></tr><tr><td colspan="2">Mean age, years</td><td>37·2 (10·7)</td><td>36·3 (11·5)</td><td>35·5 (10·1)</td></tr><tr><td colspan="5">Sex</td></tr><tr><td></td><td>Male</td><td>18 (50%)</td><td>19 (53%)</td><td>18 (50%)</td></tr><tr><td></td><td>Female</td><td>18 (50%)</td><td>17 (47%)</td><td>18 (50%)</td></tr><tr><td colspan="2">Mean body-mass index, kg/m<sup>2</sup></td><td>23·3 (2·7)</td><td>23·9 (2·7)</td><td>24·1 (3·1)</td></tr><tr><td colspan="5">Underlying diseases<div class="dropBlock reference-citations"><a href="#" id="back-tbl1fn1" data-db-target-for="tbl1fn1-d13208547e166" class="reference-citations__ctrl scroll-into-link" aria-expanded="false" aria-controls="tbl1fn1">*</a><div data-db-target-of="tbl1fn1-d13208547e166" class="dropBlock__holder"><div class="dropBlock__body"><div class="reference-citations__detials"><span>* </span><span>Seven participants had hypertension, chronic bronchitis, gout, or were a carrier of hepatitis B virus.</span></div></div><a href="#" class="dropBlock__ctrl--close" title="Close info"><i aria-hidden="true" class="icon-close_thin"></i></a></div></div></td></tr><tr><td></td><td>Yes</td><td>1 (3%)</td><td>2 (6%)</td><td>4 (11%)</td></tr><tr><td></td><td>No</td><td>35 (97%)</td><td>34 (94%)</td><td>32 (89%)</td></tr><tr><td colspan="5">Pre-existing adenovirus type-5 neutralising antibody</td></tr><tr><td></td><td>Mean GMT</td><td>168·9 (13·9)</td><td>149·5 (10·5)</td><td>115·0 (13·4)</td></tr><tr><td></td><td>≤200, titre</td><td>16 (44%)</td><td>17 (47%)</td><td>20 (56%)</td></tr><tr><td></td><td>&gt;200, titre</td><td>20 (56%)</td><td>19 (53%)</td><td>16 (44%)</td></tr></tbody></table><div class="inline-table__tail"><div class="section-paragraph">Data are n (%) or mean (SD). GMT=geometric mean titre.</div><div class="inline-table__footnote"><span>* </span><span>Seven participants had hypertension, chronic bronchitis, gout, or were a carrier of hepatitis B virus.</span></div></div><ul class="rlist--inline separator download-links"><li><a title="Open Full Table" class="table__open__ctrl" target="_blank" href="/action/showFullTableHTML?isHtml=true&amp;tableId=tbl1&amp;pii=S0140-6736%2820%2931208-3">
                            Open table in a new tab
                        </a></li></ul></div></div></div><div class="section-paragraph">87 (81%) of 108 participants reported at least one adverse reaction within the first 7 days after the vaccination: 30 (83%) in the low dose group, 30 (83%) in the middle dose group, and 27 (75%) in the high dose group (<a href="#tbl2" id="back-tbl2" class="scroll-into-link">table 2</a>). No significant difference in the overall number of adverse reactions across the treatment groups was observed. The most common injection site adverse reaction was pain, which was reported in 58 (54%) vaccine recipients. Pain was reported in 17 (47%) participants in the low dose group, 20 (56%) participants in the middle dose group, and 21 (58%) participants in the high dose group. The most commonly reported systematic adverse reactions overall were fever (50 [46%]), fatigue (47 [44%]), headache (42 [39%]), and muscle pain (18 [17%]). Fever was reported in 15 (42%) participants in the low dose group, 15 (42%) participants in the middle dose group, and 20 (56%) participants in the high dose group. Headache was reported in 14 (39%) participants in the low dose group, 11 (31%) participants in the middle dose group, and 17 (47%) participants in the high dose group. Muscle pain was reported in seven (19%) participants in the low dose group, three (8%) participants in the middle dose group, and eight (22%) participants in the high dose group. Most adverse reactions were mild or moderate in severity. Nine participants (two [6%] in the low dose group, two [6%] in the middle dose group, and five [14%] in the high dose group) had an episode of severe fever (grade 3) with axillary temperature greater than 38·5°C. Of them, one (3%) from the high dose group reported severe fever along with severe symptoms of fatigue, dyspnoea, and muscle pain. One participant in the high dose group reported severe fatigue and joint pain (<a href="#sec1" class="scroll-into-link">appendix p 3</a>). These reactions occurred within 24 h post-vaccination, and persisted for no more than 48 h. We found no significant difference in the incidences of adverse reactions or overall adverse events among the dose groups. High pre-existing Ad5 immunity (titre of &gt;1:200 <em>vs</em> ≤1:200) was associated with significantly fewer occurrences of fever post-vaccination (odds ratio 0·3, 95% CI 0·1–0·6; <a href="#sec1" class="scroll-into-link">appendix p 4</a>). No serious adverse event was reported within 28 days. At day 7 after vaccination, nine (8%) participants had mild to moderate total bilirubin increase, ten (9%) had alanine aminotransferase increase, and four (4%) had fasting hyperglycaemia (<a href="#sec1" class="scroll-into-link">appendix p 5</a>), but no instances were considered as clinically significant.<div class="floatDisplay"><div id="tbl2" class="inline-table"><div class="inline-table__head"><span class="inline-table__label">Table 2</span><span class="inline-table__title">Adverse reactions within 7 days and overall adverse events within 28 days after vaccination</span></div><table width="100%" cellpadding="0" cellspacing="0" border="0" class="scrollable bordered"><thead><tr><th class="rowsep"></th><th class="rowsep"></th><th class="rowsep"><strong>Low dose group (n=36)</strong></th><th class="rowsep"><strong>Middle dose group (n=36)</strong></th><th class="rowsep"><strong>High dose group (n=36)</strong></th><th class="rowsep"><strong>Total (N=108)</strong></th></tr></thead><tbody><tr><td colspan="6"><strong>All adverse reactions within 0–7 days</strong></td></tr><tr><td colspan="2">Any</td><td>30 (83%)</td><td>30 (83%)</td><td>27 (75%)</td><td>87 (81%)</td></tr><tr><td colspan="2">Grade 3</td><td>2 (6%)</td><td>2 (6%)</td><td>6 (17%)</td><td>10 (9%)</td></tr><tr><td colspan="6"><strong>Injection site adverse reactions within 0–7 days</strong></td></tr><tr><td colspan="2">Pain</td><td>17 (47%)</td><td>20 (56%)</td><td>21 (58%)</td><td>58 (54%)</td></tr><tr><td colspan="2">Induration</td><td>2 (6%)</td><td>1 (3%)</td><td>1 (3%)</td><td>4 (4%)</td></tr><tr><td colspan="2">Redness</td><td>2 (6%)</td><td>1 (3%)</td><td>1 (3%)</td><td>4 (4%)</td></tr><tr><td colspan="2">Swelling</td><td>4 (11%)</td><td>4 (11%)</td><td>0</td><td>8 (7%)</td></tr><tr><td colspan="2">Itch</td><td>2 (6%)</td><td>3 (8%)</td><td>0</td><td>5 (5%)</td></tr><tr><td colspan="2">Muscular weakness</td><td>0</td><td>0</td><td>1 (3%)</td><td>1 (1%)</td></tr><tr><td colspan="6"><strong>Systemic adverse reactions within 0–7 days</strong></td></tr><tr><td colspan="2">Fever</td><td>15 (42%)</td><td>15 (42%)</td><td>20 (56%)</td><td>50 (46%)</td></tr><tr><td></td><td>Grade 3 fever</td><td>2 (6%)</td><td>2 (6%)</td><td>5 (14%)</td><td>9 (8%)</td></tr><tr><td colspan="2">Headache</td><td>14 (39%)</td><td>11 (31%)</td><td>17 (47%)</td><td>42 (39%)</td></tr><tr><td colspan="2">Fatigue</td><td>17 (47%)</td><td>14 (39%)</td><td>16 (44%)</td><td>47 (44%)</td></tr><tr><td></td><td>Grade 3 fatigue</td><td>0</td><td>0</td><td>2 (6%)</td><td>2 (2%)</td></tr><tr><td colspan="2">Vomiting</td><td>1 (3%)</td><td>0</td><td>1 (3%)</td><td>2 (2%)</td></tr><tr><td colspan="2">Diarrhoea</td><td>3 (8%)</td><td>4 (11%)</td><td>5 (14%)</td><td>12 (11%)</td></tr><tr><td colspan="2">Muscle pain</td><td>7 (19%)</td><td>3 (8%)</td><td>8 (22%)</td><td>18 (17%)</td></tr><tr><td></td><td>Grade 3 muscle pain</td><td>0</td><td>0</td><td>1 (3%)</td><td>1 (1%)</td></tr><tr><td colspan="2">Joint pain</td><td>2 (6%)</td><td>2 (6%)</td><td>5 (14%)</td><td>9 (8%)</td></tr><tr><td></td><td>Grade 3 joint pain</td><td>0</td><td>0</td><td>1 (3%)</td><td>1 (1%)</td></tr><tr><td colspan="2">Throat pain</td><td>1 (3%)</td><td>3 (8%)</td><td>4 (11%)</td><td>8 (7%)</td></tr><tr><td colspan="2">Cough</td><td>1 (3%)</td><td>2 (6%)</td><td>3 (8%)</td><td>6 (6%)</td></tr><tr><td colspan="2">Nausea</td><td>2 (6%)</td><td>1 (3%)</td><td>3 (8%)</td><td>6 (6%)</td></tr><tr><td colspan="2">Functional GI disorder</td><td>1 (3%)</td><td>0</td><td>0</td><td>1 (1%)</td></tr><tr><td colspan="2">Dyspnoea</td><td>0</td><td>0</td><td>2 (6%)</td><td>2 (2%)</td></tr><tr><td></td><td>Grade 3 dyspnoea</td><td>0</td><td>0</td><td>1 (3%)</td><td>1 (1%)</td></tr><tr><td colspan="2">Appetite impaired</td><td>6 (17%)</td><td>5 (14%)</td><td>6 (17%)</td><td>17 (16%)</td></tr><tr><td colspan="2">Dizziness</td><td>1 (3%)</td><td>0</td><td>1 (3%)</td><td>2 (2%)</td></tr><tr><td colspan="2">Mucosal abnormality</td><td>0</td><td>0</td><td>1 (3%)</td><td>1 (1%)</td></tr><tr><td colspan="2">Pruritus</td><td>1 (3%)</td><td>1 (3%)</td><td>1 (3%)</td><td>3 (3%)</td></tr><tr><td colspan="6"><strong>Overall adverse events within 0–28 days</strong></td></tr><tr><td colspan="2">Any</td><td>31 (86%)</td><td>30 (83%)</td><td>27 (75%)</td><td>88 (81%)</td></tr><tr><td colspan="2">Grade 3</td><td>2 (6%)</td><td>2 (6%)</td><td>6 (17%)</td><td>10 (9%)</td></tr></tbody></table><div class="inline-table__tail"><div class="section-paragraph">Data are n (%). Any refers to all the participants with any grade adverse reactions or events. Adverse reactions and events were graded according to the scale issued by the China State Food and Drug Administration. Grade 3=severe (ie, prevented activity). GI=gastrointestinal.</div></div><ul class="rlist--inline separator download-links"><li><a title="Open Full Table" class="table__open__ctrl" target="_blank" href="/action/showFullTableHTML?isHtml=true&amp;tableId=tbl2&amp;pii=S0140-6736%2820%2931208-3">
                            Open table in a new tab
                        </a></li></ul></div></div></div><div class="section-paragraph">Rapid binding antibody responses to RBD were observed in all three dose groups from day 14 (<a href="#tbl3" id="back-tbl3" class="scroll-into-link">table 3</a>). At day 28, the recipients in the high dose group tended to have a higher binding antibody geometric mean titre of 1445·8 (95% CI 935·5–2234·5), followed by 806·0 (528·2–1229·9) in the middle dose group, and 615·8 (405·4–935·5) in the low dose group (high dose <em>vs</em> low dose 1611·5, 531·5–2691·5). At least a four-fold increase of anti-RBD antibodies was noted in 35 (97%) of 36 participants in the low dose group, 34 (94%) of 36 in the middle dose group, and 36 (100%) of 36 in the high dose group. Neutralising antibodies against live SARS-CoV-2 were all negative at day 0, and increased moderately at day 14, peaking at 28 days post-vaccination. Neutralising antibody titre with a geometric mean titre of 34·0 (95% CI 22·6–50·1) was noted in the high dose group, which was significantly higher compared with 16·2 (10·4–25·2) in the middle dose group and 14·5 (9·6–21·8) in the low dose group, with an estimated difference of 27·7 (1·0–54·4) between the high dose group and the middle dose group and 33·2 (6·5–59·9) between the high dose group and the low dose group at day 28. Meanwhile, 18 (50%) participants in the low dose group, 18 (50%) in the middle dose group, and 27 (75%) in the high dose group had at least a four-fold increase in neutralising antibody titres by day 28. Similar patterns of the binding antibody to spike glycoprotein and neutralising antibody titre to pseudovirus post-vaccination across the dose groups were also noted (<a href="#sec1" class="scroll-into-link">appendix p 6</a>). The association between the ELISA antibodies to RBD and neutralising antibody titres against live virus showed a moderate positive correlation of 0·749, and that between the ELISA antibodies to spike glycoprotein and neutralising antibody titres against live virus was 0·753, at the peak antibody response (p&lt;0·0001). The neutralising antibody titres measured using a pseudovirus were also correlated well with those measured by live SARS-CoV-2 (<a href="#sec1" class="scroll-into-link">appendix p 7</a>).<div class="floatDisplay"><div id="tbl3" class="inline-table"><div class="inline-table__head"><span class="inline-table__label">Table 3</span><span class="inline-table__title">Specific antibody responses to the receptor binding domain, and neutralising antibodies to live SARS-CoV-2</span></div><table width="100%" cellpadding="0" cellspacing="0" border="0" class="scrollable bordered"><thead><tr><th></th><th class="rowsep" colspan="4"><strong>Day 14</strong></th><th class="rowsep" colspan="4"><strong>Day 28</strong></th></tr><tr><th class="rowsep"></th><th class="rowsep">Low dose group (n=36)</th><th class="rowsep">Middle dose group (n=36)</th><th class="rowsep">High dose group (n=36)</th><th class="rowsep">p value</th><th class="rowsep">Low dose group (n=36)</th><th class="rowsep">Middle dose group (n=36)</th><th class="rowsep">High dose group (n=36)</th><th class="rowsep">p value</th></tr></thead><tbody><tr><td colspan="9"><strong>ELISA antibodies to the receptor binding domain</strong></td></tr><tr><td>GMT</td><td>76·5 (44·3–132·0)</td><td>91·2 (55·9–148·7)</td><td>132·6 (80·7–218·0)</td><td>0·29</td><td>615·8 (405·4–935·5)</td><td>806·0 (528·2–1229·9)</td><td>1445·8 (935·5–2234·5)</td><td>0·016</td></tr><tr><td>≥4-fold increase</td><td>16 (44%)</td><td>18 (50%)</td><td>22 (61%)</td><td>0·35</td><td>35 (97%)</td><td>34 (94%)</td><td>36 (100%)</td><td>0·77</td></tr><tr><td colspan="9"><strong>Neutralising antibodies to live SARS-CoV-2</strong></td></tr><tr><td>GMT</td><td>8·2 (5·8–11·5)</td><td>9·6 (6·6–14·1)</td><td>12·7 (8·5–19·0)</td><td>0·24</td><td>14·5 (9·6–21·8)</td><td>16·2 (10·4–25·2)</td><td>34·0 (22·6–50·1)</td><td>0·0082</td></tr><tr><td>≥4-fold increase</td><td>10 (28%)</td><td>11 (31%)</td><td>15 (42%)</td><td>0·42</td><td>18 (50%)</td><td>18 (50%)</td><td>27 (75%)</td><td>0·046</td></tr></tbody></table><div class="inline-table__tail"><div class="section-paragraph">Data are mean (95% CI) or n (%). The p values are the result of comparison across the three dose groups. If the difference was significant across the three groups, the differences between groups were estimated with 95% CIs. SARS-CoV-2=severe acute respiratory syndrome coronavirus 2. GMT=geometric mean titre.</div></div><ul class="rlist--inline separator download-links"><li><a title="Open Full Table" class="table__open__ctrl" target="_blank" href="/action/showFullTableHTML?isHtml=true&amp;tableId=tbl3&amp;pii=S0140-6736%2820%2931208-3">
                            Open table in a new tab
                        </a></li></ul></div></div></div><div class="section-paragraph">Before vaccination, 20 (56%) participants in the low dose group, 19 (53%) participants in the middle dose group, and 16 (44%) participants in the high dose group had a high pre-existing Ad5 neutralising antibody titre (&gt;1:200). Only five (25%) participants of 20 in the low dose group, seven (37%) participants of 19 in the middle dose group, and ten (63%) participants of 16 in the high dose group, who had high pre-existing Ad5 immunity, had at least a four-fold increase in neutralising antibody titre at day 28 post-vaccination (<a href="#sec1" class="scroll-into-link">appendix pp 8–10</a>). Multivariable analysis showed that high pre-existing Ad5 neutralising antibody titres compromised the seroconversion of neutralising antibody post-vaccination, regardless of the vaccine doses, and recipients aged 45–60 years seemed to have lower seroconversion of neutralising antibody compared with the younger recipients (<a href="#sec1" class="scroll-into-link">appendix p 11</a>). The Ad5 neutralising antibodies were significantly boosted post-vaccination (<a href="#sec1" class="scroll-into-link">appendix p 12</a>).</div><div class="section-paragraph">ELISpot responses at baseline were undetectable with spot-forming cells below the level of detection of the assay in all participants, but peaked at day 14 post-vaccination. The proportions of positive responders ranged from 83–97% across the dose groups, with a mean number of spot-forming cells per 100 000 cells of 20·8 (95% CI 12·7–34·0) in the low dose group, 40·8 (27·6–60·3) in the middle dose group, and 58·0 (39·1–85·9) in the high dose group (<a data-link="modal" data-target="#image-S0140-6736(20)31208-3gr1" href="#fig1" data-locator="fig1" id="back-gr1" class="figure-link scroll-into-link">figure 1</a>). T-cell responses in the high dose group were significantly higher than that in the low dose group (p&lt;0·0010), but not significant compared with that in the middle dose group. A slight decrease of the T-cell responses across the dose groups was noted at day 28. High levels of baseline Ad5 neutralising antibody titre reduced the peak of post-vaccination T-cell responses in all the dose groups, particularly for the low dose group. Despite the effect of high pre-existing Ad5 immunity, positive responders were identified in 15 (75%) of 20 participants in the low dose group, 18 (95%) of 19 participants in the middle dose group, and 15 (94%) of 16 participants in the high dose group at day 14, and 12 (60%) of 20 participants in the low dose group, 16 (84%) of 19 participants in the middle dose group, and 16 (100%) of 16 participants in the high dose group at day 28.<div class="floatDisplay"><figure id="fig1" class=""><img class="b-lazy" data-src="//els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/b51eaa4d-94e7-4ee7-92f5-a884b3ec2256/gr1.jpg" alt="Figure thumbnail gr1" data-locator="fig1" data-high-res="//els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/f9cea4ed-f11f-4222-9534-5e6d53540018/gr1_lrg.jpg" data-large-image="//els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/b51eaa4d-94e7-4ee7-92f5-a884b3ec2256/gr1.jpg"></img><figcaption><div class="figure__caption__body"><div class="figure__title"><span data-fv-label="Fig. 1" class="label figure__label">Figure 1</span><span class="figure__title__text">Specific T-cell response measured by ELISpot</span></div><div class="accordion"><a href="#" class="accordion__control" aria-expanded="false"><i class="icon-section_arrow_d"></i><span>Show full caption</span></a><div class="accordion__content"><div class="figure__caption__text"><div class="section-paragraph">(A) The number of specific T cells with secretion of IFNγ at days 0, 14, and 28 in all participants, and stratified by pre-existing Ad5 neutralising antibody titres. (B) The proportion of positive ELISpot responders at days 14 and 28 post-vaccination in all participants, and stratified by pre-existing Ad5 neutralising antibody titres. IFN=interferon. PBMCs=peripheral blood mononuclear cells. Ad5=adenovirus type-5. ELISpot=enzyme-linked immunospot.</div></div></div></div><ul class="rlist--inline separator download-links"><li><a target="_blank" href="//els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/b51eaa4d-94e7-4ee7-92f5-a884b3ec2256/gr1.jpg" title="View Large Image in a new tab">View Large
                                            Image
                                        </a></li><li class="download-links__figureViewer"><a href="#" class="figure__open__ctrl">Figure Viewer</a></li><li><a href="//els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/f9cea4ed-f11f-4222-9534-5e6d53540018/gr1_lrg.jpg" class="download-links__download-Hi-res" target="_blank" download="">Download Hi-res
                                            image
                                        </a></li><li class="hidden-xs"><a href="/action/downloadFigures?pii=S0140-6736(20)31208-3&amp;id=gr1.jpg" class="download-links__download-This">Download (PPT)</a></li></ul></div></figcaption></figure></div></div><div class="section-paragraph">IFNγ was detected from CD4<sup>+</sup> and CD8<sup>+</sup> T cells after the vaccination at day 14 and 28, in all dose groups (<a data-link="modal" data-target="#image-S0140-6736(20)31208-3gr2" href="#fig2" data-locator="fig2" id="back-gr2" class="figure-link scroll-into-link">figure 2</a>, <a href="#sec1" class="scroll-into-link">appendix p 13</a>). The TNFα expression from CD4<sup>+</sup> T cells tended to be significantly lower in the low dose group than that in the high dose (p&lt;0·0001) and middle dose groups (p=0·0032), on day 14. The TNFα expression from CD8<sup>+</sup> T cells showed an overall p value of less than 0·0001 across the three groups on day 14. And the TNFα expression from CD8<sup>+</sup> T cells tended to be higher in the high dose group than that in both the middle dose group (p=0·016) and the low dose group (p&lt;0·0001). The p values are for the pairwise comparisons between groups. Amounts of IL-2 detected from CD4<sup>+</sup> T cells were higher than that detected from CD8<sup>+</sup> cells. The proportions of polyfunctional phenotypes detected from memory CD4<sup>+</sup> T cells were higher than those from CD8<sup>+</sup> T cells. Higher proportions of polyfunctional phenotypes were noted with the higher vaccine doses. We also noted that pre-existing Ad5 neutralising antibody had a negative effect on the pattern of T-cell responses (<a href="#sec1" class="scroll-into-link">appendix pp 14–16</a>). A post-hoc analysis showed that 28 (78%) participants in the low dose group, 33 (92%) participants in the middle dose group, and 36 (100%) participants in the high dose group showed either positive T-cell responses to spike glycoprotein or seroconversion of neutralising antibody to live SARS-CoV-2, at day 28 post-vaccination (<a href="#sec1" class="scroll-into-link">appendix p 17</a>).<div class="floatDisplay"><figure id="fig2" class=""><img class="b-lazy" data-src="//els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/e0f206c4-7175-4293-9b88-affbc7977e0f/gr2.jpg" alt="Figure thumbnail gr2" data-locator="fig2" data-high-res="//els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/2a7b41fe-19c5-4dc6-83f7-84bcaeeff75d/gr2_lrg.jpg" data-large-image="//els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/e0f206c4-7175-4293-9b88-affbc7977e0f/gr2.jpg"></img><figcaption><div class="figure__caption__body"><div class="figure__title"><span data-fv-label="Fig. 2" class="label figure__label">Figure 2</span><span class="figure__title__text">Flow cytometry with intracellular cytokine staining before and after vaccination</span></div><div class="accordion"><a href="#" class="accordion__control" aria-expanded="false"><i class="icon-section_arrow_d"></i><span>Show full caption</span></a><div class="accordion__content"><div class="figure__caption__text"><div class="section-paragraph">(A) Percentage of cells secreting IFNγ, TNFα, and IL-2 from CD4<sup>+</sup> T cells. (B) Percentage of cells secreting IFNγ, TNFα, and IL-2 from CD8<sup>+</sup> T cells. (C) The proportion of CD4<sup>+</sup> T cells and CD8<sup>+</sup> T cells producing any combination of IFNγ, TNFα, and IL-2. The analyses are for 108 participants, with 36 in each dose group. IFN=interferon. TNF=tumour necrosis factor. IL=interleukin.</div></div></div></div><ul class="rlist--inline separator download-links"><li><a target="_blank" href="//els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/e0f206c4-7175-4293-9b88-affbc7977e0f/gr2.jpg" title="View Large Image in a new tab">View Large
                                            Image
                                        </a></li><li class="download-links__figureViewer"><a href="#" class="figure__open__ctrl">Figure Viewer</a></li><li><a href="//els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/2a7b41fe-19c5-4dc6-83f7-84bcaeeff75d/gr2_lrg.jpg" class="download-links__download-Hi-res" target="_blank" download="">Download Hi-res
                                            image
                                        </a></li><li class="hidden-xs"><a href="/action/downloadFigures?pii=S0140-6736(20)31208-3&amp;id=gr2.jpg" class="download-links__download-This">Download (PPT)</a></li></ul></div></figcaption></figure></div></div><div class="section-paragraph">To exclude any possible SARS-CoV-2 exposure during the study period, we tested the serum antibodies to nucleocapsid protein of SARS-CoV-2 in participants at day 28 using a special IgG/IgM rapid test kit (Vazyme Biotech, number CD101, Nanjing, China), but none of the participants were positive.</div></section><section id="cesec90" data-locator="cesec90"><h2 class="top" id="seccestitle150" data-left-hand-nav="Discussion"><span class="top__sub"></span><span class="top__text">Discussion</span></h2><div class="section-paragraph">To our knowledge, this is the first report on a first-in-human clinical trial of a novel Ad5 vectored COVID-19 vaccine. The Ad5 vectored COVID-19 vaccine was tolerated in healthy adults in all three dose groups. The most common adverse reactions were fever, fatigue, headache, and muscle pain with no significant difference in the incidence of adverse reactions across the groups. Most adverse events reported were mild or moderate in severity. We noticed a higher reactogenicity profile of the high dose at 1·5 × 10<sup>11</sup> viral particles, presenting as severe fever, fatigue, muscle pain, or joint pain, which might be associated with viraemia caused by Ad5 vector infection. However, the severe adverse reactions were transient and self-limiting. Additionally, no abnormal changes in laboratory measurements were clinically significant or considered to be related to the vaccine. The profile of adverse events reported in this trial is similar to that of another Ad5 vector-based Ebola vaccine expressing glycoprotein.<div class="dropBlock reference-citations"><sup><a href="#bib16" id="back-bib16" data-db-target-for="bib16-d13208547e1504" class="reference-citations__ctrl" aria-expanded="false" aria-controls="bib16">16</a></sup><div data-db-target-of="bib16-d13208547e1504" class="dropBlock__holder"><div class="dropBlock__body"><ul title="list of authors" class="rlist reference-citations__loa inline-bullet-list"><li class="loa__item">Zhu FC </li><li class="loa__item">Hou LH </li><li class="loa__item">Li JX </li><li>et al.</li></ul><div class="reference-citations__detials">Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial.<div class="popup-ref"><span class="ref__series"><i>Lancet.</i> <span class="ref__seriesDate">2015; </span><span class="ref__seriesVolume">385</span></span>: <span class="ref__seriesPages">2272-2279</span></div></div><div class="reference-citations__links"><ul class="rlist inline-bullet-list"><li><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=385&publication_year=2015&pages=2272-2279&journal=Lancet&author=Zhu+FC&author=Hou+LH&author=Li+JX&title=Safety+and+immunogenicity+of+a+novel+recombinant+adenovirus+type-5+vector-based+Ebola+vaccine+in+healthy+adults+in+China%3A+preliminary+report+of+a+randomised%2C+double-blind%2C+placebo-controlled%2C+phase+1+trial">Google Scholar</a></li></ul></div></div><a href="#" class="dropBlock__ctrl--close" title="Close info"><i aria-hidden="true" class="icon-close_thin"></i></a></div></div> To accelerate the process of clinical evaluation of the candidate COVID-19 vaccine, we selected doses for the phase 2 study mainly on the basis of the safety profile of the candidate vaccines shown in the participants within 7 days and 14 days post-vaccination. We chose the low dose (5 × 10<sup>10</sup> viral particles) and middle dose (1 × 10<sup>11</sup> viral particles) to be further assessed in a phase 2 clinical trial.</div><div class="section-paragraph">The Ad5 vectored COVID-19 vaccine was immunogenic, inducing humoral and T-cell responses rapidly in most participants. Onset of detectable immune responses was rapid, with T-cell responses peaking at day 14 after vaccination and antibodies peaking at day 28. The antibody response to the vaccine in the high dose group was slightly greater than that in the middle dose and low dose groups. A single dose of Ad5 vectored COVID-19 vaccine was able to elicit a four-fold increase in binding antibodies to RBD in 94–100% of participants, and a four-fold increase to live virus in 50–75% of participants. Despite differences in magnitudes of the antibodies measured through different methods, there was a strong positive correlation between binding antibodies and neutralising antibody titres to the live virus. High proportions of participants with positive T-cell responses were noted across the all dose groups post-vaccination. The activation of both CD4<sup>+</sup> T cells and CD8<sup>+</sup> T cells was observed in vaccine recipients, particularly for antigen-specific CD4<sup>+</sup> T cells and CD8<sup>+</sup> T cells. However, both the specific antibody response and T-cell response induced by vaccination were partly diminished by the presence of high pre-existing anti-Ad5 immunity.</div><div class="section-paragraph">Currently, correlates of protection for a vaccine against COVID-19 are unknown, and the roles of the specific antibodies or T cells in building effective protection are not yet defined. Therefore, we are unable to predict the protection of the Ad5 vectored COVID-19 vaccine on the basis of the vaccine-elicited immune responses in this study. However, previous studies investigating SARS and Middle East respiratory syndrome (MERS) found that the increases in specific antibodies were temporary, and declined quickly in patients after recovery, whereas the specific CD4<sup>+</sup> and CD8<sup>+</sup> T-cell responses played an essential role in immunity.<div class="dropBlock reference-citations"><sup><a href="#" id="back-bib17" data-db-target-for="bib17-d13208547e1536" class="reference-citations__ctrl" aria-expanded="false" aria-controls="bib17">17</a></sup><div data-db-target-of="bib17-d13208547e1536" class="dropBlock__holder"><div class="dropBlock__body"><ul title="list of authors" class="rlist reference-citations__loa inline-bullet-list"><li class="loa__item">Zhao J </li><li class="loa__item">Zhao J </li><li class="loa__item">Perlman S </li></ul><div class="reference-citations__detials">T cell responses are required for protection from clinical disease and for virus clearance in severe acute respiratory syndrome coronavirus-infected mice.<div class="popup-ref"><span class="ref__series"><i>J Virol.</i> <span class="ref__seriesDate">2010; </span><span class="ref__seriesVolume">84</span></span>: <span class="ref__seriesPages">9318-9325</span></div></div><div class="reference-citations__links"><ul class="rlist inline-bullet-list"><li><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=2010&pages=9318-9325&journal=J+Virol&author=Zhao+J&author=Zhao+J&author=Perlman+S&title=T+cell+responses+are+required+for+protection+from+clinical+disease+and+for+virus+clearance+in+severe+acute+respiratory+syndrome+coronavirus-infected+mice">Google Scholar</a></li></ul></div></div><a href="#" class="dropBlock__ctrl--close" title="Close info"><i aria-hidden="true" class="icon-close_thin"></i></a></div></div><sup>, </sup> <div class="dropBlock reference-citations"><sup><a href="#" id="back-bib18" data-db-target-for="bib18-d13208547e1536" class="reference-citations__ctrl" aria-expanded="false" aria-controls="bib18">18</a></sup><div data-db-target-of="bib18-d13208547e1536" class="dropBlock__holder"><div class="dropBlock__body"><ul title="list of authors" class="rlist reference-citations__loa inline-bullet-list"><li class="loa__item">Channappanavar R </li><li class="loa__item">Fett C </li><li class="loa__item">Zhao J </li><li class="loa__item">Meyerholz DK </li><li class="loa__item">Perlman S </li></ul><div class="reference-citations__detials">Virus-specific memory CD8 T cells provide substantial protection from lethal severe acute respiratory syndrome coronavirus infection.<div class="popup-ref"><span class="ref__series"><i>J Virol.</i> <span class="ref__seriesDate">2014; </span><span class="ref__seriesVolume">88</span></span>: <span class="ref__seriesPages">11034-11044</span></div></div><div class="reference-citations__links"><ul class="rlist inline-bullet-list"><li><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=88&publication_year=2014&pages=11034-11044&journal=J+Virol&author=Channappanavar+R&author=Fett+C&author=Zhao+J&author=Meyerholz+DK&author=Perlman+S&title=Virus-specific+memory+CD8+T+cells+provide+substantial+protection+from+lethal+severe+acute+respiratory+syndrome+coronavirus+infection">Google Scholar</a></li></ul></div></div><a href="#" class="dropBlock__ctrl--close" title="Close info"><i aria-hidden="true" class="icon-close_thin"></i></a></div></div> A similar rapid decline of the specific antibody amounts in patients with COVID-19 after recovery was also noted,<div class="dropBlock reference-citations"><sup><a href="#" id="back-bib19" data-db-target-for="bib19-d13208547e1540" class="reference-citations__ctrl" aria-expanded="false" aria-controls="bib19">19</a></sup><div data-db-target-of="bib19-d13208547e1540" class="dropBlock__holder"><div class="dropBlock__body"><ul title="list of authors" class="rlist reference-citations__loa inline-bullet-list"><li class="loa__item">Wang X </li><li class="loa__item">Guo X </li><li class="loa__item">Xin Q </li><li>et al.</li></ul><div class="reference-citations__detials">Neutralizing antibodies responses to SARS-CoV-2 in COVID-19 inpatients and convalescent patients.<div class="popup-ref"><span class="ref__series"><i>medRxiv.</i> <span class="ref__seriesDate">2020; </span><span class="ref__seriesVolume"></span> (<span class="refComment">DOI: 2020.04.15.20065623 (preprint)</span>)</span></div></div><div class="reference-citations__links"><ul class="rlist inline-bullet-list"><li><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&journal=medRxiv&author=Wang+X&author=Guo+X&author=Xin+Q&title=Neutralizing+antibodies+responses+to+SARS-CoV-2+in+COVID-19+inpatients+and+convalescent+patients">Google Scholar</a></li></ul></div></div><a href="#" class="dropBlock__ctrl--close" title="Close info"><i aria-hidden="true" class="icon-close_thin"></i></a></div></div><sup>, </sup> <div class="dropBlock reference-citations"><sup><a href="#" id="back-bib20" data-db-target-for="bib20-d13208547e1540" class="reference-citations__ctrl" aria-expanded="false" aria-controls="bib20">20</a></sup><div data-db-target-of="bib20-d13208547e1540" class="dropBlock__holder"><div class="dropBlock__body"><ul title="list of authors" class="rlist reference-citations__loa inline-bullet-list"><li class="loa__item">Wu F </li><li class="loa__item">Wang A </li><li class="loa__item">Liu M </li><li>et al.</li></ul><div class="reference-citations__detials">Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications.<div class="popup-ref"><span class="ref__series"><i>medRxiv.</i> <span class="ref__seriesDate">2020; </span><span class="ref__seriesVolume"></span> (<span class="refComment">DOI: 2020.03.30.20047365 (preprint)</span>)</span></div></div><div class="reference-citations__links"><ul class="rlist inline-bullet-list"><li><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&journal=medRxiv&author=Wu+F&author=Wang+A&author=Liu+M&title=Neutralizing+antibody+responses+to+SARS-CoV-2+in+a+COVID-19+recovered+patient+cohort+and+their+implications">Google Scholar</a></li></ul></div></div><a href="#" class="dropBlock__ctrl--close" title="Close info"><i aria-hidden="true" class="icon-close_thin"></i></a></div></div> suggesting that both specific cellular and humoral immunity are potentially important for a successful COVID-19 vaccine. Here, we only report the data within 28 days after the vaccination, but we are going to follow up the vaccine recipients for at least 6 months, so more data will be obtained.</div><div class="section-paragraph">This study was done in Wuhan, Hubei province, which was the centre of the COVID-19 epidemic in China.<div class="dropBlock reference-citations"><sup><a href="#bib21" id="back-bib21" data-db-target-for="bib21-d13208547e1546" class="reference-citations__ctrl" aria-expanded="false" aria-controls="bib21">21</a></sup><div data-db-target-of="bib21-d13208547e1546" class="dropBlock__holder"><div class="dropBlock__body"><ul title="list of authors" class="rlist reference-citations__loa inline-bullet-list"><li class="loa__item">Chen N </li><li class="loa__item">Zhou M </li><li class="loa__item">Dong X </li><li>et al.</li></ul><div class="reference-citations__detials">Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study.<div class="popup-ref"><span class="ref__series"><i>Lancet.</i> <span class="ref__seriesDate">2020; </span><span class="ref__seriesVolume">395</span></span>: <span class="ref__seriesPages">507-513</span></div></div><div class="reference-citations__links"><ul class="rlist inline-bullet-list"><li><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=395&publication_year=2020&pages=507-513&journal=Lancet&author=Chen+N&author=Zhou+M&author=Dong+X&title=Epidemiological+and+clinical+characteristics+of+99+cases+of+2019+novel+coronavirus+pneumonia+in+Wuhan%2C+China%3A+a+descriptive+study">Google Scholar</a></li></ul></div></div><a href="#" class="dropBlock__ctrl--close" title="Close info"><i aria-hidden="true" class="icon-close_thin"></i></a></div></div> People living in the city of Wuhan had a much higher risk of SARS-CoV-2 infection compared with those living in other cities outside of Hubei province, even though when we initiated this trial, the city had already begun lockdown and implemented mandatory home isolation for residents. Therefore, we did serological screening, nucleic acid testing, and chest CT to exclude participants who had been previously exposed to SARS-CoV-2 during recruitment. In addition, we arranged for all participants in our study to stay in a designated hotel for 14 days post-vaccination. This arrangement facilitated the observation of adverse events after the immunisation of the participants, and reduced the risk of SARS-CoV-2 exposure during the following 2 weeks. These measures allowed the study to be done successfully without interference by the circulation of SARS-CoV-2, which is especially important in the absence of a placebo control.</div><div class="section-paragraph">Interpretation of the results of this study is limited by the small size of the cohort, the short duration of follow-up, and the absence of a randomised control group. As it was a first-in-human study of the Ad5 vectored COVID-19 vaccine, it was not designed to measure the vaccine efficacy. However, in preclinical studies, seven out of eight ferrets were protected from having detectable virus copies when challenged by SARS-CoV-2 through nasal dripping 21 days after immunisation with the vaccine, whereas only one out of eight ferrets in the control group was negative for virus copies (Wei C, unpublished). We aimed to evaluate the safety and tolerability of the candidate vaccine in healthy adults, with no interference by underlying diseases or medicines. However, results of our study indicated that older age could have a negative effect on the vaccine-elicited responses to SARS-CoV-2. In this trial, no participants were older than 60 years and only 16% of the participants were older than 50 years, providing limited information on the capability of generating a potent cellular and humoral response in the older population. Since age has also been identified as an independent risk factor for severe disease associated with SARS-CoV-2 infection,<div class="dropBlock reference-citations"><sup><a href="#" id="back-bib4" data-db-target-for="bib4-d13208547e1552" class="reference-citations__ctrl" aria-expanded="false" aria-controls="bib4">4</a></sup><div data-db-target-of="bib4-d13208547e1552" class="dropBlock__holder"><div class="dropBlock__body"><ul title="list of authors" class="rlist reference-citations__loa inline-bullet-list"><li class="loa__item">Weiss P </li><li class="loa__item">Murdoch DR </li></ul><div class="reference-citations__detials">Clinical course and mortality risk of severe COVID-19.<div class="popup-ref"><span class="ref__series"><i>Lancet.</i> <span class="ref__seriesDate">2020; </span><span class="ref__seriesVolume">395</span></span>: <span class="ref__seriesPages">1014-1015</span></div></div><div class="reference-citations__links"><ul class="rlist inline-bullet-list"><li><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=395&publication_year=2020&pages=1014-1015&journal=Lancet&author=Weiss+P&author=Murdoch+DR&title=Clinical+course+and+mortality+risk+of+severe+COVID-19">Google Scholar</a></li></ul></div></div><a href="#" class="dropBlock__ctrl--close" title="Close info"><i aria-hidden="true" class="icon-close_thin"></i></a></div></div><sup>, </sup> <div class="dropBlock reference-citations"><sup><a href="#" id="back-bib22" data-db-target-for="bib22-d13208547e1552" class="reference-citations__ctrl" aria-expanded="false" aria-controls="bib22">22</a></sup><div data-db-target-of="bib22-d13208547e1552" class="dropBlock__holder"><div class="dropBlock__body"><ul title="list of authors" class="rlist reference-citations__loa inline-bullet-list"><li class="loa__item">Ye G </li><li class="loa__item">Pan Z </li><li class="loa__item">Pan Y </li><li>et al.</li></ul><div class="reference-citations__detials">Clinical characteristics of severe acute respiratory syndrome coronavirus 2 reactivation.<div class="popup-ref"><span class="ref__series"><i>J Infect.</i> <span class="ref__seriesDate">2020; </span><span class="ref__seriesVolume">80</span></span>: <span class="ref__seriesPages">e14-e17</span></div></div><div class="reference-citations__links"><ul class="rlist inline-bullet-list"><li><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2020&pages=e14-e17&journal=J+Infect&author=Ye+G&author=Pan+Z&author=Pan+Y&title=Clinical+characteristics+of+severe+acute+respiratory+syndrome+coronavirus+2+reactivation">Google Scholar</a></li></ul></div></div><a href="#" class="dropBlock__ctrl--close" title="Close info"><i aria-hidden="true" class="icon-close_thin"></i></a></div></div> and there is a possibility that an even lower immune response might be found in the older population, we are going to include participants who are older than 60 years in the phase 2 study considering this population as an important target population for a COVID-19 vaccine. Additionally, experience with vaccine candidates for SARS and MERS have raised concerns about the antibody-dependent enhancement in participants who are infected with a circulating SARS-CoV-2 post-vaccination.<div class="dropBlock reference-citations"><sup><a href="#bib23" id="back-bib23" data-db-target-for="bib23-d13208547e1556" class="reference-citations__ctrl" aria-expanded="false" aria-controls="bib23">23</a></sup><div data-db-target-of="bib23-d13208547e1556" class="dropBlock__holder"><div class="dropBlock__body"><ul title="list of authors" class="rlist reference-citations__loa inline-bullet-list"><li class="loa__item">Lurie N </li><li class="loa__item">Saville M </li><li class="loa__item">Hatchett R </li><li class="loa__item">Halton J </li></ul><div class="reference-citations__detials">Developing Covid-19 vaccines at pandemic speed.<div class="popup-ref"><span class="ref__series"><i>N Engl J Med.</i> <span class="ref__seriesDate">2020; </span><span class="ref__seriesVolume"></span> (<span class="refComment">NEJMp2005630.</span>)</span></div></div><div class="reference-citations__links"><ul class="rlist inline-bullet-list"><li><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&journal=N+Engl+J+Med&author=Lurie+N&author=Saville+M&author=Hatchett+R&author=Halton+J&title=Developing+Covid-19+vaccines+at+pandemic+speed">Google Scholar</a></li></ul></div></div><a href="#" class="dropBlock__ctrl--close" title="Close info"><i aria-hidden="true" class="icon-close_thin"></i></a></div></div> However, this study was not statistically powered to measure any safety outcome, especially for the concerns around immunopathology and antibody-dependent enhancement events associated with the full-length spike glycoprotein vaccine antigen.<div class="dropBlock reference-citations"><sup><a href="#bib24" id="back-bib24" data-db-target-for="bib24-d13208547e1560" class="reference-citations__ctrl" aria-expanded="false" aria-controls="bib24">24</a></sup><div data-db-target-of="bib24-d13208547e1560" class="dropBlock__holder"><div class="dropBlock__body"><ul title="list of authors" class="rlist reference-citations__loa inline-bullet-list"><li class="loa__item">Cao X </li></ul><div class="reference-citations__detials">COVID-19: immunopathology and its implications for therapy.<div class="popup-ref"><span class="ref__series"><i>Nat Rev Immunol.</i> <span class="ref__seriesDate">2020; </span><span class="ref__seriesVolume">20</span></span>: <span class="ref__seriesPages">269-270</span></div></div><div class="reference-citations__links"><ul class="rlist inline-bullet-list"><li><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2020&pages=269-270&journal=Nat+Rev+Immunol&author=Cao+X&title=COVID-19%3A+immunopathology+and+its+implications+for+therapy">Google Scholar</a></li></ul></div></div><a href="#" class="dropBlock__ctrl--close" title="Close info"><i aria-hidden="true" class="icon-close_thin"></i></a></div></div> Our study found that the pre-existing Ad5 immunity could slow down the rapid immune responses to SARS-CoV-2 and also lower the peak of the responses, particularly for humoral immunity. The high pre-existing Ad5 immunity might also have a negative effect on the persistence of the vaccine-elicited immune responses. In previous studies, heterologous prime-boost combinations or homologous prime-boost regimens with Ad5 vectored vaccines were shown to be able to induce more strong and durable immunogenic responses in populations with high pre-existing Ad5 immunity.<div class="dropBlock reference-citations"><sup><a href="#" id="back-bib25" data-db-target-for="bib25-d13208547e1564" class="reference-citations__ctrl" aria-expanded="false" aria-controls="bib25">25</a></sup><div data-db-target-of="bib25-d13208547e1564" class="dropBlock__holder"><div class="dropBlock__body"><ul title="list of authors" class="rlist reference-citations__loa inline-bullet-list"><li class="loa__item">Venkatraman N </li><li class="loa__item">Ndiaye BP </li><li class="loa__item">Bowyer G </li><li>et al.</li></ul><div class="reference-citations__detials">Safety and immunogenicity of a heterologous prime-boost Ebola virus vaccine regimen in healthy adults in the United Kingdom and Senegal.<div class="popup-ref"><span class="ref__series"><i>J Infect Dis.</i> <span class="ref__seriesDate">2019; </span><span class="ref__seriesVolume">219</span></span>: <span class="ref__seriesPages">1187-1197</span></div></div><div class="reference-citations__links"><ul class="rlist inline-bullet-list"><li><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=219&publication_year=2019&pages=1187-1197&journal=J+Infect+Dis&author=Venkatraman+N&author=Ndiaye+BP&author=Bowyer+G&title=Safety+and+immunogenicity+of+a+heterologous+prime-boost+Ebola+virus+vaccine+regimen+in+healthy+adults+in+the+United+Kingdom+and+Senegal">Google Scholar</a></li></ul></div></div><a href="#" class="dropBlock__ctrl--close" title="Close info"><i aria-hidden="true" class="icon-close_thin"></i></a></div></div><sup>, </sup> <div class="dropBlock reference-citations"><sup><a href="#" id="back-bib26" data-db-target-for="bib26-d13208547e1564" class="reference-citations__ctrl" aria-expanded="false" aria-controls="bib26">26</a></sup><div data-db-target-of="bib26-d13208547e1564" class="dropBlock__holder"><div class="dropBlock__body"><ul title="list of authors" class="rlist reference-citations__loa inline-bullet-list"><li class="loa__item">Dolzhikova IV </li><li class="loa__item">Zubkova OV </li><li class="loa__item">Tukhvatulin AI </li><li>et al.</li></ul><div class="reference-citations__detials">Safety and immunogenicity of GamEvac-Combi, a heterologous VSV- and Ad5-vectored Ebola vaccine: an open phase I/II trial in healthy adults in Russia.<div class="popup-ref"><span class="ref__series"><i>Hum Vaccin Immunother.</i> <span class="ref__seriesDate">2017; </span><span class="ref__seriesVolume">13</span></span>: <span class="ref__seriesPages">613-620</span></div></div><div class="reference-citations__links"><ul class="rlist inline-bullet-list"><li><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2017&pages=613-620&journal=Hum+Vaccin+Immunother&author=Dolzhikova+IV&author=Zubkova+OV&author=Tukhvatulin+AI&title=Safety+and+immunogenicity+of+GamEvac-Combi%2C+a+heterologous+VSV-+and+Ad5-vectored+Ebola+vaccine%3A+an+open+phase+I%2FII+trial+in+healthy+adults+in+Russia">Google Scholar</a></li></ul></div></div><a href="#" class="dropBlock__ctrl--close" title="Close info"><i aria-hidden="true" class="icon-close_thin"></i></a></div></div><sup>, </sup> <div class="dropBlock reference-citations"><sup><a href="#" id="back-bib27" data-db-target-for="bib27-d13208547e1564" class="reference-citations__ctrl" aria-expanded="false" aria-controls="bib27">27</a></sup><div data-db-target-of="bib27-d13208547e1564" class="dropBlock__holder"><div class="dropBlock__body"><ul title="list of authors" class="rlist reference-citations__loa inline-bullet-list"><li class="loa__item">Shukarev G </li><li class="loa__item">Callendret B </li><li class="loa__item">Luhn K </li><li class="loa__item">Douoguih M </li></ul><div class="reference-citations__detials">A two-dose heterologous prime-boost vaccine regimen eliciting sustained immune responses to Ebola Zaire could support a preventive strategy for future outbreaks.<div class="popup-ref"><span class="ref__series"><i>Hum Vaccin Immunother.</i> <span class="ref__seriesDate">2017; </span><span class="ref__seriesVolume">13</span></span>: <span class="ref__seriesPages">266-270</span></div></div><div class="reference-citations__links"><ul class="rlist inline-bullet-list"><li><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2017&pages=266-270&journal=Hum+Vaccin+Immunother&author=Shukarev+G&author=Callendret+B&author=Luhn+K&author=Douoguih+M&title=A+two-dose+heterologous+prime-boost+vaccine+regimen+eliciting+sustained+immune+responses+to+Ebola+Zaire+could+support+a+preventive+strategy+for+future+outbreaks">Google Scholar</a></li></ul></div></div><a href="#" class="dropBlock__ctrl--close" title="Close info"><i aria-hidden="true" class="icon-close_thin"></i></a></div></div> Nevertheless, limited information is available for the effects of multiple doses of the candidate Ad5 vectored COVID-19 vaccine in humans, which warrants further investigation.</div><div class="section-paragraph">Over the past decade, the vaccine industry and clinical research centres have been asked to provide urgent responses to epidemics of emerging infectious diseases, such as H1N1 influenza, Ebola virus, Zika, MERS, and now SARS-CoV-2.<div class="dropBlock reference-citations"><sup><a href="#bib23" id="back-bib23" data-db-target-for="bib23-d13208547e1570" class="reference-citations__ctrl" aria-expanded="false" aria-controls="bib23">23</a></sup><div data-db-target-of="bib23-d13208547e1570" class="dropBlock__holder"><div class="dropBlock__body"><ul title="list of authors" class="rlist reference-citations__loa inline-bullet-list"><li class="loa__item">Lurie N </li><li class="loa__item">Saville M </li><li class="loa__item">Hatchett R </li><li class="loa__item">Halton J </li></ul><div class="reference-citations__detials">Developing Covid-19 vaccines at pandemic speed.<div class="popup-ref"><span class="ref__series"><i>N Engl J Med.</i> <span class="ref__seriesDate">2020; </span><span class="ref__seriesVolume"></span> (<span class="refComment">NEJMp2005630.</span>)</span></div></div><div class="reference-citations__links"><ul class="rlist inline-bullet-list"><li><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&journal=N+Engl+J+Med&author=Lurie+N&author=Saville+M&author=Hatchett+R&author=Halton+J&title=Developing+Covid-19+vaccines+at+pandemic+speed">Google Scholar</a></li></ul></div></div><a href="#" class="dropBlock__ctrl--close" title="Close info"><i aria-hidden="true" class="icon-close_thin"></i></a></div></div> The risk of COVID-19 caused by SARS-CoV-2 is ongoing, making the need for effective vaccines even more urgent.<div class="dropBlock reference-citations"><sup><a href="#bib28" id="back-bib28" data-db-target-for="bib28-d13208547e1574" class="reference-citations__ctrl" aria-expanded="false" aria-controls="bib28">28</a></sup><div data-db-target-of="bib28-d13208547e1574" class="dropBlock__holder"><div class="dropBlock__body"><ul title="list of authors" class="rlist reference-citations__loa inline-bullet-list"><li class="loa__item">Richardson S </li><li class="loa__item">Hirsch JS </li><li class="loa__item">Narasimhan M </li><li>et al.</li></ul><div class="reference-citations__detials">Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area.<div class="popup-ref"><span class="ref__series"><i>JAMA.</i> <span class="ref__seriesDate">2020; </span><span class="ref__seriesVolume"></span> (<span class="refComment">published online April 22.</span>)</span><div class="citation-host"><a href="http://dx.doi.org/10.1001/jama.2020.6775" target="_blank">DOI:10.1001/jama.2020.6775</a></div></div></div><div class="reference-citations__links"><ul class="rlist inline-bullet-list"><li><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&journal=JAMA&author=Richardson+S&author=Hirsch+JS&author=Narasimhan+M&title=Presenting+characteristics%2C+comorbidities%2C+and+outcomes+among+5700+patients+hospitalized+with+COVID-19+in+the+New+York+City+area">Google Scholar</a></li></ul></div></div><a href="#" class="dropBlock__ctrl--close" title="Close info"><i aria-hidden="true" class="icon-close_thin"></i></a></div></div> We started the development of this candidate vaccine in January, 2020, when SARS-CoV-2 was first isolated and sequenced. The full-length spike glycoprotein was selected as the vaccine antigen, mainly on the basis of previous experience with SARS and MERS vaccines. Previous findings suggested that those vaccines expressing full-length spike glycoprotein can induce good immune responses and protective efficacy.<div class="dropBlock reference-citations"><sup><a href="#bib29" id="back-bib29" data-db-target-for="bib29-d13208547e1578" class="reference-citations__ctrl" aria-expanded="false" aria-controls="bib29">29</a></sup><div data-db-target-of="bib29-d13208547e1578" class="dropBlock__holder"><div class="dropBlock__body"><ul title="list of authors" class="rlist reference-citations__loa inline-bullet-list"><li class="loa__item">Yong CY </li><li class="loa__item">Ong HK </li><li class="loa__item">Yeap SK </li><li class="loa__item">Ho KL </li><li class="loa__item">Tan WS </li></ul><div class="reference-citations__detials">Recent advances in the vaccine development against Middle East respiratory syndrome-coronavirus.<div class="popup-ref"><span class="ref__series"><i>Front Microbiol.</i> <span class="ref__seriesDate">2019; </span><span class="ref__seriesVolume">10</span></span>1781</div></div><div class="reference-citations__links"><ul class="rlist inline-bullet-list"><li><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&journal=Front+Microbiol&author=Yong+CY&author=Ong+HK&author=Yeap+SK&author=Ho+KL&author=Tan+WS&title=Recent+advances+in+the+vaccine+development+against+Middle+East+respiratory+syndrome-coronavirus">Google Scholar</a></li></ul></div></div><a href="#" class="dropBlock__ctrl--close" title="Close info"><i aria-hidden="true" class="icon-close_thin"></i></a></div></div> Although the RBD comprises the critical neutralising domains for the coronaviruses, the neutralising epitopes located outside the RBD were also identified.<div class="dropBlock reference-citations"><sup><a href="#" id="back-bib30" data-db-target-for="bib30-d13208547e1582" class="reference-citations__ctrl" aria-expanded="false" aria-controls="bib30">30</a></sup><div data-db-target-of="bib30-d13208547e1582" class="dropBlock__holder"><div class="dropBlock__body"><ul title="list of authors" class="rlist reference-citations__loa inline-bullet-list"><li class="loa__item">Duan J </li><li class="loa__item">Yan X </li><li class="loa__item">Guo X </li><li>et al.</li></ul><div class="reference-citations__detials">A human SARS-CoV neutralizing antibody against epitope on S2 protein.<div class="popup-ref"><span class="ref__series"><i>Biochem Biophys Res Commun.</i> <span class="ref__seriesDate">2005; </span><span class="ref__seriesVolume">333</span></span>: <span class="ref__seriesPages">186-193</span></div></div><div class="reference-citations__links"><ul class="rlist inline-bullet-list"><li><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=333&publication_year=2005&pages=186-193&journal=Biochem+Biophys+Res+Commun&author=Duan+J&author=Yan+X&author=Guo+X&title=A+human+SARS-CoV+neutralizing+antibody+against+epitope+on+S2+protein">Google Scholar</a></li></ul></div></div><a href="#" class="dropBlock__ctrl--close" title="Close info"><i aria-hidden="true" class="icon-close_thin"></i></a></div></div><sup>, </sup> <div class="dropBlock reference-citations"><sup><a href="#" id="back-bib31" data-db-target-for="bib31-d13208547e1582" class="reference-citations__ctrl" aria-expanded="false" aria-controls="bib31">31</a></sup><div data-db-target-of="bib31-d13208547e1582" class="dropBlock__holder"><div class="dropBlock__body"><ul title="list of authors" class="rlist reference-citations__loa inline-bullet-list"><li class="loa__item">Wang Q </li><li class="loa__item">Zhang L </li><li class="loa__item">Kuwahara K </li><li>et al.</li></ul><div class="reference-citations__detials">Immunodominant SARS coronavirus epitopes in humans elicited both enhancing and neutralizing effects on infection in non-human primates.<div class="popup-ref"><span class="ref__series"><i>ACS Infect Dis.</i> <span class="ref__seriesDate">2016; </span><span class="ref__seriesVolume">2</span></span>: <span class="ref__seriesPages">361-376</span></div></div><div class="reference-citations__links"><ul class="rlist inline-bullet-list"><li><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2016&pages=361-376&journal=ACS+Infect+Dis&author=Wang+Q&author=Zhang+L&author=Kuwahara+K&title=Immunodominant+SARS+coronavirus+epitopes+in+humans+elicited+both+enhancing+and+neutralizing+effects+on+infection+in+non-human+primates">Google Scholar</a></li></ul></div></div><a href="#" class="dropBlock__ctrl--close" title="Close info"><i aria-hidden="true" class="icon-close_thin"></i></a></div></div> The full-length spike was chosen in most of the viral vectored, mRNA, or DNA COVID-19 vaccines in development.<div class="dropBlock reference-citations"><sup><a href="#bib9" id="back-bib9" data-db-target-for="bib9-d13208547e1586" class="reference-citations__ctrl" aria-expanded="false" aria-controls="bib9">9</a></sup><div data-db-target-of="bib9-d13208547e1586" class="dropBlock__holder"><div class="dropBlock__body"><div class="reference-citations__detials"><span>WHO</span><br />DRAFT landscape of COVID-19 candidate vaccines–30 April 2020.<div class="popup-ref"><div class="citation-host"><a href="https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines" target="_blank">https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines</a><div><span>Date: </span>2020</div><div><span>Date accessed: </span>May 5, 2020</div></div></div></div><div class="reference-citations__links"><ul class="rlist inline-bullet-list"><li><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=WHO&title=DRAFT+landscape+of+COVID-19+candidate+vaccines%E2%80%9330+April+2020">Google Scholar</a></li></ul></div></div><a href="#" class="dropBlock__ctrl--close" title="Close info"><i aria-hidden="true" class="icon-close_thin"></i></a></div></div> The Ad5 vector vaccine platform is highly efficient and well established as a vaccine antigen delivery system. In addition to our candidate Ad5 vectored COVID-19 vaccine, there are several other Ad5-based vaccines against COVID-19 listed in the WHO draft landscape of COVID-19 candidate vaccines, including Ad5 S (GREVAXTM platform) in the USA, and Oral Ad5 S (Stabilitech Biopharma) in the UK.<div class="dropBlock reference-citations"><sup><a href="#bib9" id="back-bib9" data-db-target-for="bib9-d13208547e1591" class="reference-citations__ctrl" aria-expanded="false" aria-controls="bib9">9</a></sup><div data-db-target-of="bib9-d13208547e1591" class="dropBlock__holder"><div class="dropBlock__body"><div class="reference-citations__detials"><span>WHO</span><br />DRAFT landscape of COVID-19 candidate vaccines–30 April 2020.<div class="popup-ref"><div class="citation-host"><a href="https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines" target="_blank">https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines</a><div><span>Date: </span>2020</div><div><span>Date accessed: </span>May 5, 2020</div></div></div></div><div class="reference-citations__links"><ul class="rlist inline-bullet-list"><li><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=WHO&title=DRAFT+landscape+of+COVID-19+candidate+vaccines%E2%80%9330+April+2020">Google Scholar</a></li></ul></div></div><a href="#" class="dropBlock__ctrl--close" title="Close info"><i aria-hidden="true" class="icon-close_thin"></i></a></div></div> However, aside from pre-existing anti-Ad5 immunity, there is a concern about the increased risk of HIV-1 acquisition associated with Ad5 activated CD4<sup>+</sup> T cells.<div class="dropBlock reference-citations"><sup><a href="#bib32" id="back-bib32" data-db-target-for="bib32-d13208547e1598" class="reference-citations__ctrl" aria-expanded="false" aria-controls="bib32">32</a></sup><div data-db-target-of="bib32-d13208547e1598" class="dropBlock__holder"><div class="dropBlock__body"><ul title="list of authors" class="rlist reference-citations__loa inline-bullet-list"><li class="loa__item">Gray GE </li><li class="loa__item">Moodie Z </li><li class="loa__item">Metch B </li><li>et al.</li></ul><div class="reference-citations__detials">Recombinant adenovirus type 5 HIV gag/pol/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 503/Phambili study.<div class="popup-ref"><span class="ref__series"><i>Lancet Infect Dis.</i> <span class="ref__seriesDate">2014; </span><span class="ref__seriesVolume">14</span></span>: <span class="ref__seriesPages">388-396</span></div></div><div class="reference-citations__links"><ul class="rlist inline-bullet-list"><li><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2014&pages=388-396&journal=Lancet+Infect+Dis&author=Gray+GE&author=Moodie+Z&author=Metch+B&title=Recombinant+adenovirus+type+5+HIV+gag%2Fpol%2Fnef+vaccine+in+South+Africa%3A+unblinded%2C+long-term+follow-up+of+the+phase+2b+HVTN+503%2FPhambili+study">Google Scholar</a></li></ul></div></div><a href="#" class="dropBlock__ctrl--close" title="Close info"><i aria-hidden="true" class="icon-close_thin"></i></a></div></div> Although the association between HIV-1 acquisition risk and Ad5 vectored vaccine is controversial and its mechanism is unclear, the potential risks should be taken into account in studies with this viral vector delivery platform. We plan to monitor the participants in our upcoming phase 2 and phase 3 studies to assess the indication for any such acquisition.</div><div class="section-paragraph">In conclusion, we found that the Ad5 vectored COVID-19 vaccine is tolerable and immunogenic in healthy adults. Specific humoral responses against SARS-CoV-2 peaked at day 28 post-vaccination, and rapid, specific T-cell responses were noted from day 14 after one shot of the vaccine. There is potential for further investigation of the Ad5 vectored COVID-19 vaccine for the control of the COVID-19 outbreak. An ongoing phase 2 trial in China (<a href="http://clinicaltrials.gov/show/NCT04341389" target="_blank">NCT04341389</a>) will provide more information on the safety and immunogenicity of the Ad5 vectored COVID-19 vaccine.</div></section><div class="section-paragraph"><strong>Contributors</strong></div><div class="section-paragraph">F-CZ and Y-HL were co-first authors. F-CZ, WW, and WC were joint corresponding authors. F-CZ is the principal investigator of this trial. X-HG and WW worked as co-principal investigators of this trial. F-CZ, WC, X-HG, L-HH, Y-HL, W-JW, J-XL, and S-YJ designed the trial and the study protocol. J-XL drafted the manuscript. WC contributed to critical review and revision of the manuscript. F-CZ, W-JW, J-XL, and S-YJ contributed to the data interpretation and revision of the manuscript. X-WW was responsible for the statistical analysis. J-JX and B-SW contributed to study supervision. WW, W-JW, ZW, LeW, S-YJ, and H-DJ led and participated in the site work, including the recruitment, follow-up, and data collection. Y-HL, TJ, YH, LiW, and S-BX were responsible for laboratory analyses. W-JW, J-XL, and S-YJ contributed to the literature search. J-BG and S-PW monitored the trial.</div><div class="section-paragraph"><strong>Declaration of interests</strong></div><div class="section-paragraph">WC reports grants from the National Key R&amp;D Program of China (2020YFC10841400), and grants from the National Science and Technology Major Project (2016ZX10004001, 2018ZX09201005). J-BG is an employee of CanSino Biologics. All other authors declare no competing interests.</div><section id="cesec100" data-locator="cesec100"><h2 class="top" id="seccestitle160" data-left-hand-nav="Data sharing"><span class="top__sub"></span><span class="top__text">Data sharing</span></h2><div class="section-paragraph">We support data sharing of the individual participant data. The individual participant data that underlie the results reported in this Article, after de-identification (text, tables, figures, and appendix) will be shared. Individual participant data will be available beginning 3 months and ending 1 year after publication. <a href="http://www.jscdc.cn/jkfw/kygz/202005/t20200517_68894.html" target="_blank">Supporting clinical documents</a> including the study protocol, statistical analysis plan, and the informed consent form will be available immediately following publication for at least 1 year. Researchers who provide a scientifically sound proposal will be allowed access to the individual participant data. Proposals should be directed to <a href="/cdn-cgi/l/email-protection#59332a233f3a192f3029772a303738773a3634" target="_blank"><span class="__cf_email__" data-cfemail="79130a031f1a390f1009570a101718571a1614">[email&#160;protected]</span></a> or <a href="/cdn-cgi/l/email-protection#2e4d591e1c1c186e484156434f4742004d4143" target="_blank"><span class="__cf_email__" data-cfemail="4e2d397e7c7c780e282136232f2722602d2123">[email&#160;protected]</span></a>. These proposals will be reviewed and approved by the sponsor, investigator, and collaborators on the basis of scientific merit. To gain access, data requesters will need to sign a data access agreement.</div></section><section><div class="section-paragraph"><strong>Acknowledgments</strong></div><div class="section-paragraph">We thank Peng Deng, Qiong Li, and Xiaoai Qian from Hubei Provincial Center for Disease Control and Prevention for participant recruitment and sample collection. We thank Miao Xu and Jingjing Liu from the National Institute for Food and Drug Control (China), Yansong Sun, Sen Zhang, and Yuchang Li from the Beijing Institute of Microbiology and Epidemiology, and Feng Wang, Hongyan Hou, Hanxiong Guan, and Bo Liu from Tongji Hospital for laboratory analysis. We thank Ke Zhang from the Academy of Military Medical Sciences, Kun Liu from the General Hospital of Central Theater Command, and Changlong Fu from Wuhan Rest Center, Chinese People's Armed Police Force for the management of the clinical trial site.</div></section><section id="sec1" data-locator="sec1"><h2 class="top" id="seccestitle170" data-left-hand-nav="Supplementary Material"><span class="top__sub"></span><span class="top__text">Supplementary Material</span></h2><div class="section-paragraph supplemental-information"><ul class="rlist"><li class="supplemental-information__item" id="ecomp10"><div class="supplemental-information__icon icon-gizmo-pdf-file2"></div><div class="supplemental-information__links clearfix"><div class="col-sm-6 gutterless"><a href="/cms/10.1016/S0140-6736(20)31208-3/attachment/d2f4d28a-f892-449e-bf56-b0e92c72609a/mmc1.pdf" class="supplemental-information__download " target="_blank">
                                            Download .pdf (1.78
                                            MB)
                                        </a></div><div class="col-sm-6 gutterless"><a href="https://service.elsevier.com/app/answers/detail/a_id/19286/supporthub/sciencedirect/" class="supplemental-information__help " target="_blank">
                                    Help with
                                    pdf files
                                </a></div></div><div class="supplemental-information__title">Supplementary appendix</div></li></ul></div></section><div data-pb-dropzone="extra-dropzone" class="extra-dropzone pb-dropzone"><!-- Empty dropzone --></div><section class="refs"><h2 class="top" id="seccestitle180" data-left-hand-nav="References"><span class="top__sub"></span><span class="top__text">References</span></h2><ol class="ref__wrapper"><li class="ref"><span class="refLabel">1.</span><ul title="list of authors" class="rlist inline-bullet-list ref__authors ref__inline-block"><li class="ref__authors__name">Zhu N </li><li class="ref__authors__name">Zhang D </li><li class="ref__authors__name">Wang W </li><li>et al.</li></ul><div class="ref__title">A novel coronavirus from patients with pneumonia in China, 2019.</div><span class="ref__series"><i>N Engl J Med.</i> <span class="ref__seriesDate">2020; </span><span class="ref__seriesVolume">382</span></span>: <span class="ref__seriesPages">727-733</span><div class="ref__controls"><a href="#back-bib1" title="View in Article" class="ref__controls__viewInArticle scroll-into-link">View
                        in Article
                        <i class="icon-section_arrow_u"></i></a><ul class="rlist inline-bullet-list"><li><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=382&publication_year=2020&pages=727-733&journal=N+Engl+J+Med&author=Zhu+N&author=Zhang+D&author=Wang+W&title=A+novel+coronavirus+from+patients+with+pneumonia+in+China%2C+2019">Google Scholar</a></li></ul></div></li><li class="ref"><span class="refLabel">2.</span><ul title="list of authors" class="rlist inline-bullet-list ref__authors ref__inline-block"><li class="ref__authors__name">Li Q </li><li class="ref__authors__name">Guan X </li><li class="ref__authors__name">Wu P </li><li>et al.</li></ul><div class="ref__title">Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia.</div><span class="ref__series"><i>N Engl J Med.</i> <span class="ref__seriesDate">2020; </span><span class="ref__seriesVolume">382</span></span>: <span class="ref__seriesPages">1199-1207</span><div class="ref__controls"><a href="#back-bib2" title="View in Article" class="ref__controls__viewInArticle scroll-into-link">View
                        in Article
                        <i class="icon-section_arrow_u"></i></a><ul class="rlist inline-bullet-list"><li><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=382&publication_year=2020&pages=1199-1207&journal=N+Engl+J+Med&author=Li+Q&author=Guan+X&author=Wu+P&title=Early+transmission+dynamics+in+Wuhan%2C+China%2C+of+novel+coronavirus-infected+pneumonia">Google Scholar</a></li></ul></div></li><li class="ref"><span class="refLabel">3.</span><ul title="list of authors" class="rlist inline-bullet-list ref__authors ref__inline-block"><li class="ref__authors__name">Grein J </li><li class="ref__authors__name">Ohmagari N </li><li class="ref__authors__name">Shin D </li><li>et al.</li></ul><div class="ref__title">Compassionate use of remdesivir for patients with severe Covid-19.</div><span class="ref__series"><i>N Engl J Med.</i> <span class="ref__seriesDate">2020; </span><span class="ref__seriesVolume"></span> (<span class="refComment">published online April 10.</span>)</span><div class="citation-host"><a href="http://dx.doi.org/10.1056/NEJMoa2007016NEJMoa2007016" target="_blank">DOI:10.1056/NEJMoa2007016NEJMoa2007016</a></div><div class="ref__controls"><a href="#back-bib3" title="View in Article" class="ref__controls__viewInArticle scroll-into-link">View
                        in Article
                        <i class="icon-section_arrow_u"></i></a><ul class="rlist inline-bullet-list"><li><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&journal=N+Engl+J+Med&author=Grein+J&author=Ohmagari+N&author=Shin+D&title=Compassionate+use+of+remdesivir+for+patients+with+severe+Covid-19">Google Scholar</a></li></ul></div></li><li class="ref"><span class="refLabel">4.</span><ul title="list of authors" class="rlist inline-bullet-list ref__authors ref__inline-block"><li class="ref__authors__name">Weiss P </li><li class="ref__authors__name">Murdoch DR </li></ul><div class="ref__title">Clinical course and mortality risk of severe COVID-19.</div><span class="ref__series"><i>Lancet.</i> <span class="ref__seriesDate">2020; </span><span class="ref__seriesVolume">395</span></span>: <span class="ref__seriesPages">1014-1015</span><div class="ref__controls"><a href="#back-bib4" title="View in Article" class="ref__controls__viewInArticle scroll-into-link">View
                        in Article
                        <i class="icon-section_arrow_u"></i></a><ul class="rlist inline-bullet-list"><li><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=395&publication_year=2020&pages=1014-1015&journal=Lancet&author=Weiss+P&author=Murdoch+DR&title=Clinical+course+and+mortality+risk+of+severe+COVID-19">Google Scholar</a></li></ul></div></li><li class="ref"><span class="refLabel">5.</span><ul title="list of authors" class="rlist inline-bullet-list ref__authors ref__inline-block"><li>WHO</li></ul><div class="ref__title">Coronavirus disease (COVID-2019) situation reports.</div><div class="citation-host"><a href="https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports" target="_blank">https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports</a><div><span>Date: </span>2020</div><div><span>Date accessed: </span>May 5, 2020</div></div><div class="ref__controls"><a href="#back-bib5" title="View in Article" class="ref__controls__viewInArticle scroll-into-link">View
                        in Article
                        <i class="icon-section_arrow_u"></i></a><ul class="rlist inline-bullet-list"><li><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=WHO&title=Coronavirus+disease+%28COVID-2019%29+situation+reports">Google Scholar</a></li></ul></div></li><li class="ref"><span class="refLabel">6.</span><ul title="list of authors" class="rlist inline-bullet-list ref__authors ref__inline-block"><li class="ref__authors__name">Cowling BJ </li><li class="ref__authors__name">Ali ST </li><li class="ref__authors__name">Ng TWY </li><li>et al.</li></ul><div class="ref__title">Impact assessment of non-pharmaceutical interventions against coronavirus disease 2019 and influenza in Hong Kong: an observational study.</div><span class="ref__series"><i>Lancet Public Health.</i> <span class="ref__seriesDate">2020; </span><span class="ref__seriesVolume">5</span></span>: <span class="ref__seriesPages">e279-e288</span><div class="ref__controls"><a href="#back-bib6" title="View in Article" class="ref__controls__viewInArticle scroll-into-link">View
                        in Article
                        <i class="icon-section_arrow_u"></i></a><ul class="rlist inline-bullet-list"><li><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2020&pages=e279-e288&journal=Lancet+Public+Health&author=Cowling+BJ&author=Ali+ST&author=Ng+TWY&title=Impact+assessment+of+non-pharmaceutical+interventions+against+coronavirus+disease+2019+and+influenza+in+Hong+Kong%3A+an+observational+study">Google Scholar</a></li></ul></div></li><li class="ref"><span class="refLabel">7.</span><ul title="list of authors" class="rlist inline-bullet-list ref__authors ref__inline-block"><li class="ref__authors__name">Gudbjartsson DF </li><li class="ref__authors__name">Helgason A </li><li class="ref__authors__name">Jonsson H </li><li>et al.</li></ul><div class="ref__title">Spread of SARS-CoV-2 in the Icelandic population.</div><span class="ref__series"><i>N Engl J Med.</i> <span class="ref__seriesDate">2020; </span><span class="ref__seriesVolume"></span> (<span class="refComment">published online April 14.</span>)</span><div class="citation-host"><a href="http://dx.doi.org/10.1056/NEJMoa2006100" target="_blank">DOI:10.1056/NEJMoa2006100</a></div><div class="ref__controls"><a href="#back-bib7" title="View in Article" class="ref__controls__viewInArticle scroll-into-link">View
                        in Article
                        <i class="icon-section_arrow_u"></i></a><ul class="rlist inline-bullet-list"><li><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&journal=N+Engl+J+Med&author=Gudbjartsson+DF&author=Helgason+A&author=Jonsson+H&title=Spread+of+SARS-CoV-2+in+the+Icelandic+population">Google Scholar</a></li></ul></div></li><li class="ref"><span class="refLabel">8.</span><ul title="list of authors" class="rlist inline-bullet-list ref__authors ref__inline-block"><li class="ref__authors__name">Amanat F </li><li class="ref__authors__name">Krammer F </li></ul><div class="ref__title">SARS-CoV-2 vaccines: status report.</div><span class="ref__series"><i>Immunity.</i> <span class="ref__seriesDate">2020; </span><span class="ref__seriesVolume">52</span></span>: <span class="ref__seriesPages">583-589</span><div class="ref__controls"><a href="#back-bib8" title="View in Article" class="ref__controls__viewInArticle scroll-into-link">View
                        in Article
                        <i class="icon-section_arrow_u"></i></a><ul class="rlist inline-bullet-list"><li><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2020&pages=583-589&journal=Immunity&author=Amanat+F&author=Krammer+F&title=SARS-CoV-2+vaccines%3A+status+report">Google Scholar</a></li></ul></div></li><li class="ref"><span class="refLabel">9.</span><ul title="list of authors" class="rlist inline-bullet-list ref__authors ref__inline-block"><li>WHO</li></ul><div class="ref__title">DRAFT landscape of COVID-19 candidate vaccines–30 April 2020.</div><div class="citation-host"><a href="https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines" target="_blank">https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines</a><div><span>Date: </span>2020</div><div><span>Date accessed: </span>May 5, 2020</div></div><div class="ref__controls"><a href="#back-bib9" title="View in Article" class="ref__controls__viewInArticle scroll-into-link">View
                        in Article
                        <i class="icon-section_arrow_u"></i></a><ul class="rlist inline-bullet-list"><li><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=WHO&title=DRAFT+landscape+of+COVID-19+candidate+vaccines%E2%80%9330+April+2020">Google Scholar</a></li></ul></div></li><li class="ref"><span class="refLabel">10.</span><ul title="list of authors" class="rlist inline-bullet-list ref__authors ref__inline-block"><li class="ref__authors__name">Zhu F-C </li><li class="ref__authors__name">Guan X-H </li><li class="ref__authors__name">Wang W </li><li>et al.</li></ul><div class="ref__title">Protocol. A single-center, open-label, dose-escalating phase I clinical trial of the recombinant novel coronavirus vaccine (adenovirus type 5 vector) in healthy adults aged between 18 and 60 years in China.</div><div class="citation-host"><a href="http://www.jscdc.cn/jkfw/kygz/202005/P020200517367817987697.pdf" target="_blank">http://www.jscdc.cn/jkfw/kygz/202005/P020200517367817987697.pdf</a><div><span>Date: </span>2020</div><div><span>Date accessed: </span>May 20, 2020</div></div><div class="ref__controls"><a href="#back-bib10" title="View in Article" class="ref__controls__viewInArticle scroll-into-link">View
                        in Article
                        <i class="icon-section_arrow_u"></i></a><ul class="rlist inline-bullet-list"><li><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=Zhu+F-C&author=Guan+X-H&author=Wang+W&title=Protocol.+A+single-center%2C+open-label%2C+dose-escalating+phase+I+clinical+trial+of+the+recombinant+novel+coronavirus+vaccine+%28adenovirus+type+5+vector%29+in+healthy+adults+aged+between+18+and+60+years+in+China">Google Scholar</a></li></ul></div></li><li class="ref"><span class="refLabel">11.</span><ul title="list of authors" class="rlist inline-bullet-list ref__authors ref__inline-block"><li>National Medical Products Administration</li></ul><div class="citation-host"><a href="http://www.nmpa.gov.cn/WS04/CL2138/373037.html" target="_blank">http://www.nmpa.gov.cn/WS04/CL2138/373037.html</a><div><span>Date: </span>2019</div><div><span>Date accessed: </span>May 20, 2020</div></div><div class="ref__controls"><a href="#back-bib11" title="View in Article" class="ref__controls__viewInArticle scroll-into-link">View
                        in Article
                        <i class="icon-section_arrow_u"></i></a><ul class="rlist inline-bullet-list"><li><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=National+Medical+Products+Administration&title=11">Google Scholar</a></li></ul></div></li><li class="ref"><span class="refLabel">12.</span><ul title="list of authors" class="rlist inline-bullet-list ref__authors ref__inline-block"><li class="ref__authors__name">Nie J </li><li class="ref__authors__name">Li Q </li><li class="ref__authors__name">Wu J </li><li>et al.</li></ul><div class="ref__title">Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2.</div><span class="ref__series"><i>Emerg Microbes Infect.</i> <span class="ref__seriesDate">2020; </span><span class="ref__seriesVolume">9</span></span>: <span class="ref__seriesPages">680-686</span><div class="ref__controls"><a href="#back-bib12" title="View in Article" class="ref__controls__viewInArticle scroll-into-link">View
                        in Article
                        <i class="icon-section_arrow_u"></i></a><ul class="rlist inline-bullet-list"><li><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2020&pages=680-686&journal=Emerg+Microbes+Infect&author=Nie+J&author=Li+Q&author=Wu+J&title=Establishment+and+validation+of+a+pseudovirus+neutralization+assay+for+SARS-CoV-2">Google Scholar</a></li></ul></div></li><li class="ref"><span class="refLabel">13.</span><ul title="list of authors" class="rlist inline-bullet-list ref__authors ref__inline-block"><li class="ref__authors__name">Ewer K </li><li class="ref__authors__name">Rampling T </li><li class="ref__authors__name">Venkatraman N </li><li>et al.</li></ul><div class="ref__title">A monovalent chimpanzee adenovirus Ebola vaccine boosted with MVA.</div><span class="ref__series"><i>N Engl J Med.</i> <span class="ref__seriesDate">2016; </span><span class="ref__seriesVolume">374</span></span>: <span class="ref__seriesPages">1635-1646</span><div class="ref__controls"><a href="#back-bib13" title="View in Article" class="ref__controls__viewInArticle scroll-into-link">View
                        in Article
                        <i class="icon-section_arrow_u"></i></a><ul class="rlist inline-bullet-list"><li><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=374&publication_year=2016&pages=1635-1646&journal=N+Engl+J+Med&author=Ewer+K&author=Rampling+T&author=Venkatraman+N&title=A+monovalent+chimpanzee+adenovirus+Ebola+vaccine+boosted+with+MVA">Google Scholar</a></li></ul></div></li><li class="ref"><span class="refLabel">14.</span><ul title="list of authors" class="rlist inline-bullet-list ref__authors ref__inline-block"><li class="ref__authors__name">De Santis O </li><li class="ref__authors__name">Audran R </li><li class="ref__authors__name">Pothin E </li><li>et al.</li></ul><div class="ref__title">Safety and immunogenicity of a chimpanzee adenovirus-vectored Ebola vaccine in healthy adults: a randomised, double-blind, placebo-controlled, dose-finding, phase 1/2a study.</div><span class="ref__series"><i>Lancet Infect Dis.</i> <span class="ref__seriesDate">2016; </span><span class="ref__seriesVolume">16</span></span>: <span class="ref__seriesPages">311-320</span><div class="ref__controls"><a href="#back-bib14" title="View in Article" class="ref__controls__viewInArticle scroll-into-link">View
                        in Article
                        <i class="icon-section_arrow_u"></i></a><ul class="rlist inline-bullet-list"><li><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2016&pages=311-320&journal=Lancet+Infect+Dis&author=De+Santis+O&author=Audran+R&author=Pothin+E&title=Safety+and+immunogenicity+of+a+chimpanzee+adenovirus-vectored+Ebola+vaccine+in+healthy+adults%3A+a+randomised%2C+double-blind%2C+placebo-controlled%2C+dose-finding%2C+phase+1%2F2a+study">Google Scholar</a></li></ul></div></li><li class="ref"><span class="refLabel">15.</span><ul title="list of authors" class="rlist inline-bullet-list ref__authors ref__inline-block"><li class="ref__authors__name">Sprangers MC </li><li class="ref__authors__name">Lakhai W </li><li class="ref__authors__name">Koudstaal W </li><li>et al.</li></ul><div class="ref__title">Quantifying adenovirus-neutralizing antibodies by luciferase transgene detection: addressing preexisting immunity to vaccine and gene therapy vectors.</div><span class="ref__series"><i>J Clin Microbiol.</i> <span class="ref__seriesDate">2003; </span><span class="ref__seriesVolume">41</span></span>: <span class="ref__seriesPages">5046-5052</span><div class="ref__controls"><a href="#back-bib15" title="View in Article" class="ref__controls__viewInArticle scroll-into-link">View
                        in Article
                        <i class="icon-section_arrow_u"></i></a><ul class="rlist inline-bullet-list"><li><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2003&pages=5046-5052&journal=J+Clin+Microbiol&author=Sprangers+MC&author=Lakhai+W&author=Koudstaal+W&title=Quantifying+adenovirus-neutralizing+antibodies+by+luciferase+transgene+detection%3A+addressing+preexisting+immunity+to+vaccine+and+gene+therapy+vectors">Google Scholar</a></li></ul></div></li><li class="ref"><span class="refLabel">16.</span><ul title="list of authors" class="rlist inline-bullet-list ref__authors ref__inline-block"><li class="ref__authors__name">Zhu FC </li><li class="ref__authors__name">Hou LH </li><li class="ref__authors__name">Li JX </li><li>et al.</li></ul><div class="ref__title">Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial.</div><span class="ref__series"><i>Lancet.</i> <span class="ref__seriesDate">2015; </span><span class="ref__seriesVolume">385</span></span>: <span class="ref__seriesPages">2272-2279</span><div class="ref__controls"><a href="#back-bib16" title="View in Article" class="ref__controls__viewInArticle scroll-into-link">View
                        in Article
                        <i class="icon-section_arrow_u"></i></a><ul class="rlist inline-bullet-list"><li><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=385&publication_year=2015&pages=2272-2279&journal=Lancet&author=Zhu+FC&author=Hou+LH&author=Li+JX&title=Safety+and+immunogenicity+of+a+novel+recombinant+adenovirus+type-5+vector-based+Ebola+vaccine+in+healthy+adults+in+China%3A+preliminary+report+of+a+randomised%2C+double-blind%2C+placebo-controlled%2C+phase+1+trial">Google Scholar</a></li></ul></div></li><li class="ref"><span class="refLabel">17.</span><ul title="list of authors" class="rlist inline-bullet-list ref__authors ref__inline-block"><li class="ref__authors__name">Zhao J </li><li class="ref__authors__name">Zhao J </li><li class="ref__authors__name">Perlman S </li></ul><div class="ref__title">T cell responses are required for protection from clinical disease and for virus clearance in severe acute respiratory syndrome coronavirus-infected mice.</div><span class="ref__series"><i>J Virol.</i> <span class="ref__seriesDate">2010; </span><span class="ref__seriesVolume">84</span></span>: <span class="ref__seriesPages">9318-9325</span><div class="ref__controls"><a href="#back-bib17" title="View in Article" class="ref__controls__viewInArticle scroll-into-link">View
                        in Article
                        <i class="icon-section_arrow_u"></i></a><ul class="rlist inline-bullet-list"><li><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=2010&pages=9318-9325&journal=J+Virol&author=Zhao+J&author=Zhao+J&author=Perlman+S&title=T+cell+responses+are+required+for+protection+from+clinical+disease+and+for+virus+clearance+in+severe+acute+respiratory+syndrome+coronavirus-infected+mice">Google Scholar</a></li></ul></div></li><li class="ref"><span class="refLabel">18.</span><ul title="list of authors" class="rlist inline-bullet-list ref__authors ref__inline-block"><li class="ref__authors__name">Channappanavar R </li><li class="ref__authors__name">Fett C </li><li class="ref__authors__name">Zhao J </li><li class="ref__authors__name">Meyerholz DK </li><li class="ref__authors__name">Perlman S </li></ul><div class="ref__title">Virus-specific memory CD8 T cells provide substantial protection from lethal severe acute respiratory syndrome coronavirus infection.</div><span class="ref__series"><i>J Virol.</i> <span class="ref__seriesDate">2014; </span><span class="ref__seriesVolume">88</span></span>: <span class="ref__seriesPages">11034-11044</span><div class="ref__controls"><a href="#back-bib18" title="View in Article" class="ref__controls__viewInArticle scroll-into-link">View
                        in Article
                        <i class="icon-section_arrow_u"></i></a><ul class="rlist inline-bullet-list"><li><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=88&publication_year=2014&pages=11034-11044&journal=J+Virol&author=Channappanavar+R&author=Fett+C&author=Zhao+J&author=Meyerholz+DK&author=Perlman+S&title=Virus-specific+memory+CD8+T+cells+provide+substantial+protection+from+lethal+severe+acute+respiratory+syndrome+coronavirus+infection">Google Scholar</a></li></ul></div></li><li class="ref"><span class="refLabel">19.</span><ul title="list of authors" class="rlist inline-bullet-list ref__authors ref__inline-block"><li class="ref__authors__name">Wang X </li><li class="ref__authors__name">Guo X </li><li class="ref__authors__name">Xin Q </li><li>et al.</li></ul><div class="ref__title">Neutralizing antibodies responses to SARS-CoV-2 in COVID-19 inpatients and convalescent patients.</div><span class="ref__series"><i>medRxiv.</i> <span class="ref__seriesDate">2020; </span><span class="ref__seriesVolume"></span> (<span class="refComment">DOI: 2020.04.15.20065623 (preprint)</span>)</span><div class="ref__controls"><a href="#back-bib19" title="View in Article" class="ref__controls__viewInArticle scroll-into-link">View
                        in Article
                        <i class="icon-section_arrow_u"></i></a><ul class="rlist inline-bullet-list"><li><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&journal=medRxiv&author=Wang+X&author=Guo+X&author=Xin+Q&title=Neutralizing+antibodies+responses+to+SARS-CoV-2+in+COVID-19+inpatients+and+convalescent+patients">Google Scholar</a></li></ul></div></li><li class="ref"><span class="refLabel">20.</span><ul title="list of authors" class="rlist inline-bullet-list ref__authors ref__inline-block"><li class="ref__authors__name">Wu F </li><li class="ref__authors__name">Wang A </li><li class="ref__authors__name">Liu M </li><li>et al.</li></ul><div class="ref__title">Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications.</div><span class="ref__series"><i>medRxiv.</i> <span class="ref__seriesDate">2020; </span><span class="ref__seriesVolume"></span> (<span class="refComment">DOI: 2020.03.30.20047365 (preprint)</span>)</span><div class="ref__controls"><a href="#back-bib20" title="View in Article" class="ref__controls__viewInArticle scroll-into-link">View
                        in Article
                        <i class="icon-section_arrow_u"></i></a><ul class="rlist inline-bullet-list"><li><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&journal=medRxiv&author=Wu+F&author=Wang+A&author=Liu+M&title=Neutralizing+antibody+responses+to+SARS-CoV-2+in+a+COVID-19+recovered+patient+cohort+and+their+implications">Google Scholar</a></li></ul></div></li><li class="ref"><span class="refLabel">21.</span><ul title="list of authors" class="rlist inline-bullet-list ref__authors ref__inline-block"><li class="ref__authors__name">Chen N </li><li class="ref__authors__name">Zhou M </li><li class="ref__authors__name">Dong X </li><li>et al.</li></ul><div class="ref__title">Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study.</div><span class="ref__series"><i>Lancet.</i> <span class="ref__seriesDate">2020; </span><span class="ref__seriesVolume">395</span></span>: <span class="ref__seriesPages">507-513</span><div class="ref__controls"><a href="#back-bib21" title="View in Article" class="ref__controls__viewInArticle scroll-into-link">View
                        in Article
                        <i class="icon-section_arrow_u"></i></a><ul class="rlist inline-bullet-list"><li><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=395&publication_year=2020&pages=507-513&journal=Lancet&author=Chen+N&author=Zhou+M&author=Dong+X&title=Epidemiological+and+clinical+characteristics+of+99+cases+of+2019+novel+coronavirus+pneumonia+in+Wuhan%2C+China%3A+a+descriptive+study">Google Scholar</a></li></ul></div></li><li class="ref"><span class="refLabel">22.</span><ul title="list of authors" class="rlist inline-bullet-list ref__authors ref__inline-block"><li class="ref__authors__name">Ye G </li><li class="ref__authors__name">Pan Z </li><li class="ref__authors__name">Pan Y </li><li>et al.</li></ul><div class="ref__title">Clinical characteristics of severe acute respiratory syndrome coronavirus 2 reactivation.</div><span class="ref__series"><i>J Infect.</i> <span class="ref__seriesDate">2020; </span><span class="ref__seriesVolume">80</span></span>: <span class="ref__seriesPages">e14-e17</span><div class="ref__controls"><a href="#back-bib22" title="View in Article" class="ref__controls__viewInArticle scroll-into-link">View
                        in Article
                        <i class="icon-section_arrow_u"></i></a><ul class="rlist inline-bullet-list"><li><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2020&pages=e14-e17&journal=J+Infect&author=Ye+G&author=Pan+Z&author=Pan+Y&title=Clinical+characteristics+of+severe+acute+respiratory+syndrome+coronavirus+2+reactivation">Google Scholar</a></li></ul></div></li><li class="ref"><span class="refLabel">23.</span><ul title="list of authors" class="rlist inline-bullet-list ref__authors ref__inline-block"><li class="ref__authors__name">Lurie N </li><li class="ref__authors__name">Saville M </li><li class="ref__authors__name">Hatchett R </li><li class="ref__authors__name">Halton J </li></ul><div class="ref__title">Developing Covid-19 vaccines at pandemic speed.</div><span class="ref__series"><i>N Engl J Med.</i> <span class="ref__seriesDate">2020; </span><span class="ref__seriesVolume"></span> (<span class="refComment">NEJMp2005630.</span>)</span><div class="ref__controls"><a href="#back-bib23" title="View in Article" class="ref__controls__viewInArticle scroll-into-link">View
                        in Article
                        <i class="icon-section_arrow_u"></i></a><ul class="rlist inline-bullet-list"><li><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&journal=N+Engl+J+Med&author=Lurie+N&author=Saville+M&author=Hatchett+R&author=Halton+J&title=Developing+Covid-19+vaccines+at+pandemic+speed">Google Scholar</a></li></ul></div></li><li class="ref"><span class="refLabel">24.</span><ul title="list of authors" class="rlist inline-bullet-list ref__authors ref__inline-block"><li class="ref__authors__name">Cao X </li></ul><div class="ref__title">COVID-19: immunopathology and its implications for therapy.</div><span class="ref__series"><i>Nat Rev Immunol.</i> <span class="ref__seriesDate">2020; </span><span class="ref__seriesVolume">20</span></span>: <span class="ref__seriesPages">269-270</span><div class="ref__controls"><a href="#back-bib24" title="View in Article" class="ref__controls__viewInArticle scroll-into-link">View
                        in Article
                        <i class="icon-section_arrow_u"></i></a><ul class="rlist inline-bullet-list"><li><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2020&pages=269-270&journal=Nat+Rev+Immunol&author=Cao+X&title=COVID-19%3A+immunopathology+and+its+implications+for+therapy">Google Scholar</a></li></ul></div></li><li class="ref"><span class="refLabel">25.</span><ul title="list of authors" class="rlist inline-bullet-list ref__authors ref__inline-block"><li class="ref__authors__name">Venkatraman N </li><li class="ref__authors__name">Ndiaye BP </li><li class="ref__authors__name">Bowyer G </li><li>et al.</li></ul><div class="ref__title">Safety and immunogenicity of a heterologous prime-boost Ebola virus vaccine regimen in healthy adults in the United Kingdom and Senegal.</div><span class="ref__series"><i>J Infect Dis.</i> <span class="ref__seriesDate">2019; </span><span class="ref__seriesVolume">219</span></span>: <span class="ref__seriesPages">1187-1197</span><div class="ref__controls"><a href="#back-bib25" title="View in Article" class="ref__controls__viewInArticle scroll-into-link">View
                        in Article
                        <i class="icon-section_arrow_u"></i></a><ul class="rlist inline-bullet-list"><li><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=219&publication_year=2019&pages=1187-1197&journal=J+Infect+Dis&author=Venkatraman+N&author=Ndiaye+BP&author=Bowyer+G&title=Safety+and+immunogenicity+of+a+heterologous+prime-boost+Ebola+virus+vaccine+regimen+in+healthy+adults+in+the+United+Kingdom+and+Senegal">Google Scholar</a></li></ul></div></li><li class="ref"><span class="refLabel">26.</span><ul title="list of authors" class="rlist inline-bullet-list ref__authors ref__inline-block"><li class="ref__authors__name">Dolzhikova IV </li><li class="ref__authors__name">Zubkova OV </li><li class="ref__authors__name">Tukhvatulin AI </li><li>et al.</li></ul><div class="ref__title">Safety and immunogenicity of GamEvac-Combi, a heterologous VSV- and Ad5-vectored Ebola vaccine: an open phase I/II trial in healthy adults in Russia.</div><span class="ref__series"><i>Hum Vaccin Immunother.</i> <span class="ref__seriesDate">2017; </span><span class="ref__seriesVolume">13</span></span>: <span class="ref__seriesPages">613-620</span><div class="ref__controls"><a href="#back-bib26" title="View in Article" class="ref__controls__viewInArticle scroll-into-link">View
                        in Article
                        <i class="icon-section_arrow_u"></i></a><ul class="rlist inline-bullet-list"><li><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2017&pages=613-620&journal=Hum+Vaccin+Immunother&author=Dolzhikova+IV&author=Zubkova+OV&author=Tukhvatulin+AI&title=Safety+and+immunogenicity+of+GamEvac-Combi%2C+a+heterologous+VSV-+and+Ad5-vectored+Ebola+vaccine%3A+an+open+phase+I%2FII+trial+in+healthy+adults+in+Russia">Google Scholar</a></li></ul></div></li><li class="ref"><span class="refLabel">27.</span><ul title="list of authors" class="rlist inline-bullet-list ref__authors ref__inline-block"><li class="ref__authors__name">Shukarev G </li><li class="ref__authors__name">Callendret B </li><li class="ref__authors__name">Luhn K </li><li class="ref__authors__name">Douoguih M </li></ul><div class="ref__title">A two-dose heterologous prime-boost vaccine regimen eliciting sustained immune responses to Ebola Zaire could support a preventive strategy for future outbreaks.</div><span class="ref__series"><i>Hum Vaccin Immunother.</i> <span class="ref__seriesDate">2017; </span><span class="ref__seriesVolume">13</span></span>: <span class="ref__seriesPages">266-270</span><div class="ref__controls"><a href="#back-bib27" title="View in Article" class="ref__controls__viewInArticle scroll-into-link">View
                        in Article
                        <i class="icon-section_arrow_u"></i></a><ul class="rlist inline-bullet-list"><li><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2017&pages=266-270&journal=Hum+Vaccin+Immunother&author=Shukarev+G&author=Callendret+B&author=Luhn+K&author=Douoguih+M&title=A+two-dose+heterologous+prime-boost+vaccine+regimen+eliciting+sustained+immune+responses+to+Ebola+Zaire+could+support+a+preventive+strategy+for+future+outbreaks">Google Scholar</a></li></ul></div></li><li class="ref"><span class="refLabel">28.</span><ul title="list of authors" class="rlist inline-bullet-list ref__authors ref__inline-block"><li class="ref__authors__name">Richardson S </li><li class="ref__authors__name">Hirsch JS </li><li class="ref__authors__name">Narasimhan M </li><li>et al.</li></ul><div class="ref__title">Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area.</div><span class="ref__series"><i>JAMA.</i> <span class="ref__seriesDate">2020; </span><span class="ref__seriesVolume"></span> (<span class="refComment">published online April 22.</span>)</span><div class="citation-host"><a href="http://dx.doi.org/10.1001/jama.2020.6775" target="_blank">DOI:10.1001/jama.2020.6775</a></div><div class="ref__controls"><a href="#back-bib28" title="View in Article" class="ref__controls__viewInArticle scroll-into-link">View
                        in Article
                        <i class="icon-section_arrow_u"></i></a><ul class="rlist inline-bullet-list"><li><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&journal=JAMA&author=Richardson+S&author=Hirsch+JS&author=Narasimhan+M&title=Presenting+characteristics%2C+comorbidities%2C+and+outcomes+among+5700+patients+hospitalized+with+COVID-19+in+the+New+York+City+area">Google Scholar</a></li></ul></div></li><li class="ref"><span class="refLabel">29.</span><ul title="list of authors" class="rlist inline-bullet-list ref__authors ref__inline-block"><li class="ref__authors__name">Yong CY </li><li class="ref__authors__name">Ong HK </li><li class="ref__authors__name">Yeap SK </li><li class="ref__authors__name">Ho KL </li><li class="ref__authors__name">Tan WS </li></ul><div class="ref__title">Recent advances in the vaccine development against Middle East respiratory syndrome-coronavirus.</div><span class="ref__series"><i>Front Microbiol.</i> <span class="ref__seriesDate">2019; </span><span class="ref__seriesVolume">10</span></span>1781<div class="ref__controls"><a href="#back-bib29" title="View in Article" class="ref__controls__viewInArticle scroll-into-link">View
                        in Article
                        <i class="icon-section_arrow_u"></i></a><ul class="rlist inline-bullet-list"><li><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&journal=Front+Microbiol&author=Yong+CY&author=Ong+HK&author=Yeap+SK&author=Ho+KL&author=Tan+WS&title=Recent+advances+in+the+vaccine+development+against+Middle+East+respiratory+syndrome-coronavirus">Google Scholar</a></li></ul></div></li><li class="ref"><span class="refLabel">30.</span><ul title="list of authors" class="rlist inline-bullet-list ref__authors ref__inline-block"><li class="ref__authors__name">Duan J </li><li class="ref__authors__name">Yan X </li><li class="ref__authors__name">Guo X </li><li>et al.</li></ul><div class="ref__title">A human SARS-CoV neutralizing antibody against epitope on S2 protein.</div><span class="ref__series"><i>Biochem Biophys Res Commun.</i> <span class="ref__seriesDate">2005; </span><span class="ref__seriesVolume">333</span></span>: <span class="ref__seriesPages">186-193</span><div class="ref__controls"><a href="#back-bib30" title="View in Article" class="ref__controls__viewInArticle scroll-into-link">View
                        in Article
                        <i class="icon-section_arrow_u"></i></a><ul class="rlist inline-bullet-list"><li><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=333&publication_year=2005&pages=186-193&journal=Biochem+Biophys+Res+Commun&author=Duan+J&author=Yan+X&author=Guo+X&title=A+human+SARS-CoV+neutralizing+antibody+against+epitope+on+S2+protein">Google Scholar</a></li></ul></div></li><li class="ref"><span class="refLabel">31.</span><ul title="list of authors" class="rlist inline-bullet-list ref__authors ref__inline-block"><li class="ref__authors__name">Wang Q </li><li class="ref__authors__name">Zhang L </li><li class="ref__authors__name">Kuwahara K </li><li>et al.</li></ul><div class="ref__title">Immunodominant SARS coronavirus epitopes in humans elicited both enhancing and neutralizing effects on infection in non-human primates.</div><span class="ref__series"><i>ACS Infect Dis.</i> <span class="ref__seriesDate">2016; </span><span class="ref__seriesVolume">2</span></span>: <span class="ref__seriesPages">361-376</span><div class="ref__controls"><a href="#back-bib31" title="View in Article" class="ref__controls__viewInArticle scroll-into-link">View
                        in Article
                        <i class="icon-section_arrow_u"></i></a><ul class="rlist inline-bullet-list"><li><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2016&pages=361-376&journal=ACS+Infect+Dis&author=Wang+Q&author=Zhang+L&author=Kuwahara+K&title=Immunodominant+SARS+coronavirus+epitopes+in+humans+elicited+both+enhancing+and+neutralizing+effects+on+infection+in+non-human+primates">Google Scholar</a></li></ul></div></li><li class="ref"><span class="refLabel">32.</span><ul title="list of authors" class="rlist inline-bullet-list ref__authors ref__inline-block"><li class="ref__authors__name">Gray GE </li><li class="ref__authors__name">Moodie Z </li><li class="ref__authors__name">Metch B </li><li>et al.</li></ul><div class="ref__title">Recombinant adenovirus type 5 HIV gag/pol/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 503/Phambili study.</div><span class="ref__series"><i>Lancet Infect Dis.</i> <span class="ref__seriesDate">2014; </span><span class="ref__seriesVolume">14</span></span>: <span class="ref__seriesPages">388-396</span><div class="ref__controls"><a href="#back-bib32" title="View in Article" class="ref__controls__viewInArticle scroll-into-link">View
                        in Article
                        <i class="icon-section_arrow_u"></i></a><ul class="rlist inline-bullet-list"><li><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2014&pages=388-396&journal=Lancet+Infect+Dis&author=Gray+GE&author=Moodie+Z&author=Metch+B&title=Recombinant+adenovirus+type+5+HIV+gag%2Fpol%2Fnef+vaccine+in+South+Africa%3A+unblinded%2C+long-term+follow-up+of+the+phase+2b+HVTN+503%2FPhambili+study">Google Scholar</a></li></ul></div></li></ol></section><section class="article-info"><h2 class="top" id="articleInformation">Article Info</h2><section><h3 class="publicationHistory__label">Publication History</h3><div class="article-info__dates"><div class="article-info__date">Published: May 22, 2020</div></div></section><section><h3>Identification</h3><p>DOI: <a href="https://doi.org/10.1016/S0140-6736(20)31208-3">https://doi.org/10.1016/S0140-6736(20)31208-3</a></p></section><section><h3>Copyright</h3><div class="copyright">© 2020 Elsevier Ltd. All rights reserved.</div></section><section><h3>ScienceDirect</h3><a href="https://www.sciencedirect.com/science/article/pii/S0140673620312083">Access this article on ScienceDirect</a></section></section><div id="figure-viewer" class="showCaption showThumbstrip figure-viewer"><nav class="nav-bar figure-viewer__top"><a href="#" title="Close Figure Viewer" class="figure-viewer__close"><i aria-hidden="true" class="icon-tools_close"></i></a><div class="figure-viewer__title"></div></nav><div class="frames"><ul class="frames__list"></ul><a href="#" title="Previous figure" class="frameButton previousFrameButton frames__prev"><i class="icon-arrow_l"></i></a><a href="#" title="Next figure" class="frameButton nextFrameButton frames__next"><i class="icon-arrow_r"></i></a></div><div class="caption"><div class="figure-viewer__caption-body"></div></div><div class="toolbar figure-viewer__toolbar"><span class="figure-viewer__counter"></span><a href="#" class="button toggle-caption-button figure-viewer__caption__ctrl"><i aria-hidden="true" class="icon icon-info"></i><span class="label">Hide Caption</span></a><a href="#" class="button download-options-button"><i aria-hidden="true" class="icon icon-gizmo-folder-in download-size-icon"></i><span class="label">Download</span></a><a href="#figures" class="button see-figures figure-viewer__see-figure__ctrl"><i aria-hidden="true" class="icon icon-gizmo-image_figure viewer-size-icon"></i><span class="label">See figure in article</span></a></div><div class="thumbstrip"><a class="toggleButton thumbstrip__ctrl"><span>Toggle Thumbstrip</span></a><a href="#" title="Previous Thumbnails" class="thumbstripButton previousThumbstripButton thumbstrip__prev"><i aria-hidden="true" class="icon-arrow_l"></i></a><a href="#" title="Next Thumbnails" class="thumbstripButton nextThumbstripButton thumbstrip__next"><i aria-hidden="true" class="icon-arrow_r"></i></a><div class="thumbstrip__wrapper"><ul class="rlist figure-viewer__thumbslist"></ul></div></div><div class="download figure-viewer__download"><div class="pointer"></div><ul class="rlist downlad__wrapper"><li><a target="_blank" href="#" title="View Large Image in a new tab" class="viewLargeImage"><i class="icon icon-gizmo-image_figure figure-viewer__download__viewer-size-icon"></i><span class="figure-viewer__download__text">View Large Image</span></a></li><li><a target="_blank" href="#" title="View high resolution image in a new tab" class="downloadThisButton" download=""><i class="icon icon-gizmo-image_figure figure-viewer__download__viewer-size-icon"></i><span class="figure-viewer__download__text">Download Hi-res image </span></a></li><li class="hidden-xs hidden-sm"><a href="#" class="downloadAllButton"><i class="icon icon-gizmo-ppt figure-viewer__download__viewer-size-icon figure-viewer__download__viewer-size-icon--ppt"></i><span class="figure-viewer__download__text"> Download .PPT</span></a></li></ul></div></div><div class="figures-placeholder"></div><div class="tables-placeholder"></div>
    

        


    

        


    

            

            

            <div data-pb-widget-type="ux3-storyCard" data-widget-id="47be90a1-303e-4ae1-883d-0bcc5c82d5de" data-widget-name="UX3StoryCardStack" class="ux3DeferredWidget" data-journal-code="lancet" data-pii="S0140-6736(20)31208-3"></div>

            

        

    

        


    

            

            

            <div data-pb-widget-type="ux3-lancetCollection" data-widget-id="3d6acba1-acea-4be2-8dc9-b7e14e5b6583" data-widget-name="UX3ArticleLancetCollections" data-article-pii="S0140673620312083" class="ux3DeferredWidget"></div>

            

        

    

        


    

            

            

            <div data-pb-widget-type="ux3-storyCard" data-widget-id="8fcef2ae-bfef-496b-b1cc-8d9a0ea1a989" data-widget-name="UX3StoryCardStack" class="ux3DeferredWidget" data-journal-code="lancet" data-pii="S0140-6736(20)31208-3"></div>

            

        

    

        


    

            

            

            <div data-pb-widget-type="ux3-storyCard" data-widget-id="909e3ba9-52f8-40e5-8e72-6e74dcb4e86b" data-widget-name="UX3StoryCardStack" class="ux3DeferredWidget" data-journal-code="lancet" data-pii="S0140-6736(20)31208-3"></div>

            

        

    

        


    

            

            

            <div data-pb-widget-type="ux3-storyTeaser" data-widget-id="e1237f8f-fba8-421f-b6e0-cb008ca30e95" data-widget-name="UX3storyTeaserView" class="ux3DeferredWidget" data-journal-code="lancet" data-pii="S0140-6736(20)31208-3"></div>

            

        

    

        


    

            

            

            <div data-pb-widget-type="ux3-storyTeaser" data-widget-id="6579bef7-5b75-4233-bc6b-5a5dda60726a" data-widget-name="UX3storyTeaserView" class="ux3DeferredWidget" data-journal-code="lancet" data-pii="S0140-6736(20)31208-3"></div>

            

        

    

        


    

            

            

            <div data-pb-widget-type="ux3-storyTeaser" data-widget-id="693a86d5-def0-4c8a-be40-235cf5297fbb" data-widget-name="UX3storyTeaserView" class="ux3DeferredWidget" data-journal-code="lancet" data-pii="S0140-6736(20)31208-3"></div>

            

        

    

        


    

        


    

        


    

        


    

        


    

        


    

        


    

        


    

        


    

        

<div id="figure-viewer" class="showCaption showThumbstrip figure-viewer"><nav class="nav-bar figure-viewer__top"><a href="#" title="Close Figure Viewer" class="figure-viewer__close"><i aria-hidden="true" class="icon-tools_close"></i></a><div class="figure-viewer__title"></div></nav><div class="frames"><ul class="frames__list"></ul><a href="#" title="Previous Frame" class="frameButton previousFrameButton frames__prev"><!--span Previous Frame--><i class="icon-arrow_l"></i></a><a href="#" title="Next Frame" class="frameButton nextFrameButton frames__next"><!--span Next Frame--><i class="icon-arrow_r"></i></a></div><div class="caption"><div class="figure-viewer__caption-body"></div></div><div class="toolbar figure-viewer__toolbar"><span class="figure-viewer__counter"></span><a href="#" class="button toggle-caption-button figure-viewer__caption__ctrl"><i aria-hidden="true" class="icon icon-info"></i><span class="label">Hide Caption</span></a><a href="#" class="button download-options-button"><i aria-hidden="true" class="icon icon-gizmo-folder-in download-size-icon"></i><span class="label">Download</span></a><a href="#figures" class="button see-figures figure-viewer__see-figure__ctrl"><i aria-hidden="true" class="icon icon-gizmo-image_figure viewer-size-icon"></i><span class="label">See figure in Article</span></a></div><div class="thumbstrip"><a class="toggleButton thumbstrip__ctrl"><span>Toggle Thumbstrip</span></a><a href="#" title="Previous Thumbnails" class="thumbstripButton previousThumbstripButton thumbstrip__prev"><i aria-hidden="true" class="icon-arrow_l"></i></a><a href="#" title="Next Thumbnails" class="thumbstripButton nextThumbstripButton thumbstrip__next"><i aria-hidden="true" class="icon-arrow_r"></i></a><div class="thumbstrip__wrapper"><ul class="rlist figure-viewer__thumbslist"></ul></div></div><div class="download figure-viewer__download"><div class="pointer"></div><ul class="rlist downlad__wrapper"><li><a target="_blank" href="/specs/products/marlin/components/figure-viewer/images/facets-2015-0010-f10-standard.jpg" title="View high resolution image in a new tab" class="downloadThisButton"><i class="icon icon-gizmo-image_figure figure-viewer__download__viewer-size-icon"></i><span class="figure-viewer__download__text">Download Hi-res image</span></a></li><li class="hidden-xs hidden-sm"><a href="/action/downloadFigures?articleNumber=e00489" target="_blank" title="Doanload .PPT" class="downloadAllButton"><i class="icon icon-gizmo-ppt figure-viewer__download__viewer-size-icon figure-viewer__download__viewer-size-icon--ppt"></i><span class="figure-viewer__download__text"> Download .PPT </span></a></li></ul></div></div><div data-toggle="transplant" data-direction="from" data-transplant="self" data-target=".adplaceholder--slot2, .adplaceholder--slot3 " data-remove="false" class="adplaceholder__transplant hidden-md hidden-lg"></div></div><div class="col-md-3 col-lg-2"></div></div></div></div></article>

            

        

        </main>
    
</div></div>

            
                </div>
            

        

        </div>
    










        <div data-widget-def="ux3-layout-widget" data-widget-id="1f4bb806-6f34-4378-a41c-8b5060df84ee" class="ux3">
        
    

        


    

            

            

            <div data-widget-id="1f4bb806-6f34-4378-a41c-8b5060df84ee" data-widget-name="ux3-layout-widget"><footer class="footer clearfix">
    

        


    

            

            

            <div data-widget-id="6c6b6950-d88f-47eb-a4a3-88a4d54a3efe" data-widget-name="UX3HTMLWidget"><div class="footer__top">
    <div class="footer__logo centered"><a href="/home" title="The Lancet logo"><img alt="logo" src="/pb-assets/ux3/logos/lancet/LANCET-1532516601370.svg"></a></div>
        <div class="footer__social-links">
                                                <ul class="rlist rlist--inline centered">
                <li><a href="https://twitter.com/TheLancet" title="Twitter"><i aria-hidden="true" class="icon-Icon_Twitter"></i></a></li>
                <li><a href="https://www.facebook.com/TheLancetMedicalJournal/" title="Facebook"><i aria-hidden="true" class="icon-Icon_Facebook"></i></a></li>
                <li><a href="https://www.linkedin.com/company/the-lancet/" title="LinkedIn"><i aria-hidden="true" class="icon-linkedin"></i></a></li>
                                                                
                                                                <li><a href="https://www.youtube.com/user/TheLancetTV" title="YouTube" target="_blank"><svg width="18px" height="13px" viewBox="0 0 18 13" version="1.1" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink"> <g stroke="none" stroke-width="1" fill="none" fill-rule="evenodd"> <g transform="translate(-76.000000, -19.000000)" fill-rule="nonzero" fill="#969696"> <g id="youtube" transform="translate(76.000000, 14.000000)"> <path d="M17.2984219,6.41974219 C16.6486641,5.64735937 15.4490625,5.33232422 13.1580703,5.33232422 L4.84175391,5.33232422 C2.49834375,5.33232422 1.27838672,5.66771484 0.631089844,6.49001953 C0,7.29172266 0,8.47304297 0,10.1080547 L0,13.2243047 C0,16.3917773 0.748792969,18 4.84175391,18 L13.1581055,18 C15.1448555,18 16.2457383,17.7219844 16.9579688,17.040375 C17.688375,16.3413984 18,15.2001211 18,13.2243047 L18,10.1080547 C18,8.38381641 17.951168,7.19553516 17.2984219,6.41974219 Z M11.5560703,12.0963867 L7.77965625,14.0700586 C7.69524609,14.1141797 7.60289062,14.136082 7.51071094,14.136082 C7.40629687,14.136082 7.30212891,14.1079922 7.20987891,14.0521289 C7.03613672,13.9468711 6.93007031,13.7585391 6.93007031,13.5554414 L6.93007031,9.62075391 C6.93007031,9.41800781 7.03585547,9.22985156 7.20924609,9.12452344 C7.38267187,9.01919531 7.59839062,9.01198828 7.77832031,9.10546875 L11.5547344,11.0664141 C11.7468633,11.1661523 11.8675195,11.3645039 11.8678008,11.5809258 C11.8680469,11.7975586 11.747918,11.9961914 11.5560703,12.0963867 Z"></path> </g> </g> </g></svg></a></li>
                                                                
                                                                <li><a href="http://weibo.com/TheLancetChina" title="Weibo" target="_blank"><svg width="18px" height="15px" viewBox="0 0 18 15" version="1.1" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink"> <g stroke="none" stroke-width="1" fill="none" fill-rule="evenodd"> <g transform="translate(-99.000000, -17.000000)" fill-rule="nonzero" fill="#969696"> <g id="weibo" transform="translate(99.000000, 14.000000)"> <g transform="translate(0.000000, 3.000000)"> <path d="M13.2402211,7.47054172 C12.9918392,7.39866484 12.821608,7.34902326 12.9514975,7.03290287 C13.232804,6.34602189 13.2622915,5.75359781 12.9571055,5.33095486 C12.3847236,4.5380684 10.8191759,4.58064295 9.02514573,5.30975376 C9.02514573,5.30889193 8.46144724,5.54882627 8.60544724,5.11515185 C8.88150754,4.25435294 8.83953769,3.53386047 8.41043216,3.11759508 C7.43716583,2.17285363 4.84824121,3.15344733 2.62745729,5.3059617 C0.964944724,6.9186238 0,8.62798358 0,10.105855 C0,12.9324952 3.73748744,14.8235294 7.39429146,14.8235294 C12.1877186,14.8235294 15.3768844,11.9501778 15.3768844,9.80576471 C15.3768844,8.50974008 14.2514774,7.77442408 13.2402211,7.47054172 Z M7.40424121,13.5561176 C4.48625126,13.8315595 1.9678794,12.5686293 1.77811055,10.7327524 C1.58870352,8.89773735 3.80098492,7.18579207 6.71861307,6.90948837 C9.63678392,6.63266758 12.1556985,7.89663201 12.3447437,9.73164706 C12.533608,11.5675239 10.3227739,13.2796416 7.40424121,13.5561176 Z M18,5.16875787 C17.9985528,2.31402189 15.5695477,0 12.5728643,0 C12.222995,0 11.9396985,0.270098495 11.9396985,0.603283174 C11.9396985,0.936640219 12.222995,1.20656635 12.5728643,1.20656635 C14.8708945,1.20656635 16.7336683,2.98159781 16.7336683,5.17099863 C16.7336683,5.50435568 17.0173266,5.77428181 17.3668342,5.77428181 C17.7167035,5.77428181 18,5.50435568 18,5.17099863 C18,5.17099863 18,5.1696197 18,5.16875787 Z M15.4841608,5.08016142 C15.1948945,3.73415048 14.0812462,2.67323393 12.6683819,2.39744733 C12.3262915,2.33039672 11.9914372,2.54051163 11.9212462,2.86680164 C11.8506935,3.19309166 12.0712161,3.51179754 12.4133065,3.57919289 C13.3319397,3.75845417 14.0559196,4.44774829 14.2438794,5.32302599 C14.3146131,5.64931601 14.6491055,5.85925855 14.9915578,5.7923803 C15.3338291,5.72498495 15.5541709,5.40627907 15.4841608,5.08016142 Z M5.90761809,8.7069275 C4.7321005,8.9320383 3.93901508,9.87126402 4.1358392,10.8044569 C4.33248241,11.7378222 5.44504523,12.311803 6.62056281,12.0865198 C7.79571859,11.861409 8.58916583,10.922528 8.3921608,9.98899042 C8.19569849,9.0559699 7.08277387,8.48181669 5.90761809,8.7069275 Z"></path> </g> </g> </g> </g></svg></a></li>
                                                                
                                                                <li><a href="//els-jbs-prod-cdn.jbs.elsevierhealth.com/pb-assets/Lancet/marketing/wechat/WeChat_website-1559811717053.jpg" title="WeChat" target="_blank"><svg width="18px" height="15px" viewBox="0 0 18 15" version="1.1" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink"> <g stroke="none" stroke-width="1" fill="none" fill-rule="evenodd"> <g transform="translate(-122.000000, -17.000000)" fill-rule="nonzero" fill="#969696"> <g id="wechat" transform="translate(122.000000, 17.000000)"> <path d="M12.375,4.5 L12.375,4.5 L12.4875,4.5 L12.4875,4.5 C12.6898579,4.48604473 12.8520408,4.32704187 12.87,4.125 C12.8705905,4.04725572 12.8470025,3.9712499 12.8025,3.9075 C11.94,1.5675 9.4425,0 6.5625,0 C2.9475,0 0,2.52 0,5.625 C0.0313772094,7.34410122 0.895513317,8.94093526 2.3175,9.9075 L1.5675,11.46 C1.49009368,11.6087816 1.52088865,11.7908702 1.64291494,11.9059236 C1.76494122,12.0209769 1.94852501,12.0410168 2.0925,11.955 L4.08,10.8225 C4.61861992,11.0129999 5.17724298,11.1413322 5.745,11.205 C5.86564124,11.2178337 5.98503738,11.1715098 6.06545426,11.0806685 C6.14587113,10.9898272 6.17737153,10.865694 6.15,10.7475 C6.06148727,10.4219419 6.01114891,10.0871918 6,9.75 C6,6.855 8.8575,4.5 12.375,4.5 Z M8.25,3 C8.66421356,3 9,3.33578644 9,3.75 C9,4.16421356 8.66421356,4.5 8.25,4.5 C7.83578644,4.5 7.5,4.16421356 7.5,3.75 C7.5,3.33578644 7.83578644,3 8.25,3 Z M4.5,4.5 C4.08578644,4.5 3.75,4.16421356 3.75,3.75 C3.75,3.33578644 4.08578644,3 4.5,3 C4.91421356,3 5.25,3.33578644 5.25,3.75 C5.25,4.16421356 4.91421356,4.5 4.5,4.5 Z"></path> <path d="M18,9.75 C18,7.2675 15.48,5.25 12.375,5.25 C9.27,5.25 6.75,7.2675 6.75,9.75 C6.75,12.2325 9.27,14.25 12.375,14.25 C12.9568557,14.2502837 13.5364258,14.1772075 14.1,14.0325 L15.96,14.9625 C16.0114248,14.9874074 16.0678613,15.0002339 16.125,15 C16.2497193,14.9993787 16.3659682,14.9367912 16.4351508,14.8330172 C16.5043335,14.7292432 16.5173955,14.5978644 16.47,14.4825 L15.96,13.2075 C17.1784092,12.4716325 17.9450305,11.1723221 18,9.75 L18,9.75 Z M10.5,9 C10.0857864,9 9.75,8.66421356 9.75,8.25 C9.75,7.83578644 10.0857864,7.5 10.5,7.5 C10.9142136,7.5 11.25,7.83578644 11.25,8.25 C11.25,8.66421356 10.9142136,9 10.5,9 Z M14.25,9 C13.8357864,9 13.5,8.66421356 13.5,8.25 C13.5,7.83578644 13.8357864,7.5 14.25,7.5 C14.6642136,7.5 15,7.83578644 15,8.25 C15,8.66421356 14.6642136,9 14.25,9 Z" opacity="0.959999979"></path> </g> </g> </g></svg></a></li>
															<li><a href="/podcasts" title="Podcasts" target="_blank"><svg version="1.1" id="Layer_1" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 29 29" enable-background="new 0 0 29 29" xml:space="preserve">
<g>
                <path fill="#969696" d="M19.8,17.5L19.8,17.5c-0.3,0.7-0.7,1.3-1.3,1.9c-1,1-2.5,1.6-4,1.6s-3-0.6-4.1-1.7c-0.5-0.5-1-1.2-1.3-1.9
                                L9,17l-1.7,0.7l0.2,0.4c0.4,0.9,0.9,1.8,1.7,2.5c1.2,1.2,2.8,2,4.5,2.2v2.4h-1.9v1.9h5.7v-1.9h-1.9v-2.4c1.7-0.2,3.3-1,4.5-2.2
                                c0.7-0.7,1.3-1.6,1.7-2.5l0.2-0.4L20,17L19.8,17.5z"></path>
                <path fill="#969696" d="M14.5,19.1c2.4,0,4.4-2,4.4-4.4V8.4c0-2.4-2-4.4-4.4-4.4s-4.4,2-4.4,4.4v6.3C10.1,17.1,12.1,19.1,14.5,19.1
                                z"></path>
                <path fill="#969696" d="M25.5,2.6l-0.3-0.3l-1.3,1.3l0.3,0.3c1.3,1.3,2,3.1,2,4.9c0,1.9-0.7,3.6-2,4.9L23.9,14l1.3,1.3l0.3-0.3
                                c1.7-1.7,2.6-3.9,2.6-6.3S27.2,4.3,25.5,2.6z"></path>
                <path fill="#969696" d="M22,5.5l-1.3,1.3L21,7.1c0.5,0.5,0.7,1.1,0.7,1.7c0,0.7-0.3,1.3-0.7,1.7l-0.3,0.3l1.3,1.3l0.3-0.3
                                c0.8-0.8,1.3-1.9,1.3-3.1s-0.5-2.2-1.3-3.1L22,5.5z"></path>
                <path fill="#969696" d="M5.2,3.6L3.8,2.3L3.5,2.6C1.8,4.3,0.9,6.5,0.9,8.8s0.9,4.6,2.6,6.3l0.3,0.3l1.3-1.3l-0.3-0.3
                                c-1.3-1.3-2-3.1-2-4.9c0-1.9,0.7-3.6,2-4.9L5.2,3.6z"></path>
                <path fill="#969696" d="M8,10.6c-0.5-0.5-0.7-1.1-0.7-1.7c0-0.7,0.3-1.3,0.7-1.7l0.3-0.3L7,5.5L6.7,5.8c-0.8,0.8-1.2,1.9-1.2,3
                                C5.5,10,6,11,6.8,11.9L7,12.2l1.3-1.3L8,10.6z"></path>
</g>
</svg></a></li>

            </ul>
        </div>
</div>

<style>

.ux3 .footer__social-links a svg {
    max-width: 26px;
    height: 1.15rem;
    width: auto;
}

.ux3 .footer__social-links a:hover svg path {
    fill: #353535;
}

</style></div>

            

        

    

        


    

            

            
                <div class="footer__bottom text-onDark">
            

            <div data-widget-id="990712f4-2a7a-4439-a11d-411ecf08e5c8" data-widget-name="ux3-layout-widget"><div class="col-sm-4 col-md-5 clearfix">
    

        


    

            

            

            <div data-widget-id="21f1d838-df27-4e30-80c7-1b97df750391" data-widget-name="UX3HTMLWidget"><div class="groups bordered">
                    <div class="group">
                      <div class="group__title">The Lancet Journals</div>
                      <ul class="rlist clearfix sided">
                        <li><a href="/journals/lancet/home">The Lancet</a></li>
                        <li><a href="/journals/lanchi/home">The Lancet Child &amp; Adolescent Health</a></li>
                        <li><a href="/journals/landia/home">The Lancet Diabetes &amp; Endocrinology</a></li>
                        <li><a href="/journals/landig/home">The Lancet Digital Health</a></li>
                        <li><a href="/journals/langas/home">The Lancet Gastroenterology &amp; Hepatology</a></li>
                        <li><a href="/journals/langlo/home">The Lancet Global Health</a></li>
                        <li><a href="/journals/lanhae/home">The Lancet Haematology</a></li>
                        <li><a href="/journals/lanhiv/home">The Lancet HIV</a></li>
                        <li><a href="/journals/laninf/home">The Lancet Infectious Diseases</a></li>
                        <li><a href="/journals/lanmic/home">The Lancet Microbe</a></li>
                        <li><a href="/journals/laneur/home">The Lancet Neurology</a></li>
                        <li><a href="/journals/lanonc/home">The Lancet Oncology</a></li>
                        <li><a href="/journals/lanplh/home">The Lancet Planetary Health</a></li>
                        <li><a href="/journals/lanpsy/home">The Lancet Psychiatry</a></li>
                        <li><a href="/journals/lanpub/home">The Lancet Public Health</a></li>
                        <li><a href="/regional-health">The Lancet Regional Health</a></li>                        
                        <li><a href="/journals/lanres/home">The Lancet Respiratory Medicine</a></li>
                        <li><a href="/journals/lanrhe/home">The Lancet Rheumatology</a></li>
                        <li><a href="/journals/ebiom/home">EBioMedicine</a></li>
                        <li><a href="/journals/eclinm/home">EClinicalMedicine</a></li>
                      </ul>
                    </div>
</div></div>

            

        
</div><div class="col-sm-4 col-md-3 col-lg-2 clearfix">
    

        


    

            

            

            <div data-widget-id="6a7e5150-5321-421f-8ce9-0223e8bdc674" data-widget-name="UX3HTMLWidget"><div class="groups bordered">
                    <div class="group">
                      <div class="group__title">CLINICAL</div>
                      <ul class="rlist clearfix">
                        <li><a href="/clinical/diseases">The Lancet Clinic</a></li>
                        <li><a href="/clinical/commissions">Commissions</a></li>
                        <li><a href="/clinical/series">Series</a></li>
                        <li><a href="/picture-quiz">Picture Quiz</a></li>
                      </ul>
                    </div>
                    <div class="group">
                      <div class="group__title">GLOBAL HEALTH</div>
                      <ul class="rlist clearfix">
                        <li><a href="/global-health">Hub</a></li>
                        <li><a href="/global-health/commissions">Commissions</a></li>
                        <li><a href="/global-health/series">Series</a></li>
                        <li><a href="/gbd">Global Burden of Disease</a></li>
                      </ul>
                    </div>
</div></div>

            

        
</div><div class="col-sm-4 col-md-4 col-lg-5 clearfix">
    

        


    

            

            

            <div data-widget-id="7e537560-25b2-4b1b-8d93-8fe6767a5b3a" data-widget-name="UX3HTMLWidget"><div class="groups ">
                    <div class="group">
                      <div class="group__title">Connect</div>
                      <ul class="rlist clearfix sided">
                        <li><a href="/about-us">About</a></li>
                        <li><a href="/contact-us">Contact Us</a></li>
                        <li><a href="https://service.elsevier.com/app/overview/lancet/" target="_blank">Customer Service</a></li>
                      </ul>
                    </div>
                    <div class="group">
                      <div class="group__title">Access</div>
                      <ul class="rlist clearfix sided">
                        <li><a href="/access-to-content">Information for Readers</a></li>
                        <li><a href="/action/registration?journal=&amp;redirectUri=https%3A%2F%2Fwww.thelancet.com%2F">Register</a></li>
                        <li><a href="/journals/lancet/subscribe">Subscription Options</a></li>
                        <li><a href="/action/showPreferences?menuTab=AccountInfo">My Account</a></li>
                        <li><a href="/action/activateClaim?journalCode=&amp;class=claimSubscribtion">Existing Print Subscribers</a></li>
                        <li><a href="http://info.thelancet.com/update-alerts?utm_campaign=tlupdates-signup&amp;utm_source=footer&amp;utm_medium=tlwebsite&amp;utm_content=updates " target="_blank">The Lancet <i>Updates</i></a></li>
                        <li><a href="http://info.thelancet.com/request-access?utm_campaign=jls-rtl&amp;utm_source=site-footer&amp;utm_medium=website " target="_blank">Recommend Lancet journals to your librarian</a></li>
                        <li><a href="/app">The Lancet App</a></li>
                        <li><a href="/choice">The Lancet Choice</a></li>
                      </ul>
                    </div>
                    <div class="group">
                      <div class="group__title">Information</div>
                      <ul class="rlist clearfix sided">
                        <li><a href="/for-authors">Authors</a></li>
                        <li><a href="/press-room">Press</a></li>
                        <li><a href="/for-advertisers">Advertisers</a></li>
                        <li><a href="http://careers.thelancet.com/home" target="_blank">Careers</a></li>
                        <li><a href="https://www.elsevier.com/legal/privacy-policy" target="_blank">Privacy Policy</a></li>
                        <li><a href="https://www.elsevier.com/legal/elsevier-website-terms-and-conditions" target="_blank">Terms and Conditions</a></li>
                        <li><a href="/cookies">Cookies</a></li>
                      </ul>
                    </div>
</div></div>

            

        
</div></div>

            
                </div>
            

        

    

        


    

                
                
                
                
                
                
                    
                
                    
                
                    
                        
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                
                    
                
                    
                
                    
                        
                        
                        
                    
                
                    
                
                    
                
                    
                        
                        
                            
                        
                        
                            
                            
                            
                        
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                
                
                <div class="widget csasSsoUrls none  widget-none  widget-compact-all" id="d3dbd9c8-ebaf-468d-bc43-063d543d0907">
                
                

                <div class="wrapped " >
                    
                    <div class="widget-body body body-none  body-compact-all"><div id="sso-urls-div" class="hidden ssoUrls">
    
        <iframe src="//acw.secure.jbs.elsevierhealth.com/SSOCore/update?acw=ec039c4b679ce64b971a222340a5868c0220gxrqa%7C%24%7CEE8BBC64F43CA1491B0BE486A6B387A7BDE26944666D33E52F0C3272A0F4995D24516E485F9EF29CCCE2BB43B8B265274BAE48610A35BC353FBA44D1BD4E4F2EB0469A67597464825D387A21AFA2E514&utt=b6d5d153f4e3271aaf9c972-21eb99cc0b7932f2"></iframe>
    
        <iframe src="//acw.evise.com/SSOCore/update?acw=ec039c4b679ce64b971a222340a5868c0220gxrqa%7C%24%7CEE8BBC64F43CA1491B0BE486A6B387A7BDE26944666D33E52F0C3272A0F4995D24516E485F9EF29CCCE2BB43B8B265274BAE48610A35BC353FBA44D1BD4E4F2EB0469A67597464825D387A21AFA2E514&utt=b6d5d153f4e3271aaf9c972-21eb99cc0b7932f2"></iframe>
    
        <iframe src="//acw.sciencedirect.com/SSOCore/update?acw=ec039c4b679ce64b971a222340a5868c0220gxrqa%7C%24%7CEE8BBC64F43CA1491B0BE486A6B387A7BDE26944666D33E52F0C3272A0F4995D24516E485F9EF29CCCE2BB43B8B265274BAE48610A35BC353FBA44D1BD4E4F2EB0469A67597464825D387A21AFA2E514&utt=b6d5d153f4e3271aaf9c972-21eb99cc0b7932f2"></iframe>
    
        <iframe src="//acw.elsevier.com/SSOCore/update?acw=ec039c4b679ce64b971a222340a5868c0220gxrqa%7C%24%7CEE8BBC64F43CA1491B0BE486A6B387A7BDE26944666D33E52F0C3272A0F4995D24516E485F9EF29CCCE2BB43B8B265274BAE48610A35BC353FBA44D1BD4E4F2EB0469A67597464825D387A21AFA2E514&utt=b6d5d153f4e3271aaf9c972-21eb99cc0b7932f2"></iframe>
    
</div>

<!-- clear SSO URLs after all iFrames are rendered or after passing a time out-->
<script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script>
    setTimeout(clearSsoUrlsFun,10000);
    var iFramesList = document.getElementById("sso-urls-div").getElementsByTagName("iframe");
    var renderedIFramesCount = 0;
    var numberOfIFrames = iFramesList.length;
    var skipRefresh = false;
    for (var i = 0; i < iFramesList.length; i++) {
        var iFrame = iFramesList[i];
        iFrame.addEventListener("load", function() {
            renderedIFramesCount = renderedIFramesCount + 1;
            if (renderedIFramesCount >= numberOfIFrames)
            {
                clearSsoUrlsFun();
            }
        });
    }

    function clearSsoUrlsFun() {
        if (skipRefresh == false && numberOfIFrames > 0)
        {
            skipRefresh = true;
            $.ajax({
                url: "https://www.thelancet.com/action/clearSsoUrls",
                type: "GET",
                dataType: "jsonp",
                error : errorCallingAjx
            });
        }
    }

    function errorCallingAjx(){
        console.log("can't delete sso urls .")
    }
</script></div>
                </div>
                </div>

        

    

        


    

            

            

            <div data-widget-id="adafe196-2eed-4691-9a63-5f1e8d920aa3" data-widget-name="UX3HTMLWidget"><!-- Global site tag (gtag.js) - AdWords: 800477382 --> 
<script async src="https://www.googletagmanager.com/gtag/js?id=AW-800477382"></script> 
<script> window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'AW-800477382'); </script></div>

            

        

    

        


    

            

            

            <div data-widget-id="ada4f5c8-9450-4183-89fc-051e378ad5b2" data-widget-name="UX3HTMLWidget"><p class="align-center copy-right">
We use cookies to help provide and enhance our service and tailor content and ads. By continuing you agree to the <a href="/cookies" target="_blank">use of cookies</a>.
<br />
Copyright © 2020 Elsevier Inc. except certain content provided by third parties.
<br>
<br>
<a href="https://www.elsevier.com/legal/privacy-policy" alt="Privacy Policy" rel="nofollow" target="_new">Privacy Policy</a>&nbsp;&nbsp;&nbsp;<a href="https://www.elsevier.com/legal/elsevier-website-terms-and-conditions" alt="Terms and Conditions" rel="nofollow" target="_new">Terms and Conditions</a>
<br>
<br>
<a href="https://www.relx.com"><img src="//els-jbs-prod-cdn.jbs.elsevierhealth.com/pb/assets/raw/Lancet/images/relx3.png" alt="RELX" rel="nofollow" target="_new"></a>
</p>
<!--
<p class="align-center copy-right">
Copyright © 2020 Elsevier Limited except certain content provided by third parties.
The Lancet is a trade mark of Elsevier Limited.
The Lancet.com website is operated by Elsevier Inc. The content on this site is intended for health professionals.
We use cookies to help provide and enhance our service and tailor content and ads. By continuing you agree to the <a href="/cookies">use of cookies</a>.
The Lancet demonstrates its commitment to accessibility by enabling access and optimising the experience for individuals with disabilities and impairments.
</p>
--></div>

            

        

    

        


    

                
                
                
                
                
                
                    
                
                    
                
                    
                        
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                
                    
                
                    
                
                    
                        
                        
                        
                    
                
                    
                
                    
                
                    
                        
                        
                            
                        
                        
                            
                            
                            
                        
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                
                
                <div class="widget sessionValidationWidget none  widget-none  widget-compact-all" id="233c371f-f0b7-4cd9-b2b9-1a94969b2c04">
                
                

                <div class="wrapped " >
                    
                    <div class="widget-body body body-none  body-compact-all"><script>
    $.ajax({
        url: "https://www.thelancet.com/ssoSessionCheck",
        type: "GET",
        dataType: "jsonp",
        success: function (data) {
            if(data.RefreshSession) {
                location.reload();
            }
        },
        error : function (){
            console.warn("can't validate CSAS session.");
        }
    });
</script></div>
                </div>
                </div>

        

    

        


    

        


    

            

            

            <div data-widget-id="a6407e18-b243-45d6-bc90-40c68f9b2152" data-widget-name="UX3HTMLWidget"><script>

function scrollToElement(id) {
// USE VARIABLE TO CALCULATE HEIGHT OF COMBINED STICKY BITS
var heightx = 0;
// IF THE HEADER/LOGO ROW EXISTS
if ($(".header__wrapper").length > 0) {
heightx = heightx + $(".header__wrapper").first().height();
}
// IF LEADERBOARD EXISTS
if ($(".widget-horizontalAd").length > 0) {
heightx = heightx + $(".widget-horizontalAd").first().height();
}
// IF ARTICLE TOOLS EXISTS
if ($(".article-tools.sticky").length > 0) {
heightx = heightx + $(".article-tools.sticky").first().height();
//heightx = heightx + $(".article-tools.sticky article-tools__wrapper").first().height();
// allow for padding
heightx = heightx + 26;
}
$('html, body').animate({
scrollTop: $(id).offset().top - heightx + "px"
}, 500);
}

var delay = 3000;
setTimeout(function() {
var relFound = 0;
var relString = "";

$('h2').each(function() {
  var header = $(this).text();
  if (header.indexOf("Related") >= 0) {
   relFound = 1;
   var headID = $(this).attr('id');
   var hrefString = "#" + headID;
   var relString = "<section id='related-section'><div class='section-paragraph' id='related-message-box'><p id='related-message-text'><span>&bull;&nbsp;</span><a id='related-message-link' href='" + hrefString + "'>View related content for this article</a></p></div></section>";
   $("#related-links-container").append(relString);
   $("#related-message-box").css("background-color", "#efefef");
   $("#related-message-box").css("padding", "10px");
   $("#related-message-text").css("padding", "0px");
   $("#related-message-text").css("margin", "0px"); 
   $('a#related-message-link').click(function() {
    scrollToElement(hrefString);
   });
   return false;
  }

});

if (relFound == 0) {
 $( "#related-section" ).hide();    
}

// addition from Andrew, to move the View Related box for Light Blue content
  if ($(".article__body section h2:contains('Summary')").length == 0 && $("h2:contains('Related')").length > 0) {
    $(".section-paragraph:not(:has(.accordion--textbox,figure))").eq(2).after($(".relatedItems-dropzone section#related-section").detach()); 
    $("section#related-section").css("margin-bottom", "0px");   
  }
   
}, delay);

</script></div>

            

        

    

        


    

            

            

            <div data-widget-id="711983b9-6e41-4e08-8776-c6541734fc01" data-widget-name="UX3HTMLWidget"><script type="text/javascript"> _linkedin_partner_id = "402924"; window._linkedin_data_partner_ids = window._linkedin_data_partner_ids || []; window._linkedin_data_partner_ids.push(_linkedin_partner_id); </script><script type="text/javascript"> (function(){var s = document.getElementsByTagName("script")[0]; var b = document.createElement("script"); b.type = "text/javascript";b.async = true; b.src = "https://snap.licdn.com/li.lms-analytics/insight.min.js"; s.parentNode.insertBefore(b, s);})(); </script> <noscript> <img height="1" width="1" style="display:none;" alt="" src="https://dc.ads.linkedin.com/collect/?pid=402924&amp;fmt=gif" /> </noscript></div>

            

        

    

        


    

            

            

            <div data-widget-id="ee88cfc7-305d-4bc3-88ee-f91eab11add1" data-widget-name="UX3HTMLWidget"><style>
.ad-section .pb-ad {
 display:block;
 height: auto; 
 margin-left: 0px;
 margin-right: auto;
}
.linkback-ad .pb-ad {
 display:block;
 height: auto; 
 margin-left: 0px;
 margin-right: auto;
}
.linkback-ad .pb-ad .linkback-image img {
 max-width:none;
}
.linkback-ad .pb-ad .linkback-link {
 font-weight:700;
}
.linkback-ad .pb-ad .linkback-image-copyright {
 font-size:75%;
}
.linkback-ad .pb-ad .teaserCopyrightMsg {
 font-size:70%;    
}
@media only screen and (min-width: 1500px) {
 .linkback-ad .pb-ad .linkback {
  margin-top:30px;
  display:flex;
 }
 .linkback-ad .pb-ad .linkback-image {
  max-width:35%;
  margin-right:5%;
 }
 .linkback-ad .pb-ad .linkback-text {
  width:auto;
 }
}
@media only screen and (max-width: 1500px) {
 .linkback-ad .pb-ad .linkback {
  margin-top:10px;
 }
 .linkback-ad .pb-ad .linkback-image {
  display: none;
 }
 .linkback-ad .pb-ad .linkback-text {
  width:auto;
 }
}
.noMargin {
  margin: 0 !important;
}
.noPadding {
  padding: 0 !important;
}
</style></div>

            

        

    

        


    

            

            

            <div data-widget-id="1f934032-5497-4118-b197-aec2515a6307" data-widget-name="UX3HTMLWidget"><style>
@media only screen and (min-width: 1500px) {
 .article__tos li a {
 /* word-wrap: normal; */
 padding-left:1px;
 }    
}
@media only screen and (min-width: 1500px) {
 /* looks like the style above has stopped working in 2018.8. So try the below instead */
 .article__body .left-side-nav li a {
  padding-left:1px;
 }    
}
</style></div>

            

        

    

        


    

            

            
                <div class="noMargin">
            

            <div data-widget-id="f8e014fb-0959-477e-8f5b-ccd252852fd6" data-widget-name="UX3HTMLWidget"><!-- Start of HubSpot Embed Code -->
<script type="text/javascript" id="hs-script-loader" async defer src="//js.hs-scripts.com/3798016.js"></script>
<!-- End of HubSpot Embed Code --></div>

            
                </div>
            

        

    

        


    

            

            

            <div data-widget-id="f13ddc3d-3149-459d-9c0e-1bc041f355f9" data-widget-name="UX3HTMLWidget"><style>
html:not([data-pb-can-design]) .pb-action-bar {
 display:none;
}
.pb-start-action-bar, .pb-start-action-bar .pb-collapse-btn-container, .pb-start-action-bar .pb-main-bar {
    top: 200px !important;
}
</style></div>

            

        

    

        


    

            

            

            <div data-widget-id="29719a1a-7635-4938-bff7-2cd07ffd9649" data-widget-name="UX3HTMLWidget"><style>
.ux3 .adplaceholder--header {
   top: 0;
}
</style></div>

            

        

    

        


    

            

            

            <div data-widget-id="33cab61c-6b21-4e99-887d-28a1e6abe1d8" data-widget-name="UX3HTMLWidget"><script>
// adding this JS as a temp fix to correct the colour of the Quick Search magnifying glass
    // determine Lancet journal color code
    var jCode = $("input[name='journalCode']").attr("value");
    jColor = '#00539e';		// Parent site color	
    if (jCode == "lancet") {
      	jColor = '#4d6a75';
    } else if (jCode == "lanchi") {
       	jColor = '#B0117F';
    } else if (jCode == "landia") {
       	jColor = '#00ab9c';
    } else if (jCode == "landig") {
       	jColor = '#76bfe8';       	
    } else if (jCode == "langas") {
       	jColor = '#677718';
    } else if (jCode == "langlo") {
       	jColor = '#930438';
    } else if (jCode == "lanhae") {
       	jColor = '#f8941d';
    } else if (jCode == "lanhiv") {
       	jColor = '#650360';
    } else if (jCode == "laninf") {
       	jColor = '#936fb1';
    } else if (jCode == "laneur") {
       	jColor = '#6cb33e';
    } else if (jCode == "lanonc") {
       	jColor = '#ee3123';
    } else if (jCode == "lanplh") {
       	jColor = '#009444';
    } else if (jCode == "lanpsy") {
       	jColor = '#00447c';
    } else if (jCode == "lanpub") {
       	jColor = '#487483';
    } else if (jCode == "lanres") {
      	jColor = '#009cd8';
    } else if (jCode == "lanrhe") {
      	jColor = '#9e5572';      	
    } else if (jCode == "eclinm") {
       	jColor = '#004896';
    } else if (jCode == "ebiom") {
       	jColor = '#004896';
    }

    $( ".ux3 .quick-search [type='submit']" ).hover(
     function() {
        $(this).css("background",jColor);
        $(this).css("color","#fff");        
     }, function() {
        $(this).css("background","#fff");
        $(this).css("color","#505050");        
     }
    );
    $( ".ux3 .quick-search [type='submit']" ).focus(
     function() {
        $(this).css("background",jColor);
        $(this).css("color","#fff");        
     }, function() {
        $(this).css("background","#fff");
        $(this).css("color","#505050");        
     }
    );    

</script></div>

            

        

    

        


    

            

            

            <div data-widget-id="9be8925e-9dbc-4133-b2bd-0aee8fde3fb0" data-widget-name="UX3HTMLWidget"><style>
html:not([data-pb-can-design]) .atypon-admin-bar-container {
 display:none !important;
}
</style></div>

            

        
</footer></div>

            

        

        </div>
    
        </div>
    </div>













        
        
            <script type="text/javascript" src="/products/marlin/lancet/releasedAssets/js/main.bundle.js"></script>
        
        


    


    <script type="text/javascript">
        WebFontConfig = {
            google: {
                families: ['Source Sans Pro']
            },
            loading: function () {

            },
            active: function () {
                $(document).trigger("resize");
            }
        };
    </script>
    <script type="text/javascript"
            src="https://ajax.googleapis.com/ajax/libs/webfont/1.6.26/webfont.js"></script>






<script type="text/javascript">
    var pageData =  {"journal":{"specialty":"Public Health,Infectious Diseases,Health Policy,Internal:Family Medicine,General Surgery,Lancet","issn":"0140-6736","name":"The Lancet","section":"Primary Research:Articles"},"page":{"loadTimestamp":"1590185586604","server":"www.thelancet.com","environment":"prod","businessUnit":"ELS:RAP:JBS","noTracking":"","name":"fulltext:html","section":"The Lancet","language":"en","type":"CP-CA","productName":"JB"},"visitor":{"departmentName":"ae:Journal Branded Solutions - Guests|ae:ScienceDirect Guests","accessType":"ae:ANON_GUEST|ae:ANON_GUEST","accountId":"ae:375335|ae:228598","accountName":"ae:Journal Branded Solutions - Guests|ae:ScienceDirect Guests","departmentId":"ae:388406|ae:291352","ipAddress":"178.79.165.171","loginStatus":"anonymous","userId":"ae:19319093|ae:12975512"},"content":[{"accessType":"article:free:standard","viewState":"fulltext","format":"MIME-HTML","id":"pii:S0140673620312083","type":"XOCS-JOURNAL:SCOPE-FULL","title":"Safety tolerability and immunogenicity of a recombinant adenovirus type5 vectored COVID19 vaccine a doseescalation openlabel nonrandomised firstinhuman trial","status":"S200"}]};
</script>

<script type="text/javascript">pageDataTracker.trackPageLoad();</script>





















    

</body>
</html>
